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Actinobacillus pleuropneumoniae (APP) is a porcine respiratory Gram-negative pathogen, 
which has a profound negative impact on the farming economy, with serotype 8 being the 
most predominant in the UK. In anticipation of an antibacterial resistance era, there is 
increasing interest in the development of novel therapeutic strategies to combat this 
disease. Small non-coding RNAs (sRNAs), involved in post-transcriptional regulation of gene 
expression, are amongst some key components employed by bacteria to mediate virulence. 
sRNAs interact with their target mRNAs to tightly regulate the turnover of virulence factors, 
resulting in altered patterns of gene expression to rapidly adapt to environmental changes. 
Identifying, targeting and disrupting the production of virulence factors is a promising novel 
strategy to treat infectious diseases. Thus, sRNAs have been identified as potential 
antimicrobial targets. However, there are no therapeutic approaches targeting sRNAs being 
currently used at the moment.  
 
This project aimed to understand and exploit the bacterial regulatory mechanism 
responsible for the control of virulence factor production by investigating and targeting 
regulatory sRNAs not yet characterised in APP. A combined approach of computational 
prediction and gene expression analysis using RNA sequencing data was designed, resulting 
in the establishment of a bioinformatic pipeline to identify novel trans-acting sRNAs from 
APP serotype 8 and predict their putative mRNA partners. Moreover, this research provides 
the first insights into the mechanisms of interaction of the sRNA GcvB and its predicted 
mRNA partners in APP. GcvB is a global regulatory sRNA involved in amino acid biosynthesis 
and peptide transport in various pathogenic Gram-negative bacteria. The expression levels 
of GcvB and its targets, quantified in different growth conditions, confirmed their presence 
in this species. The predicted interactions were then screened, validated and quantified 
using a novel RNA array technology developed at the University of Portsmouth with a 
customised protocol created to test APP molecules. After gaining a greater understanding 
of the mechanisms of sRNA-mRNA binding, a bespoke inhibitory nucleic acid mimic (NAM) 
was designed to specifically disrupt the interaction in vitro. The NAM molecule specifically 
disrupted the interaction between GcvB and its selected targets. Furthermore, the results 
showed that the novel high throughput RNA array technology can be applied and 
customised to identify and quantify interactions between sRNAs and their target 
transcripts. This work may have applications for novel therapeutics that target virulence 
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RNA-seq  ribonucleic acid sequencing 
rpm   revolutions per minute 
rRNA   ribosomal ribonucleic acid 
s   second(s) 
SA   streptavidin 
SAXS   small angle X-ray scattering 
SDS   sodium dodecyl sulphate 
sRNA   small ribonucleic acid 
ss   single-stranded 
T   thymine 
T7   RNAP T7 RNA polymerase 
TBE   Tris, Boric acid and EDTA 
TBIO-PCR  thermodynamically balanced inside-out polymerase chain reaction 
TEMED  N, N, N’, N’ - tetramethylethylenediamine 
Tm   melting temperature 
Tris   Tris (hydroxymethyl)-aminomethane 
tRNA   transfer RNA 
TY  tylosin 
TXN   transcription buffer 
U   uracil 
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UTP   uridine triphosphate 
UTR   untranslated region 
UV   ultraviolet 
V   volts 
v   volume 
WT   wild-type 
λ   wavelength 
μg   microgram(s) 
μl   microlitre(s) 
μm   micrometre(s) 
μM   micromolar 
σ   sigma 







1.1. Gene expression in bacteria 
 
Bacteria are constantly exposed to changing environmental conditions, such as 
variation in the availability of nutrients or the presence of toxic agents that can cause cell 
distress. Thus, keeping proteome homeostasis is essential to maintain metabolic activity 
and guarantee cell survival. Production of proteins in prokaryotic cells is generally 
explained according to the central dogma of molecular biology, postulated by Francis Crick 
in 1958.  
In this concept, all information necessary for life is stored in genes, which are 
stretches of deoxyribonucleic acid (DNA), consisting of a complementary double-stranded 
chain of nucleotides. The DNA is used as a template by the RNA polymerase (RNAP) enzyme 
to produce single-stranded ribonucleic acid (RNA) molecules in a process called 
transcription (Figure 1.1). The information stored in the RNA molecule codes for amino acid 
sequences, and macromolecular structures called ribosomes use this information to 
produce proteins in a process called translation.  
However, a more elaborated mosaic of processes and pathways occurs around the 
central dogma to select which proteins are produced. These processes and pathways are 
regulated by tightly controlled mechanisms, collectively known as regulation of gene 
expression, occurring throughout transcription initiation to post-translational 
modifications. Under this premise, regulation of bacterial genes maintains a stable 
production of proteins by promoting the expression of genes involved in the relevant 
metabolic processes at a stage-specific pathway such as colonisation or evasion of host in 
pathogenic bacteria for example (Vitreschak et al., 2004), and repressing the synthesis of 
gene products that are unnecessary at that specific time to conserve energy and nutrients 
(Balleza et al., 2009; Hausser et al., 2019).  
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Thus, regulation of gene expression in bacteria can efficiently occur at any time 
between transcription initiation and modifications for stabilisation of the final gene 
product. Various mechanisms of gene regulation in bacteria, of relevance to the work in 
this thesis, will be considered in more detail in later sections. 
 
Figure 1.1. Schematic of Central Dogma by Francis Crick (1958). Deoxyribonucleic acid molecule (DNA) consists of two 
chains of nucleotides complimentarily connected by hydrogen bonds between their nitrogenous bases. Purine bases, 
guanine (G) and adenine (A), interact with the pyrimidine bases cytosine (C) and thymine (T), respectively. The double 
stranded DNA forms a helix structure. A delimited region of double stranded DNA containing a gene is used as a template 
(A is the template for uracil (U) rather than T) to synthesise ribonucleic acid (RNA) by the RNA polymerase (RNAP) in a 
process called transcription. During transcription initiation, RNAP binds to the DNA, separating the DNA strands to form 
a transcription bubble. Once transcription is terminated, if the newly made RNA molecule is a messenger RNA (mRNA), 
the sequence of its nucleotides is used to produce polypeptides and proteins by the ribosome in a process called 
translation. Three consecutive bases form a codon and each codon codes for a single amino acid. Gene expression may 
be regulated by a variety of mechanisms anytime in between these processes, and examples are noted in blue arrows. 
Some RNA molecules are not translated into a protein, acting as functional non-coding RNAs, such as small RNAs (sRNAs) 
in bacteria, which play a role in post-transcriptional gene regulation (PTGR). The mechanisms of gene regulation are 
further covered in this thesis. 
 
1.1.1. Organisation of transcriptional elements in bacteria 
 
Prokaryotic DNA is organised into a circular chromosome supercoiled in the 
nucleoid region in the cell cytoplasm, where transcription and translation may take place 
simultaneously (Stonington & Pettijohn, 1971). Genes can be transcribed individually as a 
mono-cistronic unit, or in groups as poly-cistronic mRNAs, organised in operons in the DNA 
sequence. A bacterial transcriptional unit can be defined by regulatory elements on the 
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DNA, including a promoter region where the RNAP binds, a transcriptional start site (TSS) 
followed by an untranslated region (UTR), one or more gene coding regions (ORFs) and a 
termination region (Figure 1.2). This format allows bacteria to respond quickly and 
efficiently to the signals they receive, since poly-cistronic mRNAs encode ORFs that 
generally act in the same metabolic route (Jacob & Monod, 1961; Browning & Busby, 2004).  
 
 
Figure 1.2. Typical prokaryotic transcriptional unit. The transcriptional unit which contains the promoter regulatory 
region (non-coding DNA sequences which regulate transcription of target genes) and the operon (containing the genes 
to be transcribed). a) Promoter regulatory region; containing cis-regulatory sequences recognised by the RNAP sigma (σ) 
factor protein; one at position -35 (consensus TTGACG) and another at position -10 (consensus TATAAT). This region may 
contain other regulatory sequences e.g., operators (O) on which repressor molecules bind, blocking the path for the RNAP 
thus disrupting transcription. b) Transcriptional start site (TSS) noted as position +1 in the unit. c) Structural coding 
sequences with ORFs encoding proteins that typically work together. d) Termination sequence containing signals to end 
transcription. The transcribed operon is a polycistronic mRNA containing more than one gene organised in cistrons, 
containing 5’ UTRs adjacent to the coding region of each gene. The UTRs of a cistron may accommodate their ribosomal 
binding site (RBS) and other regulatory signals. Genes for trans-regulatory elements code for transcription factors, which 
are regulatory proteins that enhance or silence transcription and are usually located upstream of the transcriptional unit. 
 
1.1.2. Transcription initiation  
 
Transcription initiation is one of the most fundamental steps of gene regulation in 
prokaryotes. The start of transcription of a gene or operon depends on the RNAP 
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recognition of their promoters, and this is often assisted by additional mechanisms, 
involving the binding of molecules and regulatory proteins to specific regions of DNA called 
cis-regulatory elements, mainly located around the promoter of the target gene as 
illustrated in the schematics of the prokaryote transcriptional unit in Figure 1.2. This 
interaction may enhance or disrupt RNAP activity (Browning & Busby, 2004).  
Before transcription initiation, the RNAP assembles as a holoenzyme involving two 
main components; an enzymatic RNAP core, which is responsible for the polymerisation of 
the ribonucleotides, and the sigma (σ) factor protein, necessary for the recognition of the 
transcription start site (TSS). The RNAP core has no specific affinity for the DNA, unless it is 
associated with a σ factor (Burgess & Travers, 1969; reviewed in Feklístov et al., 2014). 
Transcription starts after identification of the promoter by the σ factor and the correct 
positioning of the RNAP holoenzyme on the TSS.  
When the forming RNA chain reaches about 8-10 bases, the σ factor detaches from 
the RNAP core enzyme, which continues RNA synthesis on the DNA template strand until a 
termination signal is reached and the RNAP dissociated from the DNA, producing a 
complete RNA transcript (reviewed in Mooney et al., 2005; Cases & De Lorenzo, 2005). 
Details of this process are illustrated in Figure 1.3. Regulation of gene expression at 
transcription initiation level is commonly performed by the RNAP σ factors, some of which 
are essential for successful infection in pathogenic bacteria, and consequently associated 






Figure 1.3. Transcription in bacteria. Diagram depicting generic transcription initiation in prokaryotes. A) Ahead of 
transcription initiation, the RNAP associates with a sigma (σ) factor which identifies and binds to promoter sequences at 
positions -35 (consensus TTGACG) and -10 (consensus TATAAT) on the DNA coding strand. This accurately places the 
RNAP in the direction of the target gene or genes. Once stabilised, the RNAP opens the DNA to start transcription on the 
template strand. The unwinding of DNA occurs at the -10 position, where the strands easily separate due to the 
predominance of the A-T base pairs that connect with only two hydrogen bonds, instead of the three from G-C base pairs. 
B) Once the sigma (σ) factor disassociates, the RNAP continues to transcribe throughout the ORFs until it finds a 
termination signal, and once this happens the RNAP transcribes a DNA sequence known as a terminator. C) The RNAP has 
finally reached the termination sequence, and a newly formed RNA may become a messenger RNA (mRNA), or a non-







1.1.2.1. The role of transcriptional sigma (σ) factors  
 
Other than recognising the promoter sequences during transcription initiation, 
bacterial σ factors play several key roles, including the opening and stabilization of the DNA 
complex in the promoter region; interaction with other regulatory molecules; and 
influencing the dissociation of RNAP from the promoter (Saecker et al., 2011; reviewed in 
Feklistov et al., 2014). Bacterial cells produce different σ factors, each responsible for 
regulating the transcription of a certain set of genes that handle conditions triggered by 
changes in the environment. Under a particular condition, a specific σ factor can direct the 
RNAP to the required genes to be transcribed. These external stimuli may include 
nutritional depletion, beginning of the stationary phase, temperature changes, or stress 
damage, such as oxidative and osmotic stress among others (reviewed in Ishihama, 2010).  
Bacterial σ factors are divided into two families, the σ70 and the σ54 families, which 
are further divided in subgroups based on their phylogenetic origins (Gruber & Gross, 2003; 
reviewed in Murakami & Darst, 2003). This therefore creates competition between the 
different σ factors for the RNAP core, guided by the current condition that the bacterial cell 
is enduring (Aertsen & Michiels, 2004). All bacteria present at least one main essential σ 
factor, which is known as the housekeeping σ factor, and is responsible for recognising 
most bacterial promoters. The σ70 family comprises a greater number of factors related to 
the most varied functions during bacterial growth.  
The members of this family are phylogenetically and structurally classified into four 
distinct subgroups, which are differentiated by the presence or absence of four conserved 
regions that correspond to four structural domains. These domains are associated with 
DNA binding in the -10 and extended -10 and -35 promoter regions (Gruber et al., 2001). 
Regulation by the RNAP transcription factors is highly dependent on DNA cis-regulatory 
elements associated to the target gene. A single gene with more than one promoter; can 
thus be regulated by more than one σ factor, which may be expressed in more than one 





1.1.2.2. Transcription factors  
 
Transcription factors (TFs) are regulatory proteins that recognize cis-regulatory 
elements in the DNA and promote the activation or inhibition of transcription of their 
target genes. TFs that stimulate transcription are called activators and act by stabilizing the 
binding of the RNAP to the promoter sequence. Their binding sites are usually located 
upstream of the -35 site but can also be found between the -35 and -10 sites. Meanwhile, 
TFs that prevent RNAP from accessing the promoter region are called repressors and their 
interaction sites are the operators usually found on the promoter region, e.g., regulation 
of the lac operon (Figure 1.4) (Jacob & Monod 1961; reviewed in Balleza et al., 2009). 
Transcriptional cis-regulatory elements may overlap within operons and there is often a 
promoter that controls the transcription of the complete set of genes in the initial cistron, 
but there may be internal promoters regulating certain genes in the operon, or even 
premature transcription termination regions, causing only a few genes to be part of the 
poly-cistronic mRNA (Browning & Busby, 2004).  
 
Figure 1.4. Regulation of the lac operon. The operon model was proposed as a mechanism for coordinated regulation of 
the gene expression related to lactose transport and catabolism by Jacob & Monod (1961). In this model, A) a repressor 
protein (lac repressor) binds on the operator, a cis-regulatory element sequence around the promoter region to which 
the repressor binds and controls the expression of the operon genes by blocking RNAP access to the promoter. B) In the 
presence of an inducer, in this case the allolactose protein, the lac repressor undergoes conformational change and loses 
affinity for the operator, resulting in de-repression of the operon and access by the RNAP resulting in the initiation of 
transcription (Lewis & Adhya, 2004). 
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1.1.3. Transcription termination 
 
In prokaryotes, transcription terminators are divided in Rho-dependent and 
independent terminators. In the Rho-dependent termination model, the Rho protein binds 
to the mRNA at specific sequences during transcription and translocate downstream along 
the forming transcript towards the transcriptional machinery. The complex is then paused 
at the termination region, where the Rho protein contributes to releasing the RNA 
transcript by dislocating the RNAP (Matsumoto et al., 1986; reviewed in Roberts, 2019). 
Alternatively, Rho-independent terminators usually contain palindromic sequences in the 
3’ extremity of the nascent RNA transcript, forming a stable stem-loop, followed by a 
conserved sequence of uracil residues known as 3’ Poly-U tail. The formation of this 
termination structure in the in RNA disrupts associations between RNA and the RNAP and 




An overview of translation in bacteria, such as Escherichia coli, is shown in Figure 
1.5. During translation initiation, the smaller 30S subunit of the ribosome recognises the 
ribosomal binding site (RBS) and attaches to the 5' UTR, before moving along the mRNA 
molecule. The RBS region has consensus sequence 5’-GGAGG- 3’ known as the Shine- 
Dalgarno sequence (Shine & Dalgarno, 1975). When the ribosome finds the start codon, 
the larger subunit (50S) binds to the smaller subunit (30S), and translation begins with the 
methionine amino acid AUG, and ends at the stop codon, usually UAG, UAA or UGA. As 
previously discussed, bacterial genes are often organised in groups and transcribed as 






Figure 1.5. Translation in bacteria. The 70S ribosome consists of two subunits (30S and a 50S). The 30S subunit contains 
the ribosomal RNA (rRNA) molecule 16S and 21 different proteins, while the 50S subunit contains two rRNAs, 23S and 5S, 
and 31 different proteins. Key activities of translation such as mRNA decoding and incorporation of amino acids are 
performed by the rRNAs, instead of its component proteins. During translation initiation, the smaller subunit (30S) of the 
ribosome recognises the ribosomal binding site (RBS) and attaches to the 5' UTR, before moving along the mRNA 
molecule. The RBS region has consensus sequence 5’-GGAGG- 3’ known as the Shine-Dalgarno sequence (Shine & 
Dalgarno, 1975). When the ribosome finds the start codon, the larger subunit (50S) binds to the smaller subunit (30S), 
and translation begins with the methionine amino acid AUG, and ends at the stop codon, usually UAG, UAA or UGA.  
 
 
1.1.5. Regulation of gene expression in bacteria 
 
Gene expression regulation in bacteria can occur at the transcriptional, post-
transcriptional or post-translation level, as noted in Figure 1.1. However, having provided 
a general background introduction into the key processes of gene expression in bacteria, 
only regulatory mechanisms of relevance to the research in this thesis will be considered. 
Specifically, this will include post-transcriptional mechanisms - with a focus on those that 
control RBS access, sometimes with an associated impact on transcript stability, as a means 




1.1.5.1. Post-transcriptional gene regulation 
 
Post-transcriptional gene regulation (PTGR) mechanisms, such as the regulation of 
translation, sometimes with associated impact on transcript stability, are essential in 
regulating metabolic pathways in prokaryotes, especially pathogenic bacteria (Browning & 
Busby, 2004). PTGR mechanisms can quickly act on the transcript levels, affecting its gene 
products as a quick response to environmental changes. This category of gene regulation 
includes the ability of the ribosome to access and bind the mRNA to initiate translation. 
Regulation of gene expression in bacteria can be mediated at a post-transcriptional level 
by translational riboswitches and regulatory small non-coding RNAs operating as trans 
(trans-acting sRNAs) or cis-acting antisense RNAs (asRNAs) (Winkler & Breaker, 2003; 
Mandin et al., 2013).  
 
1.1.5.1.1. Riboswitches  
 
At the post-transcriptional level, structures of the mRNA may form at important 
sequences of the mRNA involved in translation, such as the ribosome binding site (RBS) or 
at the translation start codon (reviewed in Mandin & Guillier, 2013). Regulation of gene 
expression by riboswitches is based on the perception of several intra and extracellular 
signals, such as presence of a particular molecule or variation in its concentration (Figure 
1.6). For example, a lysine-responsive riboswitch in the mRNA of the lysC genes in Bacillus 
subtilis, changes conformation upon a concentration of lysine, resulting in the 
downregulation of the aspartokinase LysC, involved in lysine synthesis (Grundy et al., 2003; 



















Figure 1.6. Generic diagram of post-transcriptional regulation by riboswitches. In this schematic, in the translational on 
state, the ribosomal binding site (RBS in red) is exposed for recognition and binding of the ribosome 30S subunit to initiate 
translation of the mRNA. In the presence of a ligand, the mRNA binding region (Aptamer) undergoes conformational 
change, sequestering the RBS sequence and inhibiting ribosome binding, and consequently translation initiation, affecting 
protein synthesis (adapted from Kim & Breaker, 2008; reviewed in Mauger et al., 2013). 
 
1.1.5.1.2. Small non-coding RNAs  
 
A class of molecules involved in post-transcriptional regulation of gene expression, 
the small non-coding RNAs (sRNAs), are amongst some of the key components employed 
by pathogenic bacteria to mediate virulence by regulating gene expression (reviewed by 
Vogel & Luisi, 2011). These molecules play an important role in several cellular processes, 
including sugar metabolism, transcriptional regulation, chromosomal replication, RNA 
processing and modification, protein inhibition, iron homeostasis and regulation of 
virulence in pathogenic bacteria (Man et al., 2011; reviewed in Svensson & Sharma, 2016). 
Currently, research on sRNAs is limited and represents a small proportion of the total RNA 
population in only a handful of selected bacterial species, although a study by Holmqvist et 
al. (2012) suggests that around half of E. coli genes may be regulated by sRNAs at some 
point in the bacterium cell cycle. As the focus of this thesis, more detailed insight into post-




1.2. Bacterial small non-coding RNAs   
 
Bacterial small non-coding RNAs (sRNAs) are functional transcripts, usually between 
50 and 500 nucleotides, produced in bacteria in response to environmental stresses, and 
have been observed in a multitude of species, including the widely studied E. coli. sRNAs 
function by forming a duplex with their target mRNAs through antisense base pairing on or 
around the ribosome binding site (RBS), causing diverse regulatory outcomes in protein 
synthesis (reviewed in Vogel & Luisi, 2011). They generally act as regulators of translation 
by altering access to the RBS to inhibit or activate translation. In situations of translation 
inhibition, there is often an associated impact on the stability of the target mRNAs targeting 
them for degradation (reviewed in Storz et al., 2011; Vogel & Luisi, 2011; Mandin & Guillier, 
2013).  
Some sRNAs require a facilitator protein to perform their functions. The most 
studied and widely known is the chaperone Hfq protein, long known as the host factor for 
Q-beta RNA bacteriophage replication in E. coli, which appears to facilitate the action of 
many sRNAs on their target mRNAs, mainly to stabilize the interaction between these 
molecules (reviewed in Moller, 2002a; Vogel & Luisi, 2011). Hfq participates in regulation 
via sRNAs by forming the mRNA-sRNA-Hfq ternary complex. A brief schematic of the Hfq is 

















Figure 1.7. Components of the ternary complex sRNA-mRNA-Hfq. Cartoon depiction of the structure of E. coli Hfq (PDB 
accession code 1HK9) rendered in PyMOL. Hfq has a ring-shaped structure forming a homo-hexamer (subunits alternately 
coloured in blue and purple), with a proximal face (yellow line) involved in sRNA binding and stabilisation, and a distal 
face (blue line) that recognises binding motifs important for mRNA binding (Franze de Fernandez et al., 1972; Vogel & 
Sharma, 2005; Vogel & Luisi, 2011), although some mRNAs bind to both faces (Fender et al., 2010). 
 
The first report on determining the function of sRNAs was the discovery of an RNA 
in E. coli complementary to the 5' untranslated region (UTR) of the ompF mRNA, coding for 
an outer membrane protein, resulting in the inhibition of its translation (Mizuno et al., 
1984). Larger genomes require greater complexity in gene regulation, thus the number of 
sRNAs may vary with the size of the genome. The E. coli genome contains approximately 
4,000 genes and 50 to 100 predicted sRNAs (reviewed in Gottesman, 2004). 
Small RNAs may be encoded in the DNA strand opposite to that encoding their 
target mRNA (cis encoded), or at loci physically separated or distant from the open reading 
frame (ORF) that encodes their target mRNA (trans-encoded). Cis encoded antisense sRNAs 
(asRNAs) act on the respective genes on the opposite strand from the region from which 
they were transcribed, presenting perfect complementarity to their targets, generating 
stable interactions (reviewed in Thomason & Storz, 2010; Svensson & Sharma, 2016) as 
illustrated in Figure 1.8-A. There are reports of the effects of gene regulation mediated by 
asRNAs relevant to bacterial virulence and pathogenicity (reviewed in Mandin & Guillier, 
2013; Svensson & Sharma, 2016).  
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Contrastingly, trans-acting sRNAs act on mRNAs encoded at distant loci in the 
genome from its targets (Figure 1.8-B). They interact with their target mRNAs via short 
partial base pairing to attenuate or activate their translation, and their secondary structure 
play a crucial role in transcript stabilisation and regulation (Wilson & Von Hippel, 1995; 
reviewed in Vogel & Luisi, 2011). Trans-acting sRNAs are versatile regulators due to their 
interaction by imperfect complementarity with the target, which consist of discontinuous 
base-pair matches forming structural bulges, and guanine-uracil (GU) wobble base-pairs, 
contravening the Watson-Crick base-pair rules (Crick, 1966). This allows for interaction 
between one sRNA and several mRNA targets (reviewed in Vogel & Luisi, 2011). Although 
asRNAs provide a fast regulation response by acting close to their transcription location, 
they only interact with targets encoded on the same genetic locus, while trans-acting 
sRNAs regulate a higher number of targets, allowing bacteria to adjust to various 
environmental stress signals at the same time (reviewed in Repoila & Darfeuille, 2009). 
 
 
Figure 1.8. Diagram of cis and trans-encoded sRNAs. A) Genes for cis-encoded antisense sRNAs are usually located in the 
opposite strand of their target gene, overlapping its 5’ UTR and ORF. B) Trans-encoded sRNA genes are in a different 
location from their targets and usually there is no overlap on genes on the opposite strand, and transcription signals such 
as transcription start site and 3’ Poly-U are separated from neighbouring genes (Li et al.,2012). 
 
1.2.1. Functional features of trans-acting sRNAs 
 
Trans-acting RNAs are highly structured transcripts usually transcribed from intergenic 
regions (IGRs). They are generally mono-cistronic, having their own promoter and intrinsic 
transcription terminator. Most transcribed trans-acting sRNAs have a distinct secondary 
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structure containing stem-loops that facilitate interactions with other molecules. They 
present a functional interaction region, also known as seed region, that generally acts by 
short imperfect base pairing within a discrete region (usually a minimum of 7 bases) of their 
target mRNAs (Storz et al., 2004; Vogel & Wagner, 2007; Sharma et al., 2007; Vogel & Luisi, 
2011). Seed regions have revealed a G/U-rich character in previous studies of sRNAs 
(reviewed in Updegrove et al., 2015), including Salmonella GcvB (Sharma et al., 2007), that 
target C/A-rich regions in the sequence of their mRNA targets. A poly-uracil tail (Poly-U) is 
a sequence of uracil residues that follows a stable stem-loop at the 3’ end, considered an 
important regulatory signal for transcription termination (Wilson & Von Hippel, 1995). 
Many trans-encoded sRNAs, such as DicF, OxyS, Spot42 and GcvB in E. coli, silence their 
target mRNAs using mechanisms facilitated by Hfq (Bouché, 1989; Altuvia et al., 1998; 
Urbanowski et al., 2000; Moller et al., 2002b), although it is not necessarily essential, and 
several sRNAs show no interaction with this chaperone protein (Livny, 2012). The common 
functional elements of trans-acting sRNA are shown in Figure 1.9. 
 
 
Figure 1.9. Common functional elements in trans-acting sRNAs. Diagram of a trans-encoded sRNA secondary elements 
consisting of stem-loops, the G/U rich interaction/seed region (yellow), a possible A/U-rich Hfq binding site (blue), a Rho-
independent terminator, and the Poly(U) region at the 3’ end (Gottesman & Storz, 2011; Svensson & Sharma, 2016). 
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1.2.2. Molecular mechanisms of regulation by sRNAs 
 
As mentioned above, the fundamental function of sRNAs is the regulation of protein 
expression, which is mediated by sRNA base pairing interactions with target mRNAs (Lease 
& Belfort, 2000; Vogel & Papenfort, 2006; Vogel & Luisi, 2011; Henderson et al., 2013). 
sRNA regulation can link to targeted mRNA degradation, as well as non-degradation 
mechanisms (reviewed in Vogel & Luisi, 2011) as discussed below. 
 
1.2.2.1. Non-degradation mechanisms 
 
Initially, pairing of an sRNA with its target mRNA can physically obstruct the RBS from 
ribosome binding (Figure 1.10A), preventing translation initiation by the 30S ribosome 
subunit and, consequently, down regulating protein synthesis (Vogel & Luisi, 2011). 
Alternatively, sRNA-mRNA pairing can cause conformational changes in the mRNA 
secondary structure to indirectly block the RBS (Kaminishi et al., 2007; reviewed in Vogel & 
Luisi, 2011). This occurs when the sRNA binds on a position distant from the RBS while 
inducing a change in structural conformation which indirectly affects access to the RBS 
(Figure 1.10B). A versatile example of such sRNA regulation is by the trans-acting sRNA 
GcvB in Salmonella. GcvB has been shown to inhibit translation of targets oppA and dppA 
by base-pairing on functional regions of these mRNAs, occluding the RBS to block ribosome 
access (Urbanowski et al. 2000). The same sRNA has shown to repress translation of the 
mRNA gtlI by binding on sequences distant from the RBS (Sharma et al., 2007). Regulation 
by GcvB is further discussed in section 1.2.4. 
Although less common, another mechanism of gene regulation by sRNAs is the 
activation of mRNA translation by a change in its secondary structure conformation, to 
expose the RBS for recognition and binding by the ribosome to initiate transcript 
translation (Figure 1.10C). This mechanism can further be associated with enhanced mRNA 
stability, through occlusion of ribonucleases cleavage sites, thus avoiding degradation by 
ribonucleases (Lease & Belfort, 2000). A long-known, well characterised, example of 
translation activation by sRNA is the regulation of the rpoS mRNA, encoding the σ factor 
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38, expressed in E. coli under stress conditions. Upon interaction with the sRNA DsrA, a 
RNase cleavage site in the rpoS mRNA is obstructed, stabilising the mRNA transcript, and 
providing protection against ribonucleolytic attack, thus supporting translation (Lease & 




Figure 1.10. Mechanisms of sRNA regulation of mRNA translation. Targeting of mRNAs (5’UTR - dark blue, RBS - light 
blue and ORF - orange) by sRNAs (yellow) may lead to activation or inhibition of translation. A) sRNA-mRNA interaction 
(with or without Hfq) may lead to translational repression as the sRNA (yellow) may bind near or on the ribosomal binding 
site (RBS) (light blue) in the mRNA 5’ UTR (dark blue) and block access of the ribosome. B) sRNA-mRNA interaction may 
change the mRNA secondary structure conformation, blocking access to the RBS by the ribosome C) In contrast, 
conformational change in structure may expose the RBS, facilitating the access of the ribosome to the mRNA, increasing 
the efficiency of the translation process (adapted from Vogel & Luisi, 2011). 
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1.2.2.2. Degradation mechanisms 
 
RNA degradation is an essential component of cell metabolism and plays an 
important role in regulating transcript levels (Deutscher, 2006). Interaction with sRNAs can 
affect the stability and half-life of mRNAs by recruiting ribonucleases (RNases) resulting in 
the complete degradation of both (Georg & Hess, 2011; Lawal et al. 2011, reviewed in Vogel 
& Luisi, 2011). An example of sRNA-mediated translation inhibition by degradation is the 
sRNA RyhB, expressed in response to iron depletion to regulate synthesis of the iron-
dependent superoxide dismutase, encoded in the sodB mRNA.  
When interacting with the sRNA RyhB, the cleavage site is exposed for degradation 
by RNAse E, resulting in down regulation of the iron-dependent sodB, while up-regulating 
other iron-independent dismutases (Masse et al., 2003). Further, a mechanism of sRNA-
mediated degradation of target mRNA has been shown to involve the 5’monophosphate 
of the sRNA stimulating RNase E cleavage of paired mRNA (Bandyra et al., 2012). Following 
endonucleolytic attack of the mRNA via RNase E, free 3’ ends are exposed resulting in 
exoribonuclease (e.g., PNPase) degradation of the transcript (Deutscher, 2006; De Lay & 




Figure 1.11. Schematic of an sRNA-induced mRNA degradation mechanism. Targeting of mRNAs (blue) by sRNAs (yellow) 
may lead to irreversible silencing through initial cleavage of the target molecule by ribonuclease E and then subsequent 
transcript degradation the via exoribonucleases such as PNPase (adapted from Bandyra et al., 2012).  
 
1.2.3. Role of sRNAs in virulence-associated metabolic pathways  
 
As bacteria need to tightly regulate the expression of their virulence genes to adapt 
to the microenvironments where they are forced to survive, post-transcriptional gene 
regulation (PTGR) by sRNAs has been demonstrated to play a central role in orchestrating 
the synthesis of proteins associated to bacterial virulence by regulating their mRNA targets 




1.2.3.1. Virulence factors in bacteria 
 
Bacteria are constantly exposed to environmental stimuli, such as variation in the 
availability of nutrients or the presence of toxic agents that cause stress in their cells. More 
specifically, pathogenic bacteria require an immediate metabolic response to changes in 
their host, as such impromptu adjustments are essential for their survival during 
colonisation and establishment of the infection. Generally, virulence factors are any 
molecules or proteins in bacteria that harm the host. Thus, virulence-associated metabolic 
pathways consist of molecular mechanisms producing virulence factors for pathogens to 
invade, colonize, survive, multiply and, consequently, cause disease in the host. Thus, 
bacterial virulence may be caused by over or under-production of certain proteins, and 
suppression of any of them can result in loss or reduction in virulence (Chiers et al., 2010; 
Svensson & Sharma, 2016; Sharma et al., 2017).  
Virulence factors vary across species and most are yet to be characterised, however, 
these are associated with well-established metabolic pathways that pathogenic bacteria 
utilise to cause infection in the host, including: adhesion to the host cells during 
pathogenesis by producing factors such as fimbriae, a protein structure on the bacterial cell 
surface which binds to the host specific receptors to facilitate colonisation of the host, 
usually present in Gram-negative bacteria (Proft & Baker, 2009; Chiers et al., 2010; 
Svensson & Sharma, 2016); acquisition of essential nutrients by producing siderophores, 
which are receptors involved in iron acquisition (Diarra et al., 1996; Bossé et al., 2002; 
Chiers et al., 2010), and by synthesis of enzymes associated to amino acids biosynthesis 
pathways to adjust to nutrient deprived environments (Lone et al., 2009); evasion of the 
host immunity by secreting factors and proteases that break down the host cells by 
inducing phagocytosis to increase nutrients availability, while offering protection against 
the host macrophages, thus playing a role in infection persistence (Chiers et al., 2010; 
Svensson & Sharma, 2016), including the production of capsular polysaccharides (CPS), 
lipopolysaccharides (LPS) and enzymes involved in the processing of urea (Ward and 
Inzana, 1994; Bossé & MacInnes, 2000; Chiers et al., 2010; Konieczna et al., 2012); and 
finally, induction of lesions by the release of exotoxins, with varied function across 
bacterial species, usually inducing cell death, with some possessing haemolytic and 
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cytotoxic properties, possibly damaging the host deeper tissues and cells to released 
invaluable nutrients and disabling of the host immune system (Frey, 1995; Bossé et al., 
2014; Rudkin et al., 2017).  
 
1.2.3.2. sRNAs linked to bacterial virulence  
 
As noted above, sRNAs are linked to virulence in some bacteria. Indeed, sRNAs 
already mentioned in this chapter are linked to metabolic pathways associated with 
virulence and expressed in response to environmental changes. For example, the E. coli 
sRNA RyhB is expressed in iron depleted environments and shown to down regulate the 
synthesis of an iron-dependent enzyme encoded by sodB by degradation mechanisms 
involving ribonucleases (Massé et al., 2003). Further, in Shigella dysenteriae RyhB was 
shown to be important for inhibiting virB, a transcription factor that encodes several 
virulence genes (reviewed in Matos et al., 2017). Additionally, in Salmonella cultivated in 
nutrient-rich medium, the sRNA GcvB is highly expressed and linked to inhibition of mRNAs 
of genes associated with amino acid synthesis and transport (Urbanowski et al., 2000; 
Sharma et al., 2007), suggesting involvement of this sRNA in the regulation of nutrient 
acquisition. Furthermore, in Actinobacillus pleuropneumoniae (APP), experiments by 
collaborators at Imperial College and University of Viçosa have shown that deletion of GcvB 
results in attenuation of virulence (Sanches, 2018). GcvB is conserved among widely 
characterised model organisms such as E. coli and Salmonella and, as the focus of this 
thesis, will be considered further below.  
 
1.2.4. The sRNA GcvB  
 
Amongst the widely characterised sRNAs, GcvB is one of the most well-known and 
conserved (Pulvermacher et al., 2008), and studies in model organisms E. coli and 
Salmonella have shown that GcvB has one of the largest regulons known in Gram-negative 
(Urbanowski et al., 2000; Sharma et al., 2007). In Salmonella, GcvB possesses a defined 
secondary structure containing several stem loops, a G/U-rich seed region and an Hfq-
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binding site (schematics in Figure 1.12A), which might offer protection from immediate 
degradation (Sharma et al., 2007). GcvB plays an essential role in the regulatory system of 
genes that encode virulence factors associated with bacterial amino acid synthesis, 
including IlvC, IlvE, ThrL and SerA proteins, as well as the amino acid transport proteins, 
DppA and OppA, from E. coli and Salmonella (illustrated in Figure 1.12B) (Urbanowski et al., 
2000; Sharma et al., 2007; Sharma et al., 2011; Miyakoshi et al., 2015).  
Amino acid synthesis and transport is an essential metabolic pathway for 
establishing infection in the host by pathogenic bacteria. It provides substrates for the 
synthesis of proteins required in other metabolic pathways such as iron acquisition and 
biofilm formation, for example. These are highly expensive processes, which require 
efficient gene regulation, especially during bacterial virulence phases (Vitreschak et al., 
2004). Unsurprisingly, GcvB is found in high prevalence within bacteria growing in nutrient-
rich environments, and transcription is tightly regulated by the transcription factors GcvA 
and GcvR, as observed in both for E. coli (Urbanowski et al., 2000) and Salmonella (reviewed 
in Vogel, 2009). For these reasons, coupled with the observations of collaborators 
regarding GcvB attenuating virulence in APP, GcvB is an appealing candidate for 
therapeutic targeting, envisioning attenuation of virulence-associated metabolic pathways.  
 
 
Figure 1.12. Schematic of GcvB structure and regulation. A) The Salmonella sRNA GcvB secondary structure contains five 
stem loops labelled as SL1-5, with SL5 predicted to act as a Rho-independent transcriptional terminator. The two 
consensus interaction regions are labelled in red as R1 and R2, with R1 base-pairing with target mRNAs while R2 interacts 
with the chaperone protein Hfq. These regions are highly conserved in other pathogenic bacterial species such as E. coli 
and Vibrio cholerae (Sharma et al., 2007). B) GcvB sRNA represses the mRNAs of proteins involved in amino acid uptake 
(yellow) and synthesis (purple). The schematic information is based on studies of Salmonella GcvB (Sharma et al., 2007) 
and E. coli GcvB regulation studies (Stauffer & Stauffer, 2005; adapted from Miyakoshi et al., 2015). 
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1.2.5. Anti-sRNAs in bacteria 
 
As non-coding RNAs have key roles in modulating the expression of target mRNAs, 
the question of how these elements regulated themselves naturally arises. In 2014, Tree et 
al. observed a novel class of non-coding RNAs in enterohemorrhagic E. coli termed anti-
sRNAs which act by specifically binding to complementary regions in sRNAs resulting in 
their degradation. Interestingly, this study also revealed that the bacteriophage derived 
anti-sRNA AgvB binds to the R1 seed region in GcvB by mimicking an mRNA target, which 
antagonises the function of this sRNA (Tree et al., 2014). This mechanism is illustrated in 
Figure 1.13. 
More recently, studies found the 3’ UTR derived sRNA SroC base pairs with two 
exposed loop regions in GcvB, and that this interaction leads to RNase E-mediated 
degradation of the sRNA-sRNA pair (Miyakoshi et al., 2015). It appears that nucleic acid 
binding/seed region recognition is an effective way in which bacteria regulate the activity 
of sRNAs. Therefore, a sensible therapeutic strategy would be to target virulence-
associated sRNAs in this manner; by using nucleic acid mimics such as peptide nucleic acid 







Figure 1.13. Schematic regulation of sRNAs by anti-sRNAs. A) Regulation of a mRNA target by a sRNA by base-pairing 
mechanism, for example, may repress protein synthesis. B) Bacteriophage-derived anti-sRNA antagonises the mechanism 
by binding to the seed region of the sRNA, liberating the mRNA for protein synthesis.  
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1.3. Porcine pleuropneumoniae caused by Actinobacillus pleuropneumoniae 
(APP) affects swine farming and the economy 
 
Pig meat is considered the most consumed form of protein in the world, 
representing around 38% of the total consumption (U. S. Food and Drug Administration, 
2016). In the United Kingdom, the average pork consumption is 26 kg per capita per year 
and forecasts suggests that pork consumption is on the rise (Agriculture and Horticulture 
Development Board UK, 2019). The growth in swine farming to meet market demand is 
correlated with high herd stocking densities, which promotes the propagation of infectious 
diseases, especially those of the respiratory tract. This is caused by animals being hoarded 
in restricted spaces to reduce costs and overall management. Sharing limited airspace in 
housing and transportation, combined with temperature changes, increase the 
opportunities for pathogen transmission (Chiers et al., 2010; Cho & Kim, 2011; Menzel et 
al., 2014). Endemic respiratory diseases in pigs result in high morbidity and mortality rates, 
elevating intervention costs and livestock losses. As a result, farming economy is negatively 
affected worldwide (Cho & Kim, 2011).  
A 2018 review from WanderWaal and Deen on swine infectious diseases found that 
a considerable proportion of respiratory tract pathogens in pigs belongs to the 
Pasteurellaceae family. One such pathogen is Actinobacillus pleuropneumoniae (APP) 
(Shope, 1964), the etiological agent of the lethal swine disease porcine pleuropneumoniae, 
a highly contagious infection which mainly affects the lower respiratory tract. The disease 
can develop in a super-acute, acute and chronic form, depending on the host's immunity, 
the number of bacterial cells that reach the respiratory tract and the virulence of the 
causative agent of the infection. Once APP reaches the lungs, colonisation and production 
of toxins leads to severe tissue damage and possibly death of the animal within 48 hours 
(Hensel et al., 1995; Bossé et al., 2002). Currently, porcine pleuropneumoniae treatment 
includes the use of antibiotics such as tetracycline, sulphonamides, and penicillin. However, 
although antibiotics might control acute infections and transmission, these are shown to 
be ineffective in chronic occurrences and multi-bacterial infections (Vanni et al., 2012). 
Besides, constant usage of antibiotics contributes to the development of resistance and 
surge in new strains. 
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Furthermore, current vaccines are specific to each APP strain and do not prevent 
pathogenic colonisation (Marsteller & Fenwick, 1999; Bossé et al., 2002; Ramjeet et al., 
2008). In anticipation of an antibacterial resistance era, there is increasing interest in the 
development of novel therapeutic strategies to combat this disease. Therefore, studies 
involving the identification and therapeutic targeting of novel genes producing nucleic 
acids and proteins which are relevant to the physiology, regulation and virulence of 
pathogens can represent a starting point for the discovery of new alternatives for the 
control of swine pleuropneumonia.  
 
1.3.1. Characteristics of APP 
 
APP is a facultative anaerobic Gram-negative bacterium that belongs to the 
Pasteurellaceae family, which contains the genera Haemophilus, Actinobacillus and 
Pasteurella. The genus Actinobacillus consists of non-motile, non-spore-forming 
coccobacillus rods. This species presents beta haemolysis activity and is currently divided 
into two biological variants which differ in their dependence on nicotinamide adenine 
dinucleotide (NAD) for growth, with biovar 1 being NAD-dependent and biovar 2 NAD-
independent. APP isolates are further differentiated in 18 serotypes, or serologically 
distinguishable strains, based on the polysaccharide antigens expressed on the capsule of 
the bacteria, with serotypes 13 and 14 belonging to biovar 2, and the others to biovar 1 
(Bossé et al., 2002; Sthitmatee et al., 2003; Sárközi et al., 2015; Bossé et al., 2017; 2020).  
In the onset of porcine pleuropneumoniae, APP cells escape immune response in 
the upper respiratory system of the host and reach the lower respiratory organs where 
they lysis a range of cells, including epithelial and red blood cells, causing lethal lesions in 
these tissues (Bossé et al., 2002; Rayamahji et al., 2005; Chien et al., 2009). Host cell lysis 
is crucial for APP to access nutrients from the environment and this species has developed 
intricate nutrient uptake mechanisms (reviewed in Chiers et al., 2010). Extensive lung 
damage is related to the stimulation of inflammatory cells by exotoxins and mainly to the 
combined effect of cytotoxins on different lung cells (Haesebrouck et al., 1997; Frey, 2003). 
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The injury of endothelial cells results in the activation of coagulation, formation of micro-
thrombi and localised ischaemic necrosis (Bossé et al., 2002).  
 
1.3.2. Virulence factors in APP 
 
Virulence factors utilised by a specific pathogen can be conserved across different 
species or exclusive to its own. Although all APP serotypes are pathogenic, there are 
differences in virulence and disease severity. This discrepancy may be related to the 
diversity in expression of virulent factors among strains (Fuller et al., 2000; Lone et al., 
2009; Klitgaard et al., 2010), including the quantity of endotoxins released into the host 
respiratory tissues such as capsular polysaccharides (CPS), lipopolysaccharides (LPS) and 
outer membrane proteins; production of adhesion factors used in biofilm formation; 
nutrient uptake capacity, and the production and excretion of pore forming exotoxins, 
which may cause lung lesions in the host (Lone et al., 2009; reviewed in Chiers et al., 2010; 
Bossé et al., 2010; Xu et al., 2010). 
 
1.3.2.1. APP exotoxins among serotypes 
 
The major pathogenicity factor in APP is the production of the toxins Apx. These 
cytolysins are toxic to neutrophils and macrophages, causing cell death and intensifying the 
inflammatory response. The exotoxins ApxI, ApxII, ApxIII and ApxIV, members of the pore-
forming RTX toxin group, are important factors involved in virulence. While ApxI is strongly 
haemolytic and cytotoxic, ApxII is weakly haemolytic and has moderate cytotoxicity. ApxIII 
is not haemolytic, but it is strongly cytotoxic (Frey, 1995; Haesebrouck et al., 2004; Chung 
et al., 2007; Opriessnig et al., 2011). All APP serotypes produce one or two of these toxins, 
which have been well characterised (see Table 1.1) (Chiers et al., 2010). In general, 
serotypes that produce ApxI are highly virulent, while serotypes producing ApxII and ApxIII 
present weak to moderate virulence. All strains produce the ApxIV protein in vivo, and its 
gene is used as an APP-specific biomarker in diagnostic tests (Gottschalk, 2003; Bossé et 
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al., 2014). APP serotype 8 is the most predominant in the UK and is considered of moderate 
virulence (O'Neill et al., 2010). Serotyping of APP is based on the CPS. 
 
Table 1.1.  
Example of exotoxins (Apx) and virulence profiling in fifteen different serotypes. 
Strain Biovar ApxI ApxII ApxIII ApxIV Virulence 
APP serovar 1 str. 4074 1 x x 
 
x High 
APP serovar 2 str. S1536 1 
 
x x x Moderate 
APP serovar 3 str. S1421 1 
 
x x x Moderate 
APP serovar 4 str. M62 1 
 
x x x Moderate 
APP serovar 5b str. L20 1 x x 
 
x High 
APP serovar 6 str. Femo 1 
 
x x x Moderate 





APP serovar 8 str. 405 1 
 
x x x Moderate 
APP serovar 9 str. CVJ13261 1 x x 
 
x High 
APP serovar 10 str. D13039 1 x 
  
x Weak 
APP serovar 11 str. 56153 1 x x 
 
x High 










APP serovar 14 str. 3906 2 x 
  
x High 
APP serovar 15 str. HS143 1 
 
x x x Moderate 
 
The table contains extensively studied APP serotypes (1 to 15) and their Apx content. The strains considered of high 
virulence mainly express ApxI proteins. This occurs because the ApxI toxin is strongly haemolytic and cytotoxic. Strains of 
weak to moderate virulence express a combination of ApxII and ApxIII. ApxII is weakly haemolytic and present moderate 





1.3.2.2. Other mechanisms of virulence in APP 
 
APP requires an adequate and fast reaction to changes, and while some aspects of 
its pathogenicity may be explained by the production of toxins, there are other expensive 
molecular systems, such as amino acid synthesis and transportation, that support the 
production of virulence factors as previously discussed. This ability of rapidly adapting to 
new conditions is orchestrated by a complex regulation in their molecular processes and 
pathways, including the manufacturing of a repertoire of proteins and enzymes, and it is 
possible that a part of these factors is regulated by sRNAs (Bossé, 2002; Sheehan et al., 
2003; Lone et al., 2009; Rossi et al., 2016). Chiers et al. (2010) conducted a study to deepen 
the knowledge on APP virulence by collecting information on previously investigated genes 
with confirmed or putative involvement in virulence-associated pathways, and this 




Table 1.2.  
Virulence factors with confirmed or putative involvement in APP. 
Virulence 
action 
(Putative) Virulence factor Gene 
Adhesion Type IV fimbriae  
(structural subunit 3 biogenesis components) 
apfABCD 
Lipopolysaccharide biosynthesis galU, rmlC, rfbN, 
Putative adhesin  
(OmpA outer membrane protein homologue) 
pomA 
Fibronectin binding outer membrane protein comE1 
Biofilm formation  pgaA, pgaC, tadF, apfB 
Putative fimbria-like protein 
(possibly involved in microcolony formation) 
flpD 
Putative fibronectin binding tufA 
Induction of 
Lesion 
Pore forming RTX toxin I, II, III and IV 









Cu-Zn superoxide dismutase sodC 
Capsular polysaccharide cpxDCBA 
Persistence Hemoglobin binding protein  hgbA 
Lipopolysaccharide biosynthesis galU, rmlC, rfbN, rfbP 
Branched-chain amino acid biosynthesis  IlvI 
Nutrient 
Uptake 
Iron (chelated) ABC transporter, 
periplasmic binding protein 
yfeA, yfeB, yfeC, yfeD  
 
Maltose regulon malEFG, malT, malPQ 
Putative arginine/ornithine antiporter arcD  
 




Branched-chain amino acid 




(adapted from Chiers et al., 2010) 
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Although there are no published studies confirming regulation by sRNAs in APP, a set 
of novel sRNAs in APP have been identified during a previous computational study of APP 
serovar 5 strain L20 by Rossi and colleagues (2016), which are predicted to target the 
mRNAs of various genes in Table 1.2. Interestingly, few of these putative sRNAs match 
those already characterised in various widely known bacterial species, such as the sRNA 
GcvB (Vogel & Luisi, 2011). The direct targets of the putative GcvB in APP are unknown, as 
is the role of this sRNA in APP virulence, although unpublished data from Sanches (2018) 
suggests its deletion in APP results in attenuation of virulence. This information, coupled 
with the high sequence conservation in the key seed regions of the predicted GcvB, 
highlight that there is a possibility that the known functional properties of this sRNA in E. 
coli and Salmonella may translate to APP (Rossi et al., 2016). Indeed, whilst there is little 
known on sRNA regulation in APP, leaving a gap in the understanding of the regulatory 
networks for this species, the preliminary data for APP GcvB indicate its role in regulating 
virulence. APP GcvB could therefore represent a potential target for inhibiting virulence 
through antisense approaches for therapeutic benefit.  
 
1.3.3. Exploiting therapeutic targeting of sRNAs via an antisense approach 
 
With antibiotic resistance on the rise, there is a clear and growing need for new 
antibacterial strategies targeting alternative and/or unconventional mechanisms. The key 
role of sRNAs in pathogenesis and regulating virulence identifies them as potential targets 
for antimicrobial chemotherapeutics, both for infections of animals as well as humans 
(Dersch et al., 2017). Furthermore, with the rapid growth of RNA therapeutics and 
antisense technologies over recent years, targeting sRNAs via an antisense approach is now 
possible. Antisense approaches usually involve single-stranded nucleic acid mimic (NAM) 
molecules being designed to be complementary to an RNA target, such as an mRNA, in 
order to bring about a silencing effect through either translation blocking or facilitating 
degradation through creating a site for RNase cleavage (reviewed in Sully & Geller, 2016). 
In the case of targeting an sRNA, binding of a NAM would inhibit the sRNA’s function as a 
means of bringing about the required outcome, such as inhibiting a virulence mechanism.  
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Advances in chemical modifications of NAMs such as phosphorodiamidate 
morpholino (MO), peptide nucleic acid (PNA), and locked nucleic acid (LNA) (Figure 1.14) 
have supported improvements in NAM molecule stability, as well as significantly enhancing 
its binding affinity for the RNA target (reviewed in Khvorova & Watts, 2017; Rasmussen et 
al., 2007). In addition, conjugation of the NAM to cell penetrating peptides has addressed 
challenges with cellular uptake (reviewed in Bai et al., 2010). This has supported numerous 
studies demonstrating the potential of antisense approaches, using NAMs, towards 
targeting bacterial RNAs for antibacterial effect (reviewed in Wojciechowska et al., 2020) 
 
 
Figure 1.14. Chemical structures of NAM modifications. (a) DNA is shown as a comparison to modified NAMs used in 
antisense therapies. These include (b) locked nucleic acid (LNA), (c) phosphorodiamidate morpholino (MO) and (d) 




1.4. Identifying sRNAs and predicting their mRNA targets 
 
The systematic study of complete genomes began with the use of DNA sequencing 
to expand genetic maps. In the case of prokaryotes, knowing the genes of a species can 
bring valuable information about its metabolic processes, including the genes involved in 
the production of virulence factors. However, RNA sequencing gives information on the 
DNA sequences that are actively expressed. The genes that encode proteins are identified 
by algorithms designed to recognise a set of signals in the DNA sequences that characterise 
an open reading frame (ORF), such as translation start and end codons or ribosome binding 
sites. However, these parameters are not properties of the genes encoding sRNAs, and due 
to their importance in prokaryotic gene regulation, the pursuit of novel sRNAs has become 
a rapidly growing research area, requiring novel approaches of analysis to support their 
identification within genomic and transcriptomic data. 
Genome sequence assembly, both de novo and genome-guided, are essential for 
the study of sRNAs. The mechanisms by which sRNAs regulate gene expression are 
imprinted in the transcriptome of the cell. Next Generation Sequencing (NGS) is considered 
as a most powerful methodology to explore sRNA transcriptomes of bacteria growing in 
specific physiological conditions. This process of RNA sequencing (RNA-seq) is often used 
to catalogue all RNA transcripts, such as mRNA, rRNA, tRNA and sRNA (Hrdlickova et al., 
2017). Indeed, transcriptomic studies of different organisms have revealed the existence 
of hitherto unknown transcripts and novel classes of sRNAs (Le Rhun et al., 2016).  
Initially, computational methods to predict sRNAs applied substitution patterns to 
identify conserved DNA sequences present in intergenic regions (IGRs) of phylogenetically 
related species. These also searched for promoter sequences and binding site for 
conserved transcription factor and Rho-independent terminator in intergenic regions 
(Rivas et al., 2001). Bioinformatic tools such as PePPER (de Jong, 2012) and TransTermHP 
(Kingsford, 2007), are used to identify clues alluding to transcriptional start and terminator 
sites located within a 50-600 nucleotide region. Over time, prediction approaches started 
to incorporate algorithms for gene annotation, base composition statistics, and secondary 
  
 55 
structure prediction in non-conserved RNA sequences and thermodynamic stability (Pichon 
& Felden, 2008). 
Colleagues at Imperial College London and University of Viçosa Brazil published a 
list of potential sRNAs in APP serovar 5 L20 (Rossi et al., 2016), generated by a 
computational approach using a combination of four prediction algorithms (RNAz, SIPHT, 
INFERNAL and searches in Rfam). An experimental approach using RT-PCR, Northern 
Blotting and RNA-seq data was carried out to validate the putative sRNA sequences 
contained in the list. The putative sRNA sequences were then used to predict any mRNA 
partners that they may interact, generating a map with possible sRNA-mRNA interactions. 
Although these methods validate the presence of sRNA and mRNAs in APP, the interaction 




1.5. A novel approach to testing putative sRNA-mRNA interactions  
 
Understanding the mechanistic details of the regulatory activities of RNA is critical 
for understanding both normal cellular function and disease. Given the potential numbers 
of interactions involved, this in turn requires high-throughput techniques that are capable 
of detecting RNA-based interactions and analysing their functional outputs at the 
molecular level. Array technologies, in which can allow thousands of miniature assays can 
be performed in parallel on a single surface, has immense potential in this regard. RNA 
arrays are in their infancy compared to DNA arrays but, recently, a number of methods 
have been developed for generating RNA arrays (Lietard & Somoza, 2019).  
The Callaghan group (University of Portsmouth) has developed a novel method for 
generating functional-RNA arrays through in vitro transcription from a DNA in vitro 
transcription (IVT) template array and in situ surface capture of the RNA on a facing surface 
(Phillips et al., 2018). As shown schematically in Figure 1.15, this method first involves 
producing a DNA in vitro transcription template array by spotting custom-designed DNA 
IVT templates onto a microarray slide. A DNA IVT template array – in vitro transcription 
reagent mix – RNA capture surface “sandwich” is then assembled. As in vitro transcription 
proceeds, RNA synthesised from each DNA IVT template is captured in situ on an RNA 
capture surface to generate a corresponding functional-RNA array. Applications such as 
detecting RNA-RNA (Phillips et al., 2018) and small molecule-RNA (Phillips et al., 2018, 
Henderson et al., 2019) interactions, and monitoring regulatory outputs such as protein 
expression (Norouzi et al., 2019) have been explored. Furthermore, the approach could be 
useful for situations where a particular RNA has many RNA-binding targets. This is 
recognised as the case for a number of trans-acting sRNAs, where they are known, or have 
been proposed, to interact with many mRNA targets. In this situation, a functional-RNA 
array of mRNA binding targets could be probed with a single sRNA, thus providing a high-





Figure 1.15. Schematics of the RNA array technology. The DNA immobilisation step involves biotin-tagged custom 
designed DNA in vitro transcription templates being spotted onto an SA-coated slide. The DNA slide is sandwiched 
together with a second SA-coated slide (coated with a higher concentration of SA), and with in vitro transcription (IVT) 
mixture in the middle. As the ‘sandwich’ is incubated, IVT proceeds, and the RNA is transcribed. As well as containing a 
specific RNA of interest, the transcribed RNA contains an SA aptamer (Philips et al., 2018) which support the RNA capture 
step in which the RNA is captured on the second SA coated slide, creating an RNA array slide. Following separation from 
the template DNA slide the RNA slide can be probed. The probing step involves the addition of fluorescently labelled 
control or test molecules which can then be visualised. Overall, the approach supports molecular interaction 
investigation and data analysis, specifically RNA arrays can be probed with differently labelled molecules, assessed in s 




1.6. Project Aims 
 
This research sought to explore sRNA-mRNA interactions linked to virulence in APP. With a 
specific focus on GcvB, the aims included: 
 
1 – In silico studies to create a robust and adaptable bioinformatic pipeline to identify and 
analyse the expression of novel trans-acting sRNAs and their targets in APP serovar 8 
MIDG2331 which are linked to virulence, and to select one novel sRNA candidate (namely 
GcvB) and its putative mRNA partners to be investigated using the RNA array technology. 
 
2 – In vitro studies to validated and analyse GcvB-associate interactions using the novel 
RNA array technology.  
 
3 – In vitro studies to exploit a strategy of interaction disruption between GcvB and its 
confirmed mRNA partners by designing and testing a nucleic acid mimic complementary to 













2. Materials and Methods 
 
2.1. In silico studies: Identification of novel trans-acting sRNAs involved in 
gene regulation in APP 
 
Bacterial small non-coding RNAs have been widely characterised in model 
organisms such as E. coli and Salmonella enterica (Vogel & Luisi, 2011). However, these 
versatile functional molecules are yet to be characterised in Actinobacillus 
pleuropneumoniae (APP). In Chapter 3 of this study, a combination of bioinformatics tools 
was utilised to predict and analyse sRNA-mRNA pairs. The analysis included RNA-seq from 
APP serovar 8 MIDG2331 provided by collaborators Dr Janine Bossé and Professor Paul 
Langford from Imperial College London, generated as described in the subsections below. 
 
2.1.1. Using transcriptomes to identify novel sRNAs 
 
RNA sequencing (RNA-seq), commissioned by collaborators at Imperial College 
London, was used to identify novel sRNA candidates, and to validate the presence and 
expression levels of their putative target mRNAs, in APP serovar 8 MIDG2331 grown in 
different conditions. The set of data used in this study originated from four separate RNA-
seq experiments. In the first strategy, the Ion Torrent platform was used to generate RNA-
Seq reads for samples from wild-type MIDG2331 and an isogenic Hfq::3xFLAG mutant, 
grown aerobically and anaerobically in Brain Heart Infusion (BHI) broth, prepared with and 
without co-immunoprecipitation (Co-IP) using an anti-FLAG antibody to identify Hfq-
binding sRNAs. For the other three experiments, referred to as Vertis 1-3, RNA-sequencing 
was performed by Vertis Biotechnologie AG (using the Illumina NextSeq 500 platform) for 
analysis of RNA samples prepared from MIDG2331 grown under different conditions. For 
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Vertis 1, whole transcriptome data was generated as strand specific 1x75 bp reads of rRNA-
depleted RNA samples prepared from MIDG2331 cultivated on BHI agar plates incubated 
under aerobic (+AER) and anaerobic (-ANA) conditions. For Vertis 2, similar whole 
transcriptome data was generated for rRNA-depleted RNA samples prepared from 
MIDG2331 cultivated aerobically on BHI plate (WT), in BHI broth (BR), BHI broth with added 
0.125 g/L ampicillin (AMP), and BHI broth plus 2g/L tylosin (TY), as well as from a delta-Hfq 
mutant of MIDG2331 cultivated in BHI broth (DHfq). Additionally, for each of these five 
RNA samples, a second library was prepared to allow specific enrichment of transcriptional 
start sites (TSS). For Vertis 3, whole transcriptome data was generated for rRNA-depleted 
RNA samples prepared from MIDG2331 cultivated aerobically in BHI broth (RNA-BHI) and 
porcine serum (RNA-PS). 
 
2.1.2. RNA extraction and sample preparation 
 
RNA extraction from the APP serovar 8 clinical isolate MIDG2331 was performed by 
colleagues at Imperial College, London. A DNase digest was performed and rRNA depleted 
from total RNA preparations using RiboZero rRNA Removal Kit for bacteria (Epicentre). 
Synthesis of cDNA was then performed from the rRNA depleted samples. For TSS analysis 
in the Vertis 2 set of samples, existing 5’ monophosphates in supplied RNA samples were 
identified through addition of a distinct linker sequence (CTGAAGCT), Tag1. RNA sequences 
were treated with tobacco acid pyrophosphatase (TAP), which facilitates the differentiation 
of TSS from processed 5′ ends (Argaman et al., 2001). By hydrolysing the terminal 5′-
triphosphate group, found only in primary transcripts, to 5’ monophosphate groups, a 5′ 
sequence tag (TAATGCGC), Tag2, was ligated to the 5’ monophosphate. This acts to 
enhance the signal from transcription start sites (TSS). Two distinct tags were therefore 
present for existing 5’ monophosphorylated RNA (Tag1), and newly formed 5’ 
monophosphate RNA (Tag2). RNA was fragmented with ultrasound and cDNA synthesised, 
before ligation of 5’ and 3’ sequencing adaptors to antisense 1’strand cDNA. PCR 




2.1.3. Analysis of the RNA-seq data 
 
RNA-seq files were uploaded to the NCBI-Short Read Archive (SRA) under the 
experiment SRX810211. The resulting bam files were analysed for quality control and 
processing of reads, mapped to the APP serovar 8 MIDG2331 genome, and set up for 
visualization in JBrowse (Skinner et al., 2009) in collaboration with the Hinton Group at the 
University of Liverpool. An average of 95% of the reads were successfully mapped to the 
genome. Full RNA-seq data analysis was carried out by Dr Will Rowe and Prof Jay Hinton at 




2.1.3.1. Software and approaches for analysing RNA-seq expression 
 
Analysis of RNA-seq data was carried out using a combination of R packages and 
genomic software suites. The R statistical computing language and environment (R Core 
Team, 2017) provides a suite of packages for calculations on arrays, data analysis, including 
RNA-seq for either on-screen or as a file output. R Bioconductor (Gentleman et al., 2004) 
was used to analyse RNA-seq data in this thesis. The software suite BEDTools (Quinlan & 
Hall, 2010) was used to manually re-annotate the reference sequence genome LN908249.1 
of APP serovar 8 MIDG2331 for purpose of this study only (Appendix 2). Statistical report 
on the RNA-seq data (see Appendix 5) was processed in the MultiQC software suite (Ewels 




Circos is a software package for visualising data and information in a circular layout. 
In this thesis, Circular Circos maps (Krzywinski et al., 2009) were generated to gauge the 
global representation of gene expression on the MIDG2331 chromosome and to compare 
expression in different bacterial growth conditions. The maps show coverage and relative 
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numbers of gene expression from RNA-seq data extracted from APP serovar 8 in different 
conditions, including BHI, and isolates in porcine serum medium (PS), added penicillin 
medium (AMP), added tylosin medium (TY) and anaerobic conditions (AN). 
 
2.1.4. Comparative studies 
 
The nucleotide sequence for the predicted novel small RNAs (sRNAs) of APP serovar 
8 MIDG2331 used in this study was provided by collaborators at Imperial College, with their 
transcript confirmed by Northern blot and/or RNA-seq detection, using the computational 
approach developed by Rossi and colleagues (2016). All nucleotide sequences of sRNAs 
from other species and mRNA targets used in this study were extracted from the NCBI 
(National Center for Biotechnology Information) database (Sayers et al., 2019) and 
GenBank (Clark et al., 2016) using the accession number NZ_LN908249.1 for Actinobacillus 
pleuropneumoniae serovar 8 isolate MIDG2331. 
The first part of the analysis was performed using the BLASTn algorithm (Basic Local 
Alignment Search Tool nucleotides), by querying the FASTA sequence of the sRNAs from 
APP serovar 8 MIDG2331 against the genome of selected species available in the NCBI 
database. The similarity (greatest positive%) and identity (greatest identity%) indices were 
used as criteria to infer about the conservation of the sequences.  
The species used in this analysis were selected based on whether they were well 
characterised in literature, and their similarity pattern against ARRC01/RNA05. See 
Appendix 3 for a list of species and their accession information. Subsequently, the 
sequences for RNA05/ARRC01, within species strains and across phylogeny were aligned 
using Clustal Omega (Goujon et al., 2010), and visualised and labelled with the program 






2.1.5. Structural studies 
 
The secondary structure of all the sequences used in this thesis were predicted 
using RNAfold (Gruber et al., 2008), an online web tool for RNA modelling, prediction and 
analysis. The tool predicts minimum free energy (MFE) secondary structures and base pair 
probabilities from single sequences of RNA. Structures were predicted using option MFE 
and partition function option, RNA modelling parameters set for Turner model (2004), 
measured at 37oC and remaining parameters kept as standard settings. Final image output 
choice was centroid structure drawing encoding base-pair probabilities, downloaded as 
PNG files and re-scaled accordingly. 
 




The search for potential mRNA targets of the predicted sRNAs was performed using 
the program TargetRNA2 (Kery et al., 2014), which identifies the putative sRNA binding 
positions in the target mRNA 5’ untranslated region (UTR). Interactions between sRNAs and 
their putative mRNA targets scoring a p-value less or equal to 0.05 were selected, resulting 
in a list of target mRNA candidates for each sRNA input. The APP serovar 8 genome 
MIDG2331 used in this thesis was not available in the TargetRNA2 database at the time of 
this study. Instead, the algorithm uses the APP serovar 5 L20 genome as a reference for 
subsequent searches. The sRNA sequences from both serovars were checked for nucleotide 
mismatches in the homology studied in section 3.2.6, an only 1 mismatch was found at 
position 156 (Serovar 8 has A and serovar 5 has a G). This is outside GcvB interaction 
regions, thus unlikely to disrupt interaction with mRNA targets. Only annotated mRNA 
targets with identical nucleotide sequences and chromosomal position in both genomes 






Similar to RNATarget2, IntaRNA 2.0 predicts RNA-RNA interaction based on the 
sequence, structure and binding energy between the pair (Mann et al., 2017). However, 
IntaRNA allows for manual input of the mRNA sequences as Target (T) input and sRNA as 
query (Q), while RNATarget2 only allows for sRNA sequence input, producing the mRNA 
targets list automatically. At least two different species/strain sequences for the sRNA 
query are required. In this study the sequences for APP serovar 5 and serovar 8 were used. 
The number of interactions per RNA pair was set to 4 and the minimum number of base 




STRING (Jensen et al., 2009) is an online database of both functional and physical 
relationships between proteins. Collating data held more widely from sources such as 
experimental data resources, computer driven prediction tools and public libraries, STRING 
acts as a central resource allowing the user to map all known interaction data together on 
to a common set of proteins and genomes. A list of genes from APP serovar 8 MIDG2331 
predicted mRNA targets (Chapter 3, section 3.3.2) were analysed in STRING using the 
following parameters: a moderate confidence 0.400 and Markov clustering method (MCL) 
with inflation parameter 1.1.   
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2.2. In vitro studies: sRNA-mRNA validation and disruption assays using the 
RNA array 
 
This section provides a list of materials and methods used in this study to investigate 
the putative sRNA-mRNA pairs predicted from in silico methods (Chapter 3) using the novel 
RNA array technology. The RNA array method was briefly introduced in Chapter 1, Section 
1.5, and was used in Chapter 4 to validate the predicted sRNA-mRNA interactions as well 
as to exploit disruption of the validated interactions in Chapter 5. The standard protocol 
has been described previously (Phillips et al., 2018; Henderson et al., 2019; Vincent et al., 
2021 in press) and details are provided below. Modifications in the protocol for assay 
optimisation are described in the corresponding results chapters.  
 
2.2.1. RNA Array protocol  
 
The novel RNA array technology has been briefly introduced in Chapter 1, Section 
1.5. The concept involves an ‘on array’ in vitro transcription method for producing RNA 
arrays from template DNA arrays using a sandwich arrangement. However, the 
experimental considerations and practicalities required for generating functional-RNA 
arrays include a number of steps, shown schematically in the flow diagram in Figure 2.1 




         Figure 2.1. Flow diagram schematically illustrating the steps involved in generating functional-RNA arrays for use in interaction/disruption assays. 
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Figure 2.1. Continuation. A) Double-stranded DNA in vitro transcription templates are designed to include a T7 promoter 
(purple) with an optimum number of Gs to support transcription (grey adjacent to purple) and a sequence encoding an 
RNA of interest (mRNA regions in this study; red) coupled to a streptavidin RNA aptamer to support subsequent RNA 
immobilisation (green), separated by a flexible linker (grey), and tagged at their 5’ end with a biotin-immobilisation linker 
and at their 3’ end with an optional fluorophore. B) DNA in vitro transcription templates are synthesised following the 
overlapping extension PCR method (Gao et al., 2003). Quality control checks of the PCR products involves confirming 
correct size following gel electrophoresis, and in some cases, IVT of the PCR product followed by gel analysis to ensure 
the PCR product can be used as an effective template for IVT production. C) The DNA in vitro transcription template array 
is prepared by coating a Nexterion H (Schott) slide with 1µM streptavidin and then spotting the DNA in vitro transcription 
templates using either a pipette or automated arrayer robot. If an optional fluorophore has been included in the DNA 
template molecules, then the DNA template arrays generated can be visualised by scanning at the appropriate 
wavelength. D) RNA capture slide preparation involves coating Nexterion H (Schott) slide with 16.6 µM streptavidin and 
setting this up facing the DNA template slide in a ‘sandwich’ arrangement with in vitro transcription mix in the middle. As 
in vitro transcription proceeds, the RNA generated is immediately captured through the streptavidin aptamer, thus 
immobilising the RNA to the capture surface. Only full-length transcribed RNA is immobilised due to the inclusion of the 
streptavidin aptamer at the 3’ end of the construct. E) The RNA array produced is probed with a DNA oligo, 
complementary to the streptavidin aptamer linker region, and labelled with an Alexa647 fluorophore (referred to as the 
SA-linker probe). The RNA array is then visualised using an excitation wavelength of 635 nm and a Standard Red emission 
filter to enable quantification of the RNA captured to be possible. F) For interaction/disruption assays, monitoring for 
efficiencies of partner molecule binding, the RNA array can be probed with either internally labelled binding partner RNA, 
or probed with unlabelled binding partner which is subsequently detected using a fluorescently labelled DNA oligo 
complementary to a specific region within the binding partner molecule (e.g., the Alexa488-labelled GAG-linker probe 
which binds to modified GcvB). Visualisation of the fluorophore enables assessment of partner molecule binding to 
targets on the RNA array. 
 
*Please note that DNA templates can be spotted individually or as co-spotted mixtures of two in vitro transcription 
templates together. When transcribing from co-spotted DNA template arrays, for the pair of RNAs created one will 
include the SA-aptamer to support surface-immobilisation, whilst the second will only be linked to the RNA array if it 





2.2.2. DNA in vitro transcription DNA template design 
 
The architecture for design of the DNA IVT templates was followed as indicated in 
the standard RNA protocol (Phillips et al., 2018; Henderson et al., 2019; Vincent et al., 2021 
in press). Generally, it includes: a biotinylated 5’ linker for immobilisation on the DNA slide, 
the T7 promoter for on-slide IVT, the putative mRNA target DNA sequence for the RNA of 
interest (ROI), an additional linker (SA-Linker) adjacent to a sequence coding for a 3’ 
streptavidin aptamer (SA Aptamer), which is suitable for post transcription on-surface 
immobilisation, and an optional 3’ end linker with a specific fluorophore for detection and 
quantification (Figure 2.2). The sequences for DNA IVT template are in Appendix 9. 
 
 
Figure 2.2. DNA in vitro transcription template design. A schematic of the DNA IVT template which consists of a short 
biotin-tagged immobilisation linker (dark blue), a promoter region (purple) with a transcription system-specific sequence 
(grey), sequence encoding the RNA of interest (red), an unstructured linker (light grey), sequence encoding an 






2.2.3. DNA in vitro transcription template synthesis  
 
2.2.3.1. Design of overlapping oligonucleotides 
 
Although all the DNA IVT templates were synthesised in-house by polymerase chain 
reaction (section 2.2.3.2), the overlapping oligonucleotides were ordered from Invitrogen 
(Thermo Fisher Scientific) and designed using a combination of software, including 
Microsoft Word and the Sequence Massager web-tool available from Biomodel website: 
http://biomodel.uah.es/en/lab/cybertory/analysis/massager.htm. Rules for the 
Thermodynamically Balanced Inside Out Polymerase Chain Reaction (TBIO-PCR) (Gao et al., 
2003) methodology were observed, with oligonucleotide length set to a maximum of 90 
oligonucleotides per overlapping oligo. This is slightly longer than the size used by Gao et 
al. (2003) to accommodate palindromic sequences contained in sRNAs and aptamers, as 
shorter oligos may increase unspecific binding of these sequences.  
Flanking complementary regions in the 3’ and 5’ of overlapped each oligo, and the 
melting temperature for the overlapping regions varied from 58oC to 64oC using the 
standard formula [(C+G) x4] + [(A+T) x2]. Each overlapping oligo was provided in soluble 
powder and reinstated to 100 nM in nuclease free distilled water. DNA IVT templates 
required 4, 5 or 6 overlapping oligonucleotides. See Appendix 9 for oligonucleotides 
sequences. 
 
2.2.3.2. Polymerase Chain Reaction (PCR) 
 
Oligonucleotide overlap extension PCR incorporating the Thermodynamically 
Balanced Inside Out Polymerase Chain Reaction (TBIO-PCR) (Gao et al., 2003) methodology 
was used to construct and amplify DNA IVT templates. This technique is an improved 
version of the traditional Thermodynamically Balanced Conventional (TBC). It was selected 
over the simpler Overlap Extension (OE) methods due to the cost and time implications of 
using plasmid OE PCR. Other advantages of using de novo gene design and synthesis 
includes significant decrease in corrective mutagenesis, the possibility of easily adapt cis 
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elements in the gene of interest such as promoters, efficient addition of structural features 
to a functional RNA such as loops and aptamers, insertion of mutations or deletion of 
specific regions with no need for restriction enzymes cleavage sites. 
The KOD Hot Start DNA Polymerase Kit (Merck) was used to carry out TBIO-PCR on 
the Applied Biosystems GeneAmp PCR system 9700 thermal cycler with Fisher brand 0.3 
ml thin-walled PCR tubes. Assembly was carried out at room temperature with components 
thawed on ice. Component concentrations and thermal cycling parameters used for each 
DNA IVT template synthesis and amplification were set out in Table 2.1 for shorter 
sequences requiring 4 overlapping oligonucleotides (Cy3 labelled GcvB; Figure 2.3); Table 
2.2 (Construct A; Figure 2.4) and Table 2.3 (Construct B; Figure 2.5) for longer sequences 
with 5 and 6 overlapping oligonucleotides respectively (mRNA targets); and Table 2.4 





Figure 2.3. Illustration of the 4 overlapping primers used for TBIO-PCR for GcvB-Cy3.  
 
Table 2.1.  
Reaction mixture assembly for TBIO-PCR synthesis of the DNA template for GcvB-Cy3. 
Item Initial Final Volume (L) 
dH2O - - 70 
MgSO4 25 mM 1.5 mM 6 
KOD Hot Start Buffer 10 x 1 x 10 
dNTPs 2 mM 0.2 mM 10 
KOD Hot Start DNA Polymerase 1 U/L 0.02 U/L 2 
FW1 Oligo 10 M 1 M 1 
FW2 Oligo 1 M 0.1M 1 
RV1 Oligo 1 M 0.1M 1 
RV2 Oligo 10 M 1 M 1 
Total   100 
 
The reaction components were assembled in a microfuge tube and PCR thermal cycler 
parameters set as follow: 
 
  
Temperature (C) Time No. cycles 
95 2’ 1 
95 10” 
25 58 10” 
70 10” 
70 5’ 1 




Figure 2.4. Illustration of the 5 overlapping primers used for TBIO-PCR for Construct A.  
 
Table 2.2.  
Reaction mixture assembly for TBIO-PCR synthesis of DNA template for mRNA targets using 
Construct A strategy. 
Item Initial Final Volume (L) 
dH2O - - 67 
MgSO4 25 mM 1.5 mM 6 
KOD Hot Start Buffer 10 x 1 x 10 
dNTPs 2 mM 0.2 mM 10 
KOD Hot Start DNA Polymerase 1 U/L 0.02 U/L 2 
Biotin FW oligo 100 M 1 M 1 
FW 1 Oligo 10 M 0.1 M 1 
FW2 Oligo 1 M 0.01 M 1 
SA RV Oligo 10 M 0.1 M 1 
Alexa Oligo 100 M 1 M 1 
Total   100 
 
The reaction components were assembled in a microfuge tube and PCR thermal cycler 
parameters set as follow: 
 
  
Temperature (C) Time No. cycles 
95 2’ 1 
95 10” 
25 62 10” 
70 10” 
70 5’ 1 




Figure 2.5. Illustration of the 6 overlapping primers used for TBIO-PCR for Construct B.  
 
Table 2.3.  
Reaction mixture assembly for TBIO-PCR synthesis of DNA template for mRNA targets using 
Construct B strategy. 
Item Initial Final Volume (L) 
dH2O - - 66 
MgSO4 25 mM 1.5 mM 6 
KOD Hot Start Buffer 10 x 1 x 10 
dNTPs 2 mM 0.2 mM 10 
KOD Hot Start DNA Polymerase 1 U/L 0.02 U/L 2 
Biotin FW oligo 100 M 1 M 1 
FW 1 Oligo 10 M 0.1 M 1 
FW2 Oligo 1 M 0.01 M 1 
RV1 Oligo 1 M 0.01 M 1 
SA RV Oligo 10 M 0.1 M 1 
Alexa Oligo 100 M 1 M 1 
Total   100 
 
The reaction components were assembled in a microfuge tube and PCR thermal cycler 
parameters set as follow: 
 
  
Temperature (C) Time No. cycles 
95 2’ 1 
95 10” 
35 60 10” 
70 10” 
70 5’ 1 




Figure 2.6. Illustration of the 6 overlapping primers used for TBIO-PCR for Modified GcvB (GcvB-MG).  
 
Table 2.4.  
Reaction mixture assembly for TBIO-PCR synthesis of the DNA template for GcvB-MG. 
Item Initial Final Volume (L) 
dH2O - - 66 
MgSO4 25 mM 1.5 mM 6 
KOD Hot Start Buffer 10 x 1 x 10 
dNTPs 2 mM 0.2 mM 10 
KOD Hot Start DNA Polymerase 1 U/L 0.02 U/L 2 
Biotin FW oligo 100 M 1 M 1 
FW1 Oligo 10 M 0.1 M 1 
FW2 Oligo 1 M 0.01 M 1 
RV1 Oligo 1 M 0.01 M 1 
RV2 Oligo 10 M 0.1 M 1 
RV3 Oligo 100 M 1 M 1 
Total   100 
 
The reaction components were assembled in a microfuge tube and PCR thermal cycler 
parameters set as follow: 
 
  
Temperature (C) Time No. cycles 
95 2’ 1 
95 10” 
35 58 10” 
70 10” 
70 5’ 1 
4  1 
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2.2.3.3. PCR Purification 
 
Purification of PCR products was carried using the Macherey-Nagel PCR clean up kit 
as described in the standard protocol. DNA was eluted by placing the column into a new 
tube, adding 15 L of elution buffer, incubating at room temperature for 1 minute, and 
then centrifuged for 1 minute at 11,000 x g. The concentration of the purified PCR products 
was verified using the microvolume UV-VIS NanoDrop 2000 spectrophotometer, and their 
size and quality confirmed by gel electrophoresis run on a 1.8% (w/v) agarose gel (method 
described in section 2.2.3.4). See Appendices 11 and 12 for agarose gel of DNA IVT 
templates for GcvB, GcvB-MG and mRNA targets. 
  
 
2.2.3.4. Gel electrophoresis analysis – Agarose gels 
 
Gel electrophoresis is a method for the analysis of nucleic acids and proteins. It 
consists of a gel matrix where these biomolecules are separated on the basis of their size, 
shape, charge or all three. Depending on the purpose, the gel matrix and components can 
take many forms to provide a native or denaturing environment. 
Agarose gels were used throughout as a quality control check to determine the size 
and quality of DNA products of PCR prior to RNA transcription. Due to the short size of the 
DNA templates, composition of each agarose gel was adjusted to a concentration of 1.8% 
(w/v), made with 1.8 g of agarose powder (Fisher) dissolved in 100 ml of 1 x TBE buffer 
(Appendix 14) by boiling the solution for approximately 2 minutes. Ethidium bromide was 
added to the dissolved solution in 0.5 μg/ml final concentration. The solution was poured 
into a casting tray with combs added to mould the wells. The gel was left set for 30 minutes 
before adding 500 ml of 1 x TBE running buffer and removing the combs. DNA samples 
were diluted to 100 ng in 8 μl of 1 x loading dye. Low Molecular Weight DNA Ladder was 
inserted to allow suitable calibration prior to running gels at 120 V for approximately 50 




2.2.3.5. RNA synthesis by in vitro transcription (IVT) in a tube 
 
Before being immobilized into the streptavidin-coated DNA IVT template slide, the 
DNA IVT templates of all mRNA target constructs were transcribed in vitro in a tube as a 
quality control check. To ensure transcriptional efficiency of designed array constructs, IVTs 
were carried out using the MegatScript T7 Transcription Kit (Thermo Fisher). A sample of 
each DNA IVT template was diluted accordingly to make up to 200 ng as instructed in their 
protocol. The IVT mixture was assembled in a microfuge tube for a 20 L reaction: 
 
Table 2.5.  
IVT reaction mix for making unlabelled RNAs (MegaScript T7). 
 
Component Initial [] Final [] Volume (l) 
Nuclease-free dH2O - - To 20 L 
T7 Reaction Buffer 10 x 1x 2 
DNA IVT Template - 200 ng - 
rNTPs  (each) 10 mM 1 mM 2 
RNA Pol T7 10 x 1x 2 
 
The microfuge tube was then incubated at 37oC for 2 hours usually. Subsequently, 
the removal of DNA IVT templates was carried out by adding 2 l Turbo DNAse to each tube 
and intubating for a further 10 minutes at 370 C. Please note that a modified version of this 
method was used for preparing labelled RNA (section 2.2.7.1). 
 
2.2.3.6. Gel analysis - Urea denaturing polyacrylamide gel electrophoresis (Urea-
PAGE) 
 
Following IVT, further denaturing of the secondary structures of RNA samples was 
achieved using urea polyacrylamide gel to verify whether the synthesised DNA IVT 
templates were transcribing the correct size transcripts. An 8% (w/v) denaturing Urea-
PAGE gel was used to separate the nucleic acid bases of the RNA, allowing comparative 
measurement of molecular size. A gel mixture was prepared (Table 2.6) and poured in to a 
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NovexTM Mini gel cassette with combs inserted to produce sample wells. This was allowed 
to set for 30 minutes and the cassette was then clamped into the XCell SureLockTM Mini-
Cell. A 1 x TBE running buffer was applied to the tank and after removing the comb the gel 
was pre-run at 20 Volts for 30 minutes to heat. The RNA samples were diluted to 100 ng in 
6 μl of 1 x loading dye and heated to 95o C for 5 minutes prior to loading on to the prepared 
gel. The gel was run at 200 V for 90 minutes and removed from the cast for staining using 
SYBR GoldTM (Invitrogen). Gels were visualised under a Syngene UV transilluminator. For 
RNA fluorescently labelled with Cy-3 UTP, samples were diluted to 50 ng in 6 μl of 10% (v/v) 
glycerol without loading dye. Gels containing Cy3-labelled RNA were visualised under in a 
Fuji FLA5000 phosphorimager. See Appendix 13 for 8% (w/v) denaturing Urea-PAGE gel of 
IVT products for the DNA templates for the mRNA targets and GcvB-MG. 
 
Table 2.6.  
Denaturing urea-PAGE gel reagents (National Diagnostics). 
 
Component Volume 
UreaGel concentrate 3.2 ml 
UreaGel diluent 5.8 ml 
UreaGel buffer 1 ml 
TEMED 4 l 
10 % (w/v) APS 80 l 
 
 
2.2.4. DNA in vitro transcription template array preparation  
 
2.2.4.1. Streptavidin coating of DNA template slide 
 
Nexterion® Slide H (Schott Corporation) slides were stored in the -20oC freezer 
aliquoted inside a cartridge prior to experiment to avoid surfaces damaging. Slides were 
thawed at room temperature for 30 minutes prior to use. SA was diluted: 80 µl (1 µM) in 1 




Slides were checked for dust and debris prior to SA coating and nitrogen gas was used 
to remove the debris. A volume of 80 µl of the diluted SA was pipetted in the middle of the 
slide, which was then covered with liftaslips. The slides were then incubated at 37o C for 60 
minutes in a humidified chamber, consisting of a Petri dish with 30 ml of Milli-Q dH2O, to 
avoid drying the slide. After incubation was finalised, slides were submersed in amine 
blocking buffer (Appendix 14) for 5 minutes. The slides were washed to remove unbound 
streptavidin in the following consecutive steps:  
 
- Submersed in 1 x PBST buffer for 5 minutes 
- Extra wash in Milli-Q dH2O for 30 seconds 
- Final dip into Milli-Q dH2O  
 
The slide washing steps were performed in 45 ml volumes in Falcon tubes on a roller 
mill. The slides were then transferred to Falcon tubes to be dried in the centrifuge at 1000 
rpm for 30 seconds. The slides were ready for the DNA immobilisation step. 
 
2.2.4.2. DNA in vitro transcription template immobilisation on the slide  
 
Immobilisation of DNA IVT templates on the slide was performed either manually 
by pipetting the sample onto the slide or by high throughput spotting using the QArray2 
arrayer robot. The slide coated for DNA immobilisation (1 µM SA) was placed into the robot 
in a slide slot within a humidified chamber (55%). The samples containing the DNA IVT 
templated were transferred into wells in a 384-wells cassette. Each well containing a given 
DNA IVT template was annotated to be identified by the arrayer robot and later matched 
to the correspondent spot after fluorescence visualisation under the laser scanner. The 
typical concentration for the DNA spotting was between 5 nM to 450 nM per spot, and 130 
spots required 1l of DNA sample under optimal humidity with a minimum of 5 l by well 
to avoid sample removal by evaporation. Once spotting was finished, the slides were 
immediately transferred to the 37oC incubator and left for 20 minutes in a humidified 
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chamber. The slides were washed to remove unbound DNA IVT templates in the following 
the same protocol from the previous SA coating step:  
 
- Submersed in 1 x PBST buffer for 5 minutes 
- Extra wash in Milli-Q dH2O for 30 seconds 
- Final dip into Milli-Q dH2O  
 
After the washing steps the slides were dried in the centrifuge at 1000 rpm for 30 seconds 
and were ready to be used for generating RNA arrays following in vitro transcription (IVT). 
 
2.2.4.3. Co-spotting two DNA in vitro transcription templates  
 
The same method as described in 2.2.4.2 was carried out, except mixtures of two 
DNA IVT templates were prepared for spotting together. In these situations, it was usual 
for only one of the DNA templates to be fluorescently labelled.  
 
2.2.4.4. Visualisation of the DNA in vitro transcription template array slide 
 
DNA in vitro transcription template arrays were scanned using a GenePix 4300A 
microarray scanner with integrated GenePix Pro 7 image analysis software (Molecular 
Devices). The templates commonly incorporated three choices of dye: Dy-588, Dy-532 and 
Dy-647 fluorescent-label which was visualised with a microarray scanner using an 
excitation wavelength of 488 nm (Standard Blue filter), 532 nm (Standard Green filter) and 
635 nm (Standard Red filter), respectively. The fluorescence intensity of each spot on the 






2.2.5. RNA capture slide preparation and RNA array generation by IVT and in situ capture 
 
2.2.5.1. Streptavidin coating of RNA capture slide 
 
The same method as described in section 2.2.4.1 was carried out, except the SA 
concentration used was changed to 16.6 µM to create an RNA capture slide.  
 
2.2.5.2. In vitro transcription and in situ RNA capture 
 
In this step, the DNA IVT template array slide and RNA capture slide were 
‘sandwiched’ together (Figure 2.1, D) with IVT mixture (Table 2.7) in the middle. The DNA 
IVT templates on the DNA template array slide were used to produce RNA which was then 
captured directly on the RNA capture slide. In terms of the set-up, the IVT mixture (25 l) 
was pipetted onto the RNA capture slide (Figure 2.7). This avoids starting the IVT reaction 
prior to the ‘sandwich’ being formed; something which would occur had the IVT mixture 
been put on the DNA slide prior to ‘sandwich’ arrangement set up. The IVT mixture was 
spread throughout the entire RNA capture slide area and the ‘sandwich’ created. Once 
‘sandwiched’, the slides were immediately transferred to the 37oC incubator for 20 minutes 
in a humidified chamber created with a Petri dish and 30 ml of Milli-Q dH2O. 
 
Table 2.7.  
IVT reaction mixture for the IVT step in RNA array method (MegaScript T7). 
 
Component Initial [] Final [] Volume (l) 
Nuclease-free dH2O - - To 25 L 
T7 Reaction Buffer 10 x 1x 2 
rNTPs 10 mM 1 mM 2 





Figure 2.7. Illustration of the setup of the in vitro transcription and in situ RNA capture step. A) Assembly of the DNA in 
vitro transcription template array – in vitro transcription reagent mix (IVT mix) – RNA capture surface “sandwich”. The 
RNA capture surface is position surface-side up. In vitro transcription reagent mix is pipetted onto the RNA capture surface 
and the DNA in vitro transcription template array, array-side down, is carefully lowered onto the RNA capture surface to 
complete the “sandwich” assembly. (B) The “sandwich” assembly is incubated at 37C for 20 minutes during which time 
RNA is synthesised by in vitro transcription and captured in situ by the RNA capture surface. (C) The DNA in vitro 
transcription template array and the newly generated corresponding functional-RNA array are then carefully separated.     
 
At the end of the IVT step, the slides were separated in Milli-Q dH2O and 
immediately washed as follow: 
 
- Submersed in 1 x PBST buffer for 5 minutes 
- Extra wash in Milli-Q dH2O for 30 seconds 
- Final dip into Milli-Q dH2O  
 
After the washing steps the slides were dried in the centrifuge at 1000 rpm for 30 
seconds and the transcribed unlabelled RNA immobilised in the RNA slide was ready to be 
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investigated via the RNA probing steps (section 2.2.6). Please note that for co-spotted DNA 
template array slides, the two RNAs of interest, considered as potential binding partners of 
each other, would be transcribed at the same time. The pair of RNAs typically included a 
target mRNA, appended with an SA aptamer which would surface-immobilise to the RNA 
capture slide, and a potential partner sRNA lacking the SA aptamer. Thus, the transcribed 
partner would only be identified on the RNA array via an interaction with its target RNA, 
which was surface-immobilised to the RNA capture slide. This method was developed as 
part of this work, so please see Chapter 4 for more details.  
 
2.2.5.3. Disruption assay  
 
The same IVT method as described in 2.2.5.2 was used, specifically for co-spotted 
DNA IVT template arrays containing pairs of RNAs of interest known to interact with each 
other. Inclusion of a disrupting nucleic acid mimic (NAM) molecule (i.e., PNA) within the 
IVT mixture therefore sought to explore interaction disruption. This method was developed 
as part of this work, so please see Chapter 5 for more details.  
 
2.2.6. RNA array probing and visualisation to assess RNA capture on the RNA array 
 
2.2.6.1. RNA Probing Step 
 
In the probing, the immobilised RNA was detected by hybridisation with a short 
fluorescently labelled single stranded DNA probe specifically designed to base pair to the 
SA-linker region. A probing mixture, containing the probe, was used to form a ‘probing 
sandwich’ between the RNA array slide of captured RNAs and a liftaslip. The probe was 
diluted in 2 x SSC with 0.1% (w/v) SDS (Appendix 14) to the desired concentration, usually 
500 nM. The probing sandwich was then transferred to the humidified chamber and 
incubated at room temperature protected from light for 30 minutes. At the end of the 
  
 83 
probing step, the liftaslip was removed from the RNA array slide, which was then 
transferred to a Falcon tube for the washing step as follow:  
 
- Submersed in 1 x PBST buffer for 5 minutes 
- Extra wash in Milli-Q dH2O for 30 seconds 
- Final dip into Milli-Q dH2O  
 
After the washing steps the RNA slide was dried in the centrifuge at 1000 rpm for 30 
seconds and then visualised. The process is illustrated schematically in Figure 2.8. 
 
Figure 2.8. Schematic of the RNA array probing and visualisation step to assess RNA capture. A solution of fluorescently 
labelled SA-linker probe is ‘sandwiched’ between the RNA array and a liftaslip and incubated. The probe binds to the SA-
linker region of the immobilised RNA on the array. Following washing the RNA array is visualised and the fluorescence of 
the bound-linker probe quantified; indicative of the RNA captured on the RNA array.   
 
2.2.6.2. RNA visualization and data analysis 
 
The probed RNA array from step 2.2.6.1. was scanned using a GenePix 4300A 
microarray scanner with integrated GenePix Pro 7 image analysis software (Molecular 
Devices). To detect bound Alexa647-labelled SA-linker probe, the RNA array was visualised 
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using an excitation wavelength of 635 nm and a Standard Red emission filter. The 
fluorescence intensity of each spot on the array was quantified using the integrated image 
analysis software on the microarray scanner. 
 
2.2.7. RNA array probing and visualisation for interaction/disruption assays  
 
2.2.7.1. Probing with fluorescently labelled RNA generated by IVT  
 
Fluorescently labelled RNA was produced by IVT incorporating a Cyanine 3 (Cy3) 
uridine-5'-triphosphate (UTP) (GE) in the IVT reaction described in section 2.2.3.5. The 
reaction volume was altered to include a 0.5 mM final concentration of Cy3 UTP (Table 2.8). 
All fluorescently labelled molecules were protected from light as much as possible for 
example by using amber tubes.  
 
Table 2.8.  
IVT reaction mix for making CY3-labelled RNAs (MegaScript T7 and GE). 
 
Component Initial [] Final [] Volume (l) 
Nuclease-free dH2O - - To 20 L 
T7 Reaction Buffer 10 x 1x 2 
DNA IVT Template - 200 ng - 
rNTPs (each - UTP) 10 mM 1 mM 2 
Cy3 UTP 5 mM 0.5 mM 2 
RNA Pol T7 10 x 1x 2 
 
Purification of the labelled RNA was carried out using the MegaClear (Invitrogen) 
spin columns as described in the standard protocol and eluted in 15 L. Samples were run 
on a 6% (w/v) denaturing gel using gel loading dye from MegaScript T7 Ambion kit and a 
RiboRuler Low Range RNA Ladder (both from Thermo Fisher Scientific) as a sequence size 
marker. The concentration of the purified samples was verified using the microvolume UV-
VIS NanoDrop 2000 spectrophotometer, and their size and quality confirmed by gel 
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electrophoresis run on a suitable polyacrylamide gel (method described in section 2.2.7.2). 
See Appendix 11 for gel of RNA samples for GcvB-Cy3. Probing of the RNA array with the 
labelled RNA (GcvB-Cy3) was carried out as described for the in 2.2.6, except that 500 nM 
labelled RNA was used for the probing. 
 
2.2.7.2. GAG-linker probe for detecting GcvB bound to target mRNA 
 
RNA arrays produced following co-spotting experiments potentially include two 
RNAs bound to the surface following being transcribed at the same time. This usually 
included a target mRNA surface-immobilised via an appended SA aptamer, and its sRNA 
binding partner. Detection of the binding partner sRNA involved probing with a 
fluorescently labelled antisense ssDNA probe specific for the sRNA; in this case an 
Alexa488-labelled GAG-linker probe designed to bind to a modified linker region of GvcB 
(GcvB-MG). Probing of the RNA array with the GcvB GAG-linker probe was carried out as 
described for the in 1.2.6.  
 
2.2.7.3. Visualisation and analysis 
 
Following a probing step, the RNA slide was visualised using a GenePix 4300A slide 
scanner (Molecular Devices) using three different wavelengths (488, 532 and 635 nm). For 
visualising bound GcvB-Cy3, an excitation wavelength of 532 nm and a Standard Green 
emission filter were used. For visualising bound Alexa488-GAG-linker probe an excitation 
wavelength of 488 nm and a Standard Blue emission filter were used. The photo multiplier 
tube (PMT) was adjusted as required to ensure the highest signal possible while preventing 
signal saturation. The platform integrated software GenePix was used to process the 









Biorender is a widely used web-based tool specifically created for medical and life 
science illustration, which allows the user to create high quality diagrams. It contains a 
catalogue of templates and icons commonly used by researchers and life scientists, which 
have been incorporated as scalable icons in the figures. Biorender has been used to 
generate all figures in this thesis. Biorender is available at https://app.biorender.com 
  
2.3.2. Microsoft Excel  
 
Microsoft Excel is a software package for analysing spreadsheets of data. It was 
used throughout this work to analyse data and create graphs of the findings. 
 
2.3.3. PNA design 
 
PNA molecule used in Chapter 5 was designed using the guidelines in the PNA Tool 









Chapter 3  
 
3. In silico studies: Identification of novel trans-acting sRNAs 




The strategy used in this project was organised in two parts, specifically into in silico 
studies (this Chapter) and in vitro studies; with the in vitro studies being subdivided into 
interaction (Chapter 4) and disruption studies (Chapter 5). Interaction studies heavily rely 
on accurate sequences since nucleic acids use base-pairing in designated regions of their 
sequences to bind onto each other.  
Although the APP serovar 8 MIDG2331 genome has been previously assembled, its 
transcriptome has not been publicly characterised, concealing information on RNA features 
essential to this work, such as the precise sequence boundaries of the predicted novel 
sRNAs and the untranslated region of their partners mRNAs. Current sRNA prediction tools 
identify cis and trans-acting sRNAs alike, but this study focused on trans-acting sRNAs, to 
investigate the versatility of imperfect base-paring interactions between one sRNA and a 
pool of mRNA genes from a distant locus. 
For this reason, the first part of the project focussed on developing a concise in silico 
pipeline to increase prediction accuracy of trans-acting sRNAs in APP serovar 8 from a 
database of computationally predicted novel sRNAs provided by collaborators. The pipeline 
utilised RNA-seq data and homology studies to narrow the list of sRNA candidates, before 
proceeding to the prediction of their mRNA partners.  
The final output, a single APP serovar 8 novel sRNA candidate and its mRNA 
partners, was then tested in an experimental interaction and disruption validation pipeline. 
The sRNA candidate and mRNA target sequences were used to design DNA templates, 
which were then synthetically produced for the in vitro studies, which takes advantage of 
the novel RNA Array technology, developed within the Callaghan Group at the University 
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of Portsmouth. The in vitro studies of this project are described in Chapters 4 and 5, but a 
brief description of both the in silico and in vitro approaches, and how they connect to 




Figure 3.1. Approach to studying novel sRNAs and their putative mRNA partners. 1) The first part of the strategy utilises a combination of bioinformatics methods to identify, predict and 
analyse novel sRNAs and their putative mRNA targets. The sequences of the selected sRNA-mRNA pairs are used to design and synthetise the molecules probed in the second part of the strategy, 
including sRNAs, mRNAs and inhibitory molecules. 2) An RNA array method is established to validate the predicted sRNA-mRNA interactions and exploit their disruption in vitro using an inhibitory 
molecule, as a means of proof of concept for the development of a novel antibacterial therapeutic approach.
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3.1.1. Novel sRNAs candidates in APP serovar 8 
 
The genome of a clinical isolate APP serovar 8 MIDG2331 was annotated and 
published in 2016 by collaborators from Imperial College London and University of Viçosa, 
Brazil (Bossé et al., 2016). The group commissioned the RNA-seq data from the APP species 
used in this study and provided a comprehensive database of predicted sRNA candidates 
for MIDG2331, named ICL_UoV_2016 in this manuscript (Appendix 1). Details of RNA-seq 
data such as full QC report, TPM values and feature counts are reported in Appendix 2.  
ICL_UoV_2016 was created using methods established by the collaborators 
previous studies on APP serovar 5 described in section 1.4 of this manuscript (Rossi et al., 
2016), and by visual inspection of the RNA-seq data graphic representation in the RNA-seq 
visualisation software Artemis (Carver et al., 2012) by Dr Janine Bossé, a collaborator at 
Imperial College London. The sRNA candidates added by visual inspection were not 
identified by the available prediction tools at the time of this analysis, and apart for being 
expressed in intergenic regions (IGRs) in RNA-seq experiments, these transcripts displayed 
sRNA characteristics such as promoters, terminators and 3’ Poly-U tail.  
Computationally predicted sRNAs in APP serovar 8 MIDG2331 were obtained using 
the strategy from previous studies on APP serovar 5 L20 (Rossi et al., 2016) and were named 
ARRC## (APP Regulatory RNA Candidate and a two-digit number), and the sRNAs identified 
by RNA-seq data from co-immunoprecipitation of RNAs with Hfq (Co-IP) were labelled 
RNA## by the collaborators. However, sRNA candidates spotted by RNA-seq visual 
inspection by Dr Janine Bossé were designated the initials JB followed by a number (JB_##) 
in this thesis. Both, RNA-seq and sRNA prediction data for MIDG2331 were unpublished 








3.1.2. A pipeline to identify trans-acting sRNA candidates and their putative mRNA targets  
 
The ICL_UoV_2016 database was particularly extensive for the purpose of this 
project, and initially required an analysis to create a reduced list of sRNA candidates and a 
set of its predicted mRNA targets for interaction testing using the RNA array technology. 
Thus, a pipeline (Figure 3.2) consisting of computational approaches was created with 
three specific and sequential objectives; to use APP genomic, and transcriptome data 
(Figure 3.2 - A) to constrict ICL_UoV_2016 to a refined selection of predicted sRNAs (P-
sRNAs) that exhibit structural and regulatory elements present in characterised trans-
acting sRNAs (Figure 3.2 - B); to select a set of predicted mRNA targets for the chosen P-
sRNAs using predictions tools combined with expression information from RNA-seq data 
(Figure 3.2 - C); to select sRNA candidates whose mRNA partners are involved in metabolic 
pathways possibly supporting or linked to known virulence factors in APP (Figure 3.2 - D); 
and finally, to use the output of this pipeline to design and synthetically produce DNA 
templates required for the RNA array relevant to the selected sRNA and mRNA targets to 
be investigated in the interaction studies, and to design the inhibitory molecules used in 






Figure 3.2. Bioinformatics pipeline. A computational approach to identify novel trans-acting sRNA candidates and their 
putative mRNA partners linked to virulence in APP. The pipeline consists of a selection of genomic tools to identify which 
predicted sRNA-mRNA pairs are applicable candidates to be investigated using the RNA array. The steps and results for 
each section of the pipeline are describe in the following sections.  
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3.2. Selecting novel trans-acting sRNA candidates in APP serovar 8 
 
The workflow was initiated with the input data from the above-mentioned 
collaborators (Figure 3.2. - A). The aim of the analysis set in Figure 3.2. – B was to scrutinise 
the initial database and to select sRNA candidates displaying all the elements established 
as features of trans-acting sRNAs necessary for this research. To achieve this, one of the 
strategies was to select predicted sRNAs displaying consistent transcriptional features, and 
to remove those displaying elements common in cis-acting sRNAs, such as antisense sRNAs 
and riboswitches. For this reason, a new set of quantitative and binary parameters was 
added to the ICL_UoV_2016 database, making it possible to filter them in or out, and select 
only predicted sRNAs with trans-acting characteristics and regular transcriptional signals.  
The initial database contained 93 sequences from APP serovar 8 predicted as sRNA 
candidates, and among them, 22 sequences were computationally identified by Rfam 
(Nawrocki et al., 2014) while 71 were not previously annotated in the MIDG2331 genome. 
Those that were not already annotated in the MIDG2331 RefSeq file were manually added, 
and a re-annotated RefSeq draft file (Appendix 2) was created for the purpose of this study 
only. All 93 sequences showed positive expression levels in wild type and anaerobic growth 
conditions. However, the final number of predicted sRNA candidates decreased to 27 after 
selecting for parameters based on sequence conservation and transcriptional signals 
consistent with trans-acting sRNAs in the first section of the pipeline. A further selection 
for sRNAs identified in Co-IP RNA-seq data showed that only 13 sRNAs were detected. From 
these, only 9 sRNAs showed full sequence conservation in APP serovar 5 L20.  
Biophysical features of each of the final 9 sRNAs were analysed by secondary 
structure prediction analysis (section 3.2.3), and the draft RefSeq was used to quantify 
expression levels of these sRNAs in different growth conditions (graphically represented in 
section 3.2.4). The values for the parameters set for sRNA type, transcription features, 
expression levels and structural information of these 9 sRNAs was stored in a database 
named UoP_ICL_UoV_2020 (Appendix 2). Finally, because the RNA array is a new 
technology, only one putative sRNA candidate was initially selected from the final database 
to validate the technical strategy and establish the system to create a standardised and 
universal interaction and disruption validation pipeline to study novel sRNAs. 
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3.2.1. Annexing parameters to the initial database of novel sRNAs candidates 
 
The ICL_UoV_2016 database already contained binary data related to the 
expression patterns of its predicted sRNAs (P-sRNAs), and qualitative and quantitative 
information on transcription signal elements including promoter region, transcription start 
site (TSS), transcription termination and 3’ Poly-U tail, among other essential fields such as 
transcript ID, name, size, function, locus tag, location in the genome, sequence and 
experimental validation by the collaborators in previous studies. Table 3.1 below was 
created to describe the original (black) and added (red) parameters, and to establish the 
expected value for each parameter used to filter the database. While some parameters 
depend on prediction tools that use genomic sequence such as OperonMapper (Taboada 
et al., 2018), others are only identifiable using RNA-seq data combined with R pipelines and 
visualisation tools. This is the case for the first two parameters in the table, which were 
used as a guide to detect transcripts during visual inspection by collaborators. 
 
The table contains a column for the parameter measured (newly added parameters in red), a description of that 
parameter, an expected binary value (yes or no) to filter the database and increase trans-acting sRNA prediction accuracy, 
and the software used to process the data from RNA-seq or APP serovar 8 sequences.  
 
Parameter 1 (RNA-seq) unconditionally required that P-sRNAs in the original 
database ICL_UoV_2016 were expressed within intergenic regions (IGRs) of the annotated 
genome in at least one growth condition of the RNA-seq experiments. This allowed P-sRNAs 
predicted by computational approaches presenting no expression to be negatively flagged 
Table 3.1. 
List of parameters used to select trans-acting novel sRNAs candidates for this study. 
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and removed from the list. All 93 P-sRNAs were expressed in both, wild type and anaerobic 
conditions. Parameter 2 (Co-IP) disclosed whether a P-sRNA is present in the Hfq Flag (Co-
IP) experiments, using featureCounts from R Bioconductor. P-sRNAs showing reads >10 
(arbitrary minimum) had their expected value set to a non-mandatory binary positive. This 
is because a great number of known sRNAs show no interaction with Hfq (Livny, 2012), 
meaning that a portion of sRNA candidates would be excluded if this parameter is set to a 
mandatory positive, where only Hfq binding P-sRNAs would be considered. 
The values of parameters 3 to 5 are based on RNA-seq data combined with ORF and 
operon prediction tools. These parameters were added to the original database, and 
although they cannot accurately predict the category of a sRNA on their own, the 
expression patterns that they represent may resemble those of cis-acting sRNAs or patterns 
that are exceptionally inconclusive to be considered in this study. A general overview of 
how expression patterns of cis and trans-acting may be graphically represented is 
illustrated in Figure 3.3. 
 
Figure 3.3. Expression patterns of cis and trans-encoding sRNAs. A variety of visualisation software and UTR finding 
scripts use transcript reads from RNA-seq data to represent expression boundaries. In this figure, transcript expression is 
represented in blue and green shaded areas and the boundaries may indicate signals such as a transcription start site 
(TSS). A) Genes for cis-encoded sRNAs are usually located in the opposite strand of their target gene, overlapping its 5’ 
UTR and ORF. B) Riboswitches are situated on the 5’ UTR of the gene that they regulate. C) Trans-encoded sRNA genes 
occupy a different location from their targets and although their expression pattern may conflict with an unrelated gene, 
transcription signals such as transcription start site and Poly-U are separated from neighbouring genes (Li et al.,2012).  
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Parameter 3 (ORF) enquires whether a P-sRNA expression overlaps the ORF of a 
gene on the opposite strand, a characteristic of cis-acting antisense sRNAs, and because 
the aim is to identify trans-acting sRNAs this value was set to mandatory negative. Some 
parameters were set to determine if the expression pattern of a P-sRNA is noticeably 
conflicting to be considered. This may happen because the P-sRNA is located within an 
operon (parameter 4), where expression boundaries of the transcripts are indistinguishable 
between cistronic UTR and P-sRNA. Parameter 5 (UTR) selects for P-sRNAs with expression 
patterns that overlap the 5’ UTR of a gene on the same strand, a trait observed in 
riboswitches. However, some P-sRNAs may be located downstream the 5’ UTR of a gene 
and display undeniable independent start of transcription (TSS) and expression pattern. For 
the reasons presented, values for parameter 4 to 5 were set to mandatory negative. 
Parameters 6 to 10 contained qualitative and quantitative information in 
ICL_UoV_2016 which were converted to binary values to represent the presence of 
transcription signals (Promoter, TSS, Terminator and Poly-U), and sequence conservation 
in other APP strains and species (Homology). Although most information was created by 
collaborators, these values were updated in this research. Promoter and Rho-independent 
terminator predictions remained the same, but the terminator parameter was set as non-
mandatory, as some P-sRNAs may present a stem loop at the 3’ end not detected by 
TransTerm. A poly-uracil tail (Poly-U) is a sequence of a minimum of three uracil residues 
that follow a stable stem-loop at the 3’ end and is considered an important regulatory signal 
for transcription termination (Wilson & Von Hippel, 1995), and thus considered mandatory 
in this work.  
Values for TSS included extra manual curation of locally enriched transcript 
expression by identifying regions where frequency of reads dropped or surged drastically. 
Graphically, these regions are similar to expression cliffs illustrated in Figure 3.3 and their 
patterns are calculated using BAM files generated from RNA-seq experiments. Finally, the 
homology parameter was set to mandatory conservation to filter the P-sRNA list, as trans-
acting sRNAs are highly conserved across the different strains of APP. More specifically, 
only P-sRNAs showing > 90% sequence similarity to the APP serovar 5 L20 strain were 
selected for further studies, because mRNA target prediction tools such as TargetRNA2 and 
other genomic software used in this study consistently contain the genome for this strain. 
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3.2.2. Selecting plausible sRNAs candidates presenting trans-encoding features  
 
The parameters were organised in a graph (Figure 3.4), which shows the ratio of the 
binary values for each, and the decision flow taken to narrow the initial database, resulting 
in a reduced selection of 9 predicted novel trans-acting sRNA candidates. All 9 P-sRNA 
candidates presented the expected values set in Table 3.1, including RNA01, RNA03, RNA05 
(computationally predicted ARRC01 in APP serovar 5 L20), RNA16, RNA17, RNA19, RNA20, 
JB_04 and JB_39, which were further analysed for insights on predicted secondary 
structure regulatory elements and transcript expression levels in the next sections.  
 
Figure 3.4. Distribution of binary values by parameter and decision flow. The database started with 93 P-sRNAs detected 
by prediction tools and RNA-seq. All P-sRNAs displaying cis-encoding features were removed from the list in step 1, and 
step 2 filtered for P-sRNAs presenting transcriptional elements, leaving 27 candidates. Although Hfq binding and 
sequence conservation parameters were not a mandatory characteristic of trans-acting sRNAs, these parameters were 
relevant to lessen the number of candidates for this study in step 3 and 4, thus only candidates with positive values were 




3.2.3. Structural analysis of the selected sRNA candidates 
 
When investigating RNA-RNA interactions, the structures established during and 
after RNA transcription deserves special attention, since they are directly involved in the 
biological processes regulated by non-coding sRNAs. Although the geometry associated 
with these structures gives clues about the interplay between these molecules, including 
sRNA-mRNA interactions, the RNA interactome is generally not well characterised 
(reviewed in Zampetaki et al., 2018). Palindromic sequences are a common feature found 
in sRNAs. These sequences form double stranded regions arranged in stem-loops along the 
sRNA, making it more structurally compact and less prone to degradation by RNases 
(Zundel et al., 2009; reviewed in Deutscher, 2015). Secondary structure prediction (Figure 
3.5) by RNAFold (Gruber et al., 2008) shows that all of the 9 P-sRNAs may form at least 2 
stem-loops and, apart from JB_04, display a stem-loop at the 3’ end, with high base-pairing 
probability (indicated with red arrows in Figure 3.5), demonstrating the presence of a 
possible transcriptional termination signal. The predicted Gibbs free energy change (ΔG) 
showed a negative value for all predicted secondary structures in RNAFold, and 
RNA05/ARRC01 and JB_39 revealed the lowest values suggesting the most stable structure 
in comparison with the other sRNAs.  
The segments of sequence in sRNAs that interact with mRNA targets through 
imperfect base-paring are usually located in single strand regions and referred as seed 
regions or simply interaction regions. This element is computationally predictable with a 
variety of tools including TargetRNA2 and IntaRNA. Target prediction of the P-sRNAs by 
TargetRNA2 identified preferable interaction regions in all of the 9 P-sRNAs, which are 
indicated with green arrows in Figure 3.5. However, the sRNAs RNA03 and RNA16 revealed 
their seed region in double stranded areas of predicted stem-loops with low base-pair 
probability. Although analysis of structural elements is based on predictions rather than 
experimental results, it offers important insights to support an informed selection of an 
sRNA candidate. P-sRNAs with a predicted stable 3’ stem-loop and with its preferred seed 





Figure 3.5. Structural analysis of trans-acting sRNA candidates. The predicted secondary structures of the selected sRNA 
candidates by RNAFold forecast the formation of stem-loops in all of them. A red arrow indicates the presence of a 3’ end 
stem-loop with a high base-pairing probability in a coloured gradient scale (0 < p > 1), where a pair of sites with 100% 
canonical pairs is coloured dark red. A green arrow indicates the TargetRNA2-identified preferable target interaction 
region. All structures present a negative ΔG representing spontaneous formation at 37oC. Neighbouring genes are 
represented in black arrows which indicates their location in either, forward or reverse strand in relation to the sRNA. 




3.2.4. RefSeq re-annotation and expression analysis of the selected sRNAs 
 
The sequence information of the selected sRNAs such as gene name and 
boundaries, were manually added to the RefSeq file MIDG2331 and saved as a draft. This 
made it possible to quantify the expression levels of these putative sRNAs, which were 
previously invisible to expression quantification tools such as featureCounts (Liao et al., 
2014) in Bioconductor (Gentleman et al., 2004) and BEDtools (Quinlan & Hall, 2010), which 
counts gene reads generated by RNA-seq experiments that are mapped to the associated 
ORF and non-coding RNA (ncRNA) features. RNA-seq experiments were commissioned and 
planned by collaborators (details on methods section 2.1). Because the main goal of these 
experiments was to investigate novel sRNAs in APP serovar 8 MIDG2331, the technical 
repeats for each growth condition were pooled in one sample prior to sequencing. This is 
a common procedure utilised to reduce costs and optimise statistical outputs by obtaining 
a higher RNA quantity, which aids detection of smaller transcript sequences, and by 
averaging the transcript levels across samples (Auer & Doerge, 2010; Assefa et al., 2020). 
However, sample pooling presents risk of bias, as it is not possible to verify the exact total 
amount of RNA from each pooled sample or whether they contributed equally to the final 
pool (Rajkumar et al., 2015; Conesa et al., 2016).  
Another obstacle is related to differential expression analysis pipelines, which 
usually require technical repeats to present a more accurate picture to establish expression 
levels. For this reason and for the purpose of this study only, RNA-seq analysis focussed on 
two factors from RNA-seq data; first to verify whether these putative sRNAs were 
expressed by examining their transcript count reads when APP serovar 8 MIDG2331 is 
cultivated in aerobic and anaerobic growth conditions, and from MIDG2331 Hfq Co-IP 
experiments. Second, to analyse the expression ratio of the predicted sRNA transcripts of 
MIDG2331 grown in a specific condition in comparison to MIDG2331 aerobically grown in 
Brain, Heart Infusion (BHI) broth or BHI Agar plate media, named as wild type (WT for 
reference in this thesis). Expression ratio was normalised (log2ratio) and graphically 





Figure 3.6. Relative transcript expression of the predicted trans-acting sRNAs. Transcript levels of the selected sRNA 
candidates were quantified in all growth conditions considered in this study (Table 3.1), and their transcript yield relative 
to their WT in broth or Agar plate media was calculated and normalised (Ratio2log) for all 9 P-sRNAs. Expression levels of 
MIDG2331 wild type (WT) in anaerobic (ANA) BHI Agar plate was compared against WT in aerobic growth condition in 
Agar plate (blue bars). MIDG2331 WT with added AMP (red bars) and TY (orange bars) experiments were carried out in 
BHI broth in aerobic growth conditions and both compared to MIDG2331 WT grown in aerobic BHI broth. The yield of 
MIDG2331 Hfq knockout (DHfq) in BHI broth (green bars) was compared against MIDG2331 WT grown in BHI broth. 
Finally, transcript ratio of MIDG2331 WT grown in porcine serum (PS) was compared against MIDG2331 WT grown in 
aerobic BHI broth (purple bars). 
 
 Bacterial RNA-seq experiments benefit from different growth and media conditions 
which simulate, as close as possible, the different environments in which pathogenic 
bacteria survive and thrive in the host to become virulent. APP is a facultative anaerobic 
pathogen, and RNA-seq experiments carried out in anaerobic growth conditions offers 
insights on which sRNA transcripts are present when APP cells are free of molecular oxygen 
in relation to aerobic environments. The results showed that compared to aerobic growth 
conditions, most P-sRNAs have negative or very low transcript yield when MIDG2331 WT 




Many trans-acting sRNAs interact with the facilitator protein Hfq, that may protect 
sRNAs from ribonucleases cleavage. However, Hfq may induce cleavage of some sRNAs 
when paired with their mRNA partners (Massé et al., 2003). Thus, MIDG2331 Hfq-knockout 
experiments were undertaken to investigate how the number of sRNA transcripts may be 
altered without the presence of Hfq. Delta-Hfq MIDG2331 grown in aerobic BHI broth 
shows a positive fold in transcript reads for the predicted sRNAs, with RNA01, RNA16, 
RNA19 and RNA20 displaying an even higher yield (~> +2.0-fold).  
When grown in selective media, with added antibiotics ampicillin (AMP) and tylosin 
(TY), all 9 P-sRNAs have a low transcript ratio output (~< 0.5-fold). This result may suggest 
a lower total RNA extraction from AMP and TY samples due to antibiotic activity affecting 
bacterial cell growth, or/and lower expression/high degradation of these P-sRNA 
transcripts. In comparison to added antibiotic media, a much higher change in transcript 
yield (~> 2.0-fold) appears when MIDG2331 WT is grown in aerobic porcine serum media, 
with exception of RNA03 and RNA20 (~< 0.5-fold). The choice of porcine serum media for 
RNA-seq experiments is an attempt to simulate the physiological conditions from host cells 
from pig respiratory organs, especially regarding levels of nutrient availability during 
virulence stages. The P-sRNA RNA05/ARRC01 displayed the higher transcript fold (> +6.0-
fold) in porcine serum growth media in comparison to all other sRNAs in any condition. 
Except for RNA01, RNA03 and RNA19, sRNA transcript yields in anaerobic and porcine 
serum display opposite fold directions.  
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3.2.5. A refined table of trans-acting sRNA candidates for APP serovar 8 
 
Once the predicted sRNAs had been scrutinised, information on transcript expression levels and secondary structure prediction was 
added to the final database UoP_ICL_UoV_2020, and a table with the 9 selected putative sRNAs for APP MIDG2331 was created (Table 3.2 
below). The bioinformatics pipeline part of the project strategy was designed to serve the interaction and validation pipeline for the RNA array 
by selecting only the most viable predicted trans-acting sRNAs. All the 9 P-sRNAs presented the characteristics desired for this project.   
Table 3.2.  
List of putative trans-acting sRNAs in APP serovar 8 MIDG2331 
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3.2.6. RNA05/ARRC01 is the global sRNA regulator GcvB 
 
Sequence identity studies of the selected putative sRNAs have been previously 
inferred by collaborators by homology search using BLASTn (Johnson et al., 2008). The 
sequence of RNA05/ARRC01 is homologous to the sRNA GcvB, a widely characterised trans-
acting sRNA in E. coli and Salmonella (Urbanowski et al, 2000; Sharma et al, 2007; 
Miyakoshi, 2015). However, the 8 remaining sRNAs are novel trans-acting sRNA candidates, 
not previously identified in other species. From this point in the thesis, the sequence for 
RNA05/ARRC01 is referred as the putative sRNA GcvB in APP serovar 8 MIDG2331 or simply 
APP8 GcvB for short. 
Genomic comparative studies are relevant to identify whether known interaction 
regions and structural conformation of an sRNA are conserved within and across the 
species, especially as the APP8 GcvB is yet to be characterised, thus this was carried out 
using APP8 GcvB DNA nucleotide sequence extracted from this study. The first homology 
investigation compared APP8 GcvB against a selected set of well characterised virulent 
bacteria (Appendix 3), including pathogenically relevant species within and outside the 
Pasteurellaceae family to study conservation along bacterial phylogeny. The sequences 
were then aligned using the web tool ClustalW (Goujon et al., 2010) and visualised and 
labelled with the program JalView (Waterhouse et al., 2009) as detailed in Figure 3.7. 
Residues matching 100% identity threshold were coloured purple in an attempt to identify 
sequence conservation shared by all species in the alignment. 
The two most significant conservation regions, labelled as CV1 (APP8 GcvB position 
78-90, sequence 5’ – UGUUGUGUUUGCA – 3’) and CV2 (APP8 GcvB position 137-146, 
sequence 5’ – ACUUCCUGUA – 3’), reveals a G/U-rich region characterised in previous 
studies of GcvB for Salmonella (Sharma et al., 2007) and other sRNAs (reviewed in 
Updegrove et al., 2015) that targets C/A-rich regions in the sequence of their mRNA targets. 
The alignment reveals that although APP8 GcvB has a low sequence similarity across 
Protobacteria (average < 40%), the highly conserved regions shared with these species may 




Figure 3.7. Sequence alignment of GcvB across Gram-negative species.  The putative APP8 GcvB was aligned with other 
virulent bacterial species including members of the Pasteurellaceae family. The species selected were abbreviated as the 
following: AP: Actinobacillus pleuropneumoniae, AS: Actinobacillus suis, PMP: Pasteurella multocida, MH: Mannheimia 
haemolytica, HPP: Haemophilus parasuis, EC: Escherichia coli, ST: Salmonella enterica, HI: Haemophilus influenza, HP: 
Haemophilus parainfluenzae, PM: Proteus mirabilis, YP: Yersinia pestis, and VC: Vibrio Cholerae. Residues with 100% 
similarity identity were coloured purple and their consensus highlighted at the bottom of the alignments. Two significant 
conservation regions were labelled in red as CV1 (AP position 79-91) and CV2 (AP position 138-147), and a third region 
covering a repetition of uracil (Poly-U) at the 3’ end was highlighted in blue. 
 
 All species display a varied size of Poly-U at the 3’ end, indicating that other 
structural elements may be conserved in APP8 GcvB, but not revealed in the alignment 
such as palindromic sequences forming stem-loops. For this reason, the characterised 
Salmonella GcvB was selected from the list of Gram-negative species to investigate 
whether these two conserved regions in APP8 GcvB (CV1 and CV2) were located in similar 
regulatory regions of Salmonella GcvB, and to investigate the location of predicted stem-
loops. The secondary structure of GcvB was predicted using RNAFold for both, APP8 and 
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Salmonella, and annotation of structural elements of GcvB in Salmonella, proposed by 
Sharma and colleagues (2007), were labelled in Figure 3.8. 
 
 
Figure 3.8. Predicted structural comparison of APP8 GcvB and Salmonella GcvB. Predicted stem-loops were highlighted 
by grey boxes and named SL 1 to 5. The two proposed interaction regions of Salmonella GcvB were indicated with a red 
line and labelled R1 and R2. These locations were matched in the APP8 GcvB to represent positional homology. The 
conserved sequences CV1 and CV2 were highlighted in bold purple and its location matched R1 and R2 for both sRNAs. 
 
Although the nucleotide sequences of these sRNAs have a similarity of around 60% 
only, both predicted structures presented folding similarities such as the presence of 5 
stem-loops (SL1 to SL5), each in approximately corresponding locations along the sRNA, 
including the termination region. The conserved regions in the alignment for Salmonella, 
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position 79-91 and position 138-147, consecutively overlapped regions that interact with 
target mRNAs (R1 and R2) as revealed in a study in Salmonella (Sharma et al., 2011). When 
compared to APP8 GcvB, R1 and R2 have approximate positions in the sRNA, which reveals 
a partially single stranded area, where the conserved regions overlap at 78-90 for R1 and 
137-148 for R2 in APP8 GcvB. Predicted structural comparison with Salmonella reveals that 
APP8 GcvB may hold functional elements that are conversed in well-characterised 
Protobacteria species and across the Pasteurellaceae family.  
The second alignment analysed how the sequence of APP8 GcvB is conserved across 
a selected set of APP strains (Appendix 4), and the output (Figure 3.9) revealed 100% 
conservation of key predicted functional elements such as G/U-rich sequences in the 
predicted interaction regions (R1 and R2) and a 3’ Poly-U of 6 uracil residues. The only 
discrepancies displayed in the compared serovars involved a two-nucleotide mismatch at 
positions 35 and 36 among serovars 1, 9 and 12, and a one-nucleotide disparity at position 
154 among all serovars except serovar 2. The alignment revealed that the putative GcvB is 












Figure 3.9. GcvB among different APP serovars. Alignments were performed using MIDG2331 GcvB sequence as a 
reference against a selection of 13 annotated strains of APP (1-4074, 2-4226, 3-JL03, 4-M62, 5b-L20, 6-Femo, 7-AP76, 9-
CVJ13261, 10-D13038, 11-56153, 12-1096 and 13-N273, accession numbers in Appendix 4) using the software JalView. 
The predicted interaction regions R1 and R2 are indicated in red, similarity identity coloured purple for 100% and 




3.2.7. Selecting the best sRNA candidate to set up the RNA array pipeline 
 
From all the sequences from the predicted sRNAs in Table 3.2, the only predicted 
sRNA presenting a homologous sequence to a well characterised trans-acting sRNAs was 
RNA05/ARRC01, the putative APP8 GcvB. The sequences relevant to the remaining 
predicted sRNAs were not previously annotated in other species, making them the perfect 
candidates for the RNA array validation pipeline. However, because the RNA array is a novel 
biotechnology, only one set of sRNA and its mRNA pairs was initially required to set up the 
system and create a standardised RNA array methodology for use as a pipeline to 
consistently predict, validate and disrupt sRNA-mRNA interactions of novel bacterial 
sRNAs. 
Thus, APP8 GcvB is the best initial candidate to set up the RNA array as it is not 
characterised in APP, but its sequence homology studies show that functional features are 
conserved in well characterised trans-acting sRNAs. This offers two advantages, including 
higher probability of predicting true mRNA partners, based on its predicted structural 
features such as target interaction region located in single strand area of the sRNA, and a 
better change of synthetically producing a stable molecule due to the presence of various 
palindromic sequences possibly forming structured stem-loops. Besides, the conservation 
of G/U-rich sequences are extremely important to predict mRNA partners in programs such 
as TargetRNA2 and IntaRNA, that uses structural profiling information for characterising 
sRNA-mRNA interactions rather than base-paring probability alone. For this reason, APP8 
GcvB was taken forward to the next set of analysis of mRNA target predictions.
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3.3. Prediction of mRNA targets of putative sRNA GcvB in APP 
 
3.3.1. Using TargetRNA2 to predict mRNA targets 
 
A search for potential mRNA targets of the putative sRNA GcvB in APP serovar 8 
MIDG2331 (APP8 GcvB) was performed using the program TargetRNA2 (Kery et al., 2014), 
which identifies the putative sRNA interaction regions in the target mRNA 5’ untranslated 
region (5’ UTR). However, genome MIDG2331 used in this study was not available in the 
TargetRNA2 databases during the course of this analysis. Instead, the algorithm was set to 
use ORFs annotated in the APP serovar 5 L20 genome as reference for APP mRNA partner 
searches. Putative GcvB sequences from both serovars have only a nucleotide mismatch at 
the 154 position, located outside its predicted seed regions (Figure 3.9), so unlikely to affect 
the prediction of its mRNA partners.  
In this analysis, only predicted interactions between GcvB and its putative mRNA 
targets with the lowest hybridisation energy and scoring p-value less or equal to 0.05 were 
considered (standard value in TargetRNA2), resulting in 50 GcvB target mRNA candidates 
with energy scores between -18.62 and -8.35 kcal/mol. From this selection, all predicted 
targets displaying ORFs matched to non-annotated or hypothetical proteins were removed 
from the list leaving a selection of 30 targets (Appendix 7). This decision was made to 
increase the likelihood to relate these targets to annotated metabolic pathways in genomic 
databases and, consequently, to link the predicted sRNA to a regulatory pathway in APP.  
 
3.3.2. Predicted interactome of putative targets  
 
The remaining 30 predicted targets of APP8 GcvB were compared against STRING 
databases (Snel et al., 2000; Jensen et al., 2009), using APP serovar 5 L20 genome for 
reference, to enquire whether their gene products share a function in similar metabolic 
pathways based on gene ontology (GO) terms. The output is illustrated in Figure 3.10 and 
enrichment values presented in the Appendix 6. Functional enrichment of 10 genes (ilvD, 
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leuC, dapA, trpD, ilvC, dapE, hisG, dxs, ureA and gcp) matched STRING annotation for 
biological processes of 11 GO-terms connected to amino-acid biosynthesis. This result 
aligned with validated experimental data from studies on GcvB in Salmonella, whose 
amino-acid transport biosynthesis regulon involves targeting of 45 mRNAs (Sharma et al., 
2011). From the 30 genes entered in the query, 15 of them share at least one functional 
association based on parameters such as co-expression, gene fusion experimental data 
(ilvI, ilvE, ilvC, ilvD, thrC, leuC, serA, serB, serC, dxs, hisC, hisD, hisG, hisI and trpD. 
 
 
Figure 3.10. Protein-protein associations predicted by STRING for the predicted targets of APP8 GcvB. Grey lines 
represent protein-protein associations, and their thickness indicates the strength of data support. Associations are meant 
to be specific and meaningful, for example, proteins that jointly contribute to a shared function. This does not necessarily 
mean they are physically binding each other. Genes were analysed with a moderate confidence 0.400 and Markov 
clustering method (MCL) with inflation parameter 1.1. Interaction enrichments investigate whether proteins have more 
interactions among themselves than would be expected for a random set of proteins. Associated proteins share colour 
of the network and the red circles indicate proteins associated with amino acid biosynthesis. This set PPI enrichment p-








When the same approach to predict and analyse mRNA targets was applied to the 
next putative trans-acting sRNA in the list (RNA01 in Table 3.2), STRING analysis of its 
selected mRNAs show few protein associations and a disperse functional enrichment 
(Figure 3.11). Rather than implying that RNA01 is not a plausible novel sRNA candidate 
because it lacks a major associated predicted metabolic pathway to regulate, this output 
may suggest that target prediction by the existent tools lack profiling information on novel 
sRNAs, as previously suggested in this work. For example, one of RNA01 targets is ompP2, 
the gene for the outer membrane protein P2, which forms pores that allow passive 
diffusion of small molecules across the outer membrane. This is an antigenic protein and 
has been identified as a potential virulence factor in Haemophilus parasuis (Zhang et al., 
2012). Targeting of ompP2 suggests that RNA01 could be an interesting novel sRNA to be 
investigated using the RNA array to explore interaction with potential mRNA partners. 
 
Figure 3.11. Protein-protein associations predicted by STRING of the predicted targets of RNA01. A quick query into the 
targets of the predicted novel sRNA RNA01 using the same parameters from Figure 3.10, shows a scattered protein-
protein association distribution when compared to protein-protein associations for the predicted targets of APP8 GcvB.  





3.3.3. Selecting predicted targets using RNA-seq data 
 
As previously mentioned, mRNA elements such as transcription start site (TSS) and 
5’ untranslated regions (5’ UTR) may not be easily identified without the support of 
transcriptome insights provided by RNA-seq data. For this reason, a table (Appendix 7) was 
created containing basic information on the 30 predicted targets (gene name, description, 
free energy, p-value, interaction region and similarity to APP serovar 8 MIDG2331) and by 
adding information gathered from the RNA-seq TSS-enriched experiments to identify the 
TSS of the target transcripts, and ultimately the precise 5’ UTR sequence. Data mining for 
this information was carried out in a similar manner used to select for novel trans-acting 
sRNAs in the beginning of this pipeline, by analysing expression cliffs of each transcript in 
JBrowse, and removing predicted targets displaying conflicting expression and lacking 
consistent TSS boundaries.  
Other parameters included selecting for targets with identical nucleotide sequences 
in both APP genomes (L20 and MIDG2331), interaction with the predicted seed region of 
APP8 GcvB, and the location of the predicted binding regions in the putative targets. For 
example, sRNA-mRNA interaction regions in the mRNA are usually located around the 
ribosome binding site (RBS) or the start codon of the gene ORF. The RBS is located in the 5’ 
UTR of the target transcript, thus predicted seed regions located outside the 5’ UTR defined 
in the RNA-seq data, or more than 45 bases upstream the ORF data were removed from 
the selection. The 45 bases cut off was established to accommodate RNA array 
experimental design. Once these parameters were applied to the list of 30, the number of 
targets was then reduced to 9 mRNA target candidates of APP8 GcvB, including ilvI, ilvE, 
thrC, serB, serC, tehB, ilvC, menA and hisG. Their sequences, including 5’ UTR boundary 
from RNA-seq, were extracted from GenBank for both APP serovar 5 L20 and 8 MIDG2331, 
to check for sequence similarity mismatches. Except for menA, all these sequences 
presented 100% similarity in both serovars, reducing the set to 8 mRNA targets. However, 
due to its role in pathogenicity in APP (Bossé & MacInnes, 2000), the predicted target ureA 
(urease gamma subunit) was added to the list, despite being part of an operon. The final 
list of plausible predicted targets of APP8 GcvB contains 9 targets (ilvI, ilvE, thrC, serB, serC, 




Table 3.3.  
List of predicted mRNA targets of the putative APP8 GcvB 
 
 
The list rank is ordered by the lowest hybridisation energy and p-values (Appendix 7) to show the most likely mRNA partners of APP8 
GcvB. Description of targets suggests that most are directly involved in amino-acid biosynthesis. The parameters similarity, operon, RNA-seq TSS, 
interaction region distance on the mRNA and seed region position in the sRNA were used to select the most consistent and structurally plausible 
candidates from the initial TargetRNA2 output of 50 candidates. Some targets have their interaction region nearby or overlapping the start codon 
of the gene coding region +1 residue (thrC, serC, serB, ilvE and tehB), while others (ilvC, ilvI, ureA and hisG) sit on the 5’UTR within -62 nucleotide 
position. These regions are C/A-rich sequences. All targets are predicted to preferably interact with APP8 GcvB within the boundaries of its 
predicted seed region R1 (78-90, sequence 5’ – UGUUGUGUUUGCA – 3’, CV1 in alignment Figure 3.7).  
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3.3.4. The predicted mRNA targets of the putative GcvB are involved in pathogenicity 
 
From the selection of candidates, most are associated with amino-acid biosynthesis 
pathways (ilvE, ilvI, ilvC, thrC, serB, serC, and hisG). Genes ilvC, ilvE and ilvI are involved in 
in the metabolic pathway that synthesizes L-isoleucine and L-valine, while serB and serC 
are involved in a sub-pathway that synthesizes L-serine. Gene thrC synthesizes L-threonine 
and hisG L-histidine. Genes involved in amino-acid biosynthesis contribute to bacterial 
pathogenicity by supporting survival and infection persistence. Bacteria unable to 
synthesize branched-chain amino acids may be attenuated, as suggested in a study with 
deletion-disruption mutants of the ilvI in APP by Subashchandrabose et al. (2009).  
The predicted target ureA, a gene coding for the urease subunit gamma, is part of 
a sub-pathway that synthesizes CO2 and NH3 from urea, which is part of the urea 
degradation pathway. Urease is a known virulence factor characterised in APP strains, 
whose activity is involved in avoiding the host’s defence mechanisms by impairing 
macrophage function (Bossé et al., 1997; 2000; 2001). The putative GcvB in APP may 
regulate expression of a mRNA from a gene (tehB) that codes for a tellurite resistance 
protein (S-adenosyl methyltransferase), involved in resistance to oxidative stress in APP 
(Subashchandrabose et al., 2013), therefore supporting bacterial pathogenicity. 
 
3.3.5. Putative GcvB sRNA may bind predicted mRNA targets on A/C-rich sequences 
 
Salmonella GcvB binds to extended C/A-rich regions in its mRNA targets (Sharma et 
al., 2007). Alignment of the predicted preferable binding regions of the APP8 GcvB mRNA 
targets predicted by TargetRNA2 (Figure 3.12), shows that the varied A/C-rich repeats in all 
the mRNA targets may form a consensus order AAACACAA, despite random mismatches in 
each target. Imperfect alignment goes in line with imperfect pairing of sRNA-mRNA 
interactions, a mechanism that may have been conserved/evolved to accommodate for 
genomic alterations such as point mutations, gene duplication and horizontal gene transfer 
among others, as one sRNA can regulate a plethora of targets (reviewed in Updegrove et 





Figure 3.12. Alignment of the predicted APP8 GcvB mRNA target binding regions. The predicted binding regions of the 
selected mRNA targets were aligned using ClustalOmega and visualised by JalView. Percentage identity was coloured in 
purple gradient and consensus sequence histogram displayed at the bottom of the alignment. Schematics of APP8 GcvB 
predicted structure with 5 stem-loops and the sequence of the first conserved region (R1) was designed in purple in the 
opposite direction (3’ to 5’) of the mRNAs (5’ to 3’) to illustrate sRNA-mRNA hybridisation, based on an imperfect 
complementary base-paring interaction. The highest alignment consensus sequence (AAACACAA) complementarily 
matches a region in the centre of APP8 GcvB R1 (location 79 to 90 in the sRNA) without sequence mismatches. See 





3.3.6. Expression analysis of the predicted mRNA targets 
 
Expression analysis of the selected predicted mRNA targets of APP8 GcvB was 
carried out following the same rationale used for the analysis of the 9 selected P-sRNAs 
(section 3.2.4). As previously mentioned, transcript measurements in this study do not 
represent their differential expression, but rather the transcript yield of MIDG2331 in 
various growth conditions in relation to the aerobically grown MIDG2331 wild type (Figure 
3.13).  
 
Figure 3.13. Relative transcript expression of the predicted mRNA targets of APP8 GcvB. Transcript yield relative to WT 
in broth or Agar plate media was calculated and normalised (Ratio2log) for all 9 predicted mRNAs. Expression levels of 
MIDG2331 wild type (WT) in anaerobic (ANA) BHI Agar plate was compared against WT in aerobic growth condition in 
Agar plate (blue bars). MIDG2331 WT with added AMP (red bars) and TY (orange bars) experiments were carried out in 
BHI broth in aerobic growth conditions and both compared to MIDG2331 WT grown in aerobic BHI broth. The yield of 
MIDG2331 Hfq knockout (DHfq) in BHI broth (green bars) was compared against MIDG2331 WT grown in BHI broth. 
Finally, transcript ratio of MIDG2331 WT grown in porcine serum (PS) was compared against MIDG2331 WT grown in 




The graph shows that targets ilvE, ilvI and ilvC, involved in the synthesis of L-
isoleucine and L-valine, have similar transcript yield patterns when grown in anaerobic (~> 
+0.5-fold), AMP (~> +0.1-fold), TY (~< -0.3-fold) and DHfq (~< -0.1-fold) conditions in 
contrast to wild type aerobic. This group of genes only have different positive and negative 
yield trends in PS, with ilvI presenting the highest yield for this condition (~ +1.5-fold) 
among all other targets, while ilvC shows little change (~ +0.1-fold) in PS. Targets serB and 
serC, involved in the synthesis of L-serine, also have similar yield trends, except for AMP 
condition, with serB demonstrating a negative yield (~ -0.2-fold) and serB slightly positive 
(~ +0.1-fold). The remaining targets belonging to different sub pathways show a very varied 
trend instead, with ureA displaying very low transcript yields in most conditions, except for 
a slightly positive fold in AMP (~ +0.1-fold). Target thrC implies a similar negative fold 
pattern in most conditions, except for PS, with nearly the double of total transcripts of this 
gene in wild type. Finally, hisG shows positive transcript fold in most conditions, except for 
anaerobic (~ -1.5-fold) when compared to wild type grown in aerobic conditions. 
An overall glimpse at the graph shows that, generally, most targets had a decreased 
transcript fold in most conditions. However, although this data provides a snapshot of the 
transcript yields of the studied sRNAs and targets at the time of their extraction, it offers 
no information on sRNA-mRNA interactions, or whether these mRNAs are in fact being 
targeted and regulated by APP8 GcvB under these conditions. This reinforces the need for 
the strategy created in this project, to couple increased prediction accuracy with in vitro 
testing of these sRNA-mRNA pairs using the RNA array technology. 
 
3.3.7. Expression map of APP serovar 8 
 
While in this work only a selected group of genes were investigated, the software 
Circos allowed a global analysis of gene expression in MIDG2331 by simultaneously 
comparing transcript yields of all its genes in different bacterial growth conditions in a 
circular graph. Novelty is one of the main reasons to use this visualisation tool, which 
identifies generalised changes in expression patterns. By closely inspecting the Circos graph 
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in Figure 3.14, is possible to identify localised transcript yield discrepancies in regions of 




































Figure 3.14. Circular graph of MIDG2331 transcript yield. Transcript yield related to expression levels of MIDG2331 wild 
type (WT) in anaerobic (ANA) BHI Agar plate was compared against WT in aerobic growth condition in Agar plate (blue). 
MIDG2331 WT with added AMP (red) and TY (orange) experiments were carried out in BHI broth in aerobic growth 
conditions and both compared to MIDG2331 WT grown in aerobic BHI broth. The yield of MIDG2331 Hfq knockout (DHfq) 
in BHI broth (green) was compared against MIDG2331 WT grown in BHI broth. Finally, transcript ratio of MIDG2331 WT 
grown in porcine serum (PS) was compared against MIDG2331 WT grown in aerobic BHI broth (purple). 
  





3.4. Summary and Discussion 
 
 
The in silico pipeline used in this chapter has identified novel trans-acting sRNA 
candidates in APP with potential links to virulence. Comparative studies have confirmed 
that the predicted trans-acting sRNA RNA05/ARRC01 has a high identity to GcvB from E. 
coli and Salmonella, which are both well characterised (Urbanowski et al., 2000; Sharma et 
al., 2007; Miyakoshi, 2015). GcvB is known to repress the mRNAs of proteins involved in 
amino acid uptake and synthesis; processes which are involved in bacterial virulence. The 
pipeline used here identified mRNA targets for RNA05/ARRC01 which are connected to 
amino acid biosynthesis pathways.  
Whilst GcvB has been identified in Pasteurella multocida, a closely related pathogenic 
member of the Pasteurellaceae family (Gulliver et al., 2018), gene ontology studies for APP 
serovar 5 and Salmonella have also identified several putative target mRNAs (including ilvC, 
ilvI and ilvE) which are involved in amino acid biosynthesis and associated with virulence 
(Chiers et al., 2010; Sharma et al., 2011; Rossi et al., 2016). Therefore, the observation that 
the predicted mRNA targets for RNA05/ARRC01 include ilvC, ilvI, ilvE, and others linked to 
amino acid biosynthesis pathways, which impact virulence, gives confidence in suggesting 
the trans-acting sRNA RNA05/ARRC01 is GcvB in APP8. Importantly, the other remaining 
trans-acting sRNAs in the UoP_ICL_UoV_2020 list showed no homology to other species, 
making them completely novel sRNAs across species. 
RNA-seq data from collaborators was used to allow comparison of transcript expression 
yields across the different growth conditions. However, it was not possible to directly 
convert these measurements to differential expression analysis. Statistical methods cannot 
remove noise from experiments which were not designed for this purpose and, although 
these experiments confirm that transcripts for the putative sRNAs and mRNA targets are 
present in APP8 at a determined condition, whether those are in fact sRNAs interacting 
with mRNA targets is yet to be confirmed. This set of data provided only a snapshot of the 
APP MIDG2331 transcriptome, which is not a definitive rate of gene expression throughout 
host infection, but a picture of which sRNAs are present at the stage of RNA extraction. 
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Transcript yield may provide insights into mRNA levels linked to a given metabolic pathway 
during pathogenicity, as expression of different genes are turned on and off during the 
stages of bacterial infection, affecting the number of transcripts of a gene. For example, 
the genes analysed by STRING in section 3.3.2 Figure 3.10 are associated with amino acid 
biosynthesis and looking at their expression yields in different growth conditions shines a 
light on their presence in relation to GcvB.  
RNA-seq data on GcvB suggests a higher transcript yield when bacteria grow in nutrient-
rich media such as PS. In this context, a possible suggestion is that GcvB may be regulating 
its targets to optimize the energetically expensive biosynthesis of amino acids (Sharma et 
al., 2007) by reducing their transcript yield. Apart from ilvI, thrC and hisG transcripts, yield 
is reduced for all other mRNA targets when APP is grown in this media in relation to BHI 
broth wild type. 
Collectively, the work in this chapter has output a putative trans-acting sRNA, proposed 
to be APP8 GcvB, as well as its predicted mRNA targets. Whilst the RNA-seq data is 
suggestive of biological relevance, it cannot provide interaction information. By contrast, 
computational analysis as part of the pipeline has predicted the sRNA-mRNA binding 
regions, and relative binding energies. In the next chapter, in vitro testing of these sRNA-
mRNA pairs will be undertaken using in the RNA array technology to explore the 






4. In vitro studies: Analysis of virulence-associated sRNA-




In Chapter 3, novel trans-acting sRNAs that are linked to virulence in APP serovar 8 
MIDG2331 were identified using RNA-seq data, and bioinformatic methods were used to 
predict their putative mRNA targets. This chapter establishes an experimental pipeline that 
could be used to test the binding interaction between these predicted sRNA-mRNA pairs in 
vitro. Among the identified APP sRNAs, APP8 GcvB (predicted sRNA ARRC01/RNA05 in 
Chapter 3, referred to as GcvB in this chapter) and its selected putative mRNA targets (ilvI, 
ilvE, ilvC, serB, serC, tehB, ureA and hisG) stand out as viable first candidates to be 
investigated. This is because GcvB and its mRNA targets have been characterised in other 
organisms (Urbanowski et al., 2000; Sharma et al., 2007; Miyakoshi, 2015) and its function 
in APP is supported by experimental data from colleagues at Imperial College London and 
Universidade de Viçosa in Brazil (Rossi et al., 2016).  
As previously covered in Chapter 1 (section 1.2.1), bacterial trans-acting sRNAs 
regulate gene expression by base-pairing to specific sequences of their target mRNAs. This 
base-pairing interaction typically regulates translation of the mRNA by modulating the 
accessibility of the mRNA ribosomal binding site (RBS) to ribosomes. The sRNA-mRNA base-
pairing interaction consists of partial sequence complementarity over a short stretch of 
sequence, and in vivo, the interaction is often facilitated by Hfq. The ternary sRNA-mRNA-
Hfq complex, and its mechanism-of-action, have been extensively studied elsewhere for E. 
coli and Salmonella (Vogel & Luisi, 2011; Henderson et al., 2013; Westermann et al., 2019) 
and will not be investigated here. Instead, this study focusses on the direct interaction 
between an sRNA and its mRNA targets, which is frequently observed in vitro, even in the 
absence of Hfq (Henderson et al.; Vincent et al., 2013).  
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The aim of this chapter was to investigate whether GcvB can interact with its 
putative mRNA targets (ilvI, ilvE, ilvC, serB, serC, tehB, ureA and hisG) in vitro using the novel 
RNA array technology developed at the University of Portsmouth by the Callaghan group. 
The RNA array technology is an adaptable technique that can be used to investigate a 
variety of RNA based interactions (Phillips et al., 2018; Norouzi et al., 2019; Henderson et 
al., 2019). As discussed in Chapter 1 (section 1.5) and Chapter 2 (section 2.2.1), the first 
step is to generate an RNA array through a method that involves in vitro transcription (IVT) 
of a DNA IVT template array and in situ surface capture of the RNA on a facing surface. The 
RNA array can then be used to investigate RNA-RNA binding (Phillips et al., 2018, Norouzi 
et al., 2019) or RNA-small molecule binding (Henderson et al., 2019).  
This chapter first describes the design of the DNA IVT templates for each of the APP 
GcvB putative mRNA targets. It then details the production of the DNA IVT template array 
on slide and the visualisation and analysis of the levels of DNA on the DNA IVT template 
array. Next, the generation of the RNA array of mRNA targets by IVT and in situ RNA capture 
is presented, together with the visualisation and analysis of the levels of RNA on the mRNA 
target array. Quantification of the DNA and RNA levels on the respective arrays then 
allowed for an investigation into the relative transcription efficiency of each of the mRNA 
targets. Finally, two strategies were devised to screen the mRNA targets for GcvB binding. 
The first involved probing the mRNA target array with GcvB post-array production and the 
second involved co-transcribing GcvB with the putative mRNA targets. The workflow for 
this in vitro RNA array-based sRNA-mRNA interaction validation pipeline is illustrated in 





Figure 4.1. Developing an in vitro RNA array-based sRNA-mRNA interaction validation pipeline. The first stage of the in vitro RNA array-based sRNA-mRNA interaction validation pipeline is the 
biodesign and synthesis of a DNA IVT template array. The DNA IVT template array is used to generate an RNA array of mRNA targets by IVT and in situ RNA capture. A fluorescent label 
incorporated into the immobilised DNA IVT templates, and a fluorescently labelled oligonucleotide probe that binds specifically to the immobilised mRNA targets, allows for detection and 
quantification of the immobilised DNA IVT template and mRNA target levels. Analysis of the DNA IVT template and mRNA target levels is used to calculate transcription efficiencies. Addition of 
the sRNA to the mRNA target array allows for validation of sRNA-mRNA interactions.
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The first step in the in vitro RNA array-based sRNA-mRNA interaction validation 
pipeline was the design and synthesis of the DNA IVT templates, and the production of the 
DNA IVT template array. This section describes the key elements of the DNA IVT template 
design, both manual and automated methods for producing the DNA IVT template array 
and the strategy for visualisation and quantification of the DNA IVT template levels on the 
DNA IVT template array.  
 
4.2.2. DNA IVT template design and synthesis 
 
DNA IVT templates were designed for each of the nine GcvB putative mRNA targets. 
The key features and sequence elements of the DNA IVT templates are described in Figure 
4.2 and stablished in the RNA array standard protocol (Phillips et al., 2018, Henderson et 
al., 2019, Vincent et al., 2021 in press). Each DNA IVT template consists of a series of 
functional sequence features that are required for producing the DNA IVT template array, 
producing the RNA array or visualising the arrays. These include: 1 – A biotinylated linker 
at the 5 end to facilitate DNA IVT template immobilisation onto a streptavidin (SA)-coated 
slide; 2 – A T7 bacteriophage RNA polymerase (RNAP) promoter for IVT; 3 – A three guanine 
(GGG) nucleotide repeat to optimise transcription by the T7 RNAP; 4 – Sequence encoding 
the RNA of interest (ROI); 5 – Sequence encoding an unstructured linker (SA-linker) to 
physically separate the mRNA target and the downstream streptavidin-binding RNA 
aptamer (SA aptamer) and to serve as the recognition region for a fluorescently labelled 
antisense single-stranded DNA (ssDNA) probe used for visualisation and quantification of 
the mRNA target levels on the RNA array; 6 – Sequence encoding the SA aptamer to 
facilitate in situ capture of the transcribed RNA by an SA-coated capture slide. 7 – A 
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fluorophore at the 3 end to allow visualisation and quantification of the DNA IVT template 
levels on the DNA IVT template array.  
 
 
Figure 4.2. Design of the DNA in vitro transcription templates. A schematic of the DNA IVT template. The DNA sequence 
for each component is indicated. An example RNA of interest (ROI) sequence is given for the ilvI mRNA target. This consists 
of the predicted GcvB-interacting region within the 5 UTR (orange – seed region) and 45 nucleotides of the ORF.  
The final 201-nucleotide sequence for the ilvI DNA IVT template is: 5’-biotin-
ctcgagTAATACGACTCACTATAGGGTCATTATAAAGCAAACACAATATTTCACTTAAAAATCGTTGGAGGATTCAATGAAAAAACTTT
CCGGAGCAGAAATGGTTGTTCAATCCTTGAAAACACACACACACACACACACGCATGCATACCGACCAGAATCATGCAAGTGCGTA
AGATAGTCGCGGGCCGGGATGCATGC-Alexa(488, 532 or 647)-3’. Sequences for the DNA IVT templates for the other 
mRNA targets are given in Appendix 9.  
 
The RNAs of interest (ROIs) used in this chapter are not the full-length mRNA 
targets. Each ROI consists of the 5’ untranslated region (UTR) of the GcvB putative mRNA 
target, defined by the TSS-enriched RNA-seq data from Chapter 3, and 45 nucleotides (15 
codons) of the mRNA target’s open reading frame (ORF). This region of the mRNA target 
includes the region predicted to base-pair with GcvB and also the functional sequence 
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features, such as A/C-rich regions, which are known to be required for target recognition. 
The sequences of the mRNA target ROIs are presented in Appendix 9. The DNA IVT 
templates are named based on the mRNA target ROI. For example, the DNA IVT template 
shown in Figure 4.2 is the mRNA target ilvI DNA IVT template and will be referred to simply 
as ilvI. When referred to the mRNA target ROI generically, it will simply be referred to as 
the mRNA or mRNA target.  
In order to bind GcvB, the mRNA must fold correctly and, in order to facilitate 
capture by the SA-coated capture surface, the SA aptamer must fold correctly. Therefore, 
RNAFold (Gruber et al., 2008) was used to predict the secondary structure for the expected 
RNA product for each of the DNA IVT templates to confirm that conjugation of the mRNA 
to the SA aptamer does not affect the structure of either RNA. For each RNA product the 
mRNA and the SA aptamer were predicted to fold as expected (Appendix 10).  
Following DNA IVT template design, gene synthesis primers were designed for each 
of the IVT DNA templates and obtained from Invitrogen (Thermo Fisher Scientific). The IVT 
DNA templates were synthetised de novo in-house by TBIO-PCR (Chapter 2, section 
2.2.3.2). The 5 biotin and the 3 fluorophore were incorporated using a 5-biotinylated 
primer and a 5-fluorescently labelled reverse primer. The size of each DNA IVT template 
was verified by gel electrophoresis (Appendix 12). Each DNA template produced an IVT 
product of the expected length in solution (Appendix 13). 
 
4.2.3. Generating the DNA template array: spotting methods 
 
Having designed and synthesised the 5-biotinylated and 3-fluorescently labelled 
DNA IVT templates, the next step was to produce a DNA IVT template array. This was 
achieved by spotting the DNA IVT templates onto an SA-coated slide so that the DNA IVT 
templates are immobilised via their 5 biotin. Two spotting methods were employed, 
manual spotting, using a pipette, and automated spotting, using an arrayer robot.  
Schematics of manual and automated spotting of the IVT DNA templates are illustrated in 





Figure 4.3. Spotting and visualisation of the DNA IVT template array. The 5-biotinylated and 3-fluorescently labelled 
DNA IVT templates are spotted onto an SA-coated slide by manual spotting with a pipette or by automated spotting using 
an arrayer robot. The top slide (blue) represents the spotting pattern and volume achieved for each spotting method. 
Manual spotting requires a higher volume of DNA IVT template than automated spotting. For example, 1 µl of DNA IVT 
template can be used to generate 5 spots by manual spotting or 130 spots by automated spotting. The middle slide (black) 
illustrates visualisation of the spots using a slide scanner following a wash step to remove any excess unbound molecules. 
Both methods result in discrete spots containing multiple molecules of the immobilised DNA IVT template, with the larger 
spots containing a higher level of immobilised DNA IVT template compared to the smaller spots, for the same solution 
spotting concentration.  
 
Manual spotting allows for the generation of low- to medium-density arrays. It is 
possible to pipette as little as 0.2 µl per spot, resulting in 24 spots per slide (Phillips et al., 
2018). Therefore, manual spotting was typically used for preliminary experiments e.g., to 
check the functionality of a newly synthesised DNA IVT template or to test an experimental 
strategy when a yes/no output was all that was required. However, it is difficult to produce 
uniform spots by manual spotting. 
On the other hand, automated spotting generates high-density arrays. For example, 
the Qarray2 arrayer robot (Genetix), fitted with a 200 µm pinhead and spotting at a spot 
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separation of 1250 µm results in a spot density of approximately 400 spots per slide 
(Vincent et al., 2021 in press; Appendix 15). Furthermore, the spots produced by 
automated spotting are more homogenous with regard to volume, size and shape. 
Automated spotting was used for all high throughput experiments in this thesis.  
 
4.2.4. Visualisation and quantification of the DNA IVT template levels on the DNA IVT 
template array 
 
It is useful to visualise and quantify the levels of DNA IVT template immobilised on 
the slide, both as a quality control checkpoint to ensure that the DNA IVT template array 
has been generated successfully, but also for downstream analysis such as calculating the 
transcription efficiency of a DNA IVT template. To enable visualisation and quantification, 
the DNA IVT templates are designed and synthesised with a fluorophore incorporated at 
their 3 end. Fluorophore fluorescence can then be detected using a microarray scanner 
which reports the emitted fluorescence from the fluorophore as fluorescence intensity (FI), 
in arbitrary units (a.u.). Although FI does not provide information about the absolute 
amount of DNA on the array, it is directly proportional to the amount DNA present and can 
be used to determine the relative amounts of DNA present between different array spots.   
 
4.2.4.1. Fluorescence intensity (FI) measurements  
 
In order to accurately measure the FI for a DNA IVT array spot, it is important to 
carefully define the boundaries of an array spot. The integrated scanner software can 
automatically recognise spots on a DNA IVT template array (Figure 4.4). The software then 
measures the FI for each pixel inside each spot boundary and also for each pixel outside 
the boundaries of the spots. FI for pixels outside the boundaries of the spots is considered 
to be background and can be subtracted from the spot FI. There are various possible 
sources of background fluorescence including auto-fluorescence of the slide or non-specific 





Figure 4.4. Spot visualisation using the integrated scanner software (GenePix). A screenshot of an array of 3-
AlexaFluor532 labelled DNA IVT templates visualised using an excitation wavelength of 532 nm and a Standard Green 
emission filter in the integrated scanner software. The panel at the left-hand side of the software interface contains 
excitation wavelength options, Tools for feature editing to position the spot boundaries, and the Feature Viewer that 
displays the FI for the different excitation wavelengths by pixel, the total FI for the spot and the background FI. Statistical 
analysis can be accessed from the tabs at the top of the panel, including the Results tab, where a table containing the 
median, mean and total FI for each feature can be found. The spots are shown in the panel on the right-hand side of the 
interface. White lines mark the spot boundary and the array field boundary.  
 
4.2.4.2. Median, mean and total Fluorescence Intensity (FI) 
 
The scanner software offers several options for statistical analysis of the FI. These 
include calculation of the total FI, median FI and mean FI. Total FI is the sum of the FI for 
every pixel inside the spot boundary, the median FI considers the distribution of FI for pixels 
inside the spot boundary and the mean FI is the total FI for the spot divided by the number 
of pixels inside the spot. The software also calculates the mean background FI and there is 
the option to automatically subtract the mean background FI from the mean FI. For the 
data reported in this thesis, the mean FI with the mean background FI automatically 




4.2.4.3. Defining array spot boundaries with regular and irregular spot shapes 
 
As mentioned above, in order to accurately measure the FI for a DNA IVT template 
array spot, it is important to carefully define the boundary of the spot. The scanner 
software allows the spot to be defined with a regular feature shape or an irregular feature 
shape (Figure 4.5). With a regular circle feature shape (Figure 4.5, 1A), in order to ensure 
that all of the spot FI is included, background FI is inadvertently included in the mean FI 
calculation. In contrast, with the irregular feature shape (Figure 4.5, 1B) only spot FI is 
included in the mean FI calculation. 
 
Figure 4.5. Defining spot boundaries using regular and irregular feature shapes. A spot of 100 nM 3-AlexaFluor532 
labelled DNA IVT template visualised using an excitation wavelength of 532 nm and a Standard Green emission filter. 
The spot has been defined with a regular circular feature (1A) or an irregular feature shape, adjusted to the shape of 
the spot (1B).  
 
The DNA IVT template spot size and shape are influenced by the volume of DNA IVT 
template solutions spotted. DNA IVT template spots that have been spotted using an 
automated arrayer robot usually have a relatively uniform shape and size and it can be 
tempting to define the spot boundary using a regular feature shape. However, using the 
regular feature shape assumes that an identical volume has been spotted at each spot 
location and that an identical boundary (shape and size) can be defined for each spot. 
Consequently, if spotting leads to variable spot volumes, non-uniform spot may lead to 
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inaccurate FI statistical analysis using a regular feature shape to define the spot boundary 
(Figure 4.6). For example, in the case of a smaller, misshapen spot, when the spot boundary 
is defined using a regular circle feature shape, significant background FI is included in the 
mean FI calculation (Figure 4.6, Spot 3). On the other hand, when using an irregular feature 
shape to define the spot boundary, the mean FI output is more representative of the actual 
volume of DNA IVT template that was spotted and the immobilised level of DNA IVT 
template on the array. For this reason, in this thesis irregular feature shapes have been 




Figure 4.6. Defining spot boundaries using circular and irregular feature alignments for DNA. Three spots of 200 nM 3-
AlexaFluor532 labelled ilvI DNA IVT template visualised using an excitation wavelength of 532 nm and a Standard Green 
emission filter. Spot 3 is visibly smaller than Spot 1 or 2, indicating that a smaller volume may have been spotted at the 
location of Spot 3. This may be the result of human error e.g., when manually spotting samples. (Upper panel) FI statistical 
analysis for the three spots using a regular circle feature shape to define the spot boundaries. Using the regular circle 
feature shape to define the spot boundary for Spot 3 incorrectly includes a significant amount of background FI in the 
mean FI calculation. (Lower panel) FI statistical analysis for the three spots using an irregular feature shape to define the 
spot/feature boundaries.  
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Following the production of the DNA IVT template array, the next step was to use 
this to generate the corresponding RNA array using the standard RNA array method (Figure 
4.7A; Chapter 2 (section 2.2); Phillips et al., 2018, Henderson et al., 2019; Vincent et al., 
2021 in press, Appendix 15). A DNA IVT template array slide – IVT mixture – SA-coated RNA 
capture slide “sandwich” was assembled. As IVT proceeds, RNA synthesised from each of 
the DNA IVT templates was captured in situ on an SA-coated RNA capture slide, via its 3 SA 
aptamer, to generate the corresponding RNA array. It is possible to label the RNA in situ by 
supplementing the IVT mixture with Cy-labelled UTP (Phillips et al., 2018). Alternatively, 
the levels of unlabelled RNA can be visualised and quantified by probing the RNA array, 
post-array production, with a fluorescently labelled antisense ssDNA probe 
complementary to the SA linker region between the mRNA and the SA aptamer (Norouzi 
et al., 2019; Henderson et al., 2019; Vincent et al., 2021 in press). In this thesis, RNA arrays 



















Figure 4.7. Generation of an RNA array. (A) Generation of an RNA array by IVT and in situ RNA capture. A DNA IVT 
template array – IVT mixture – SA-coated RNA capture surface “sandwich” is assembled. The surface of the DNA IVT 
template array slide with the spots of immobilised DNA IVT template and the SA-coated surface of the RNA capture slide 
both face inwards. The IVT mixture is pipetted between the DNA IVT template array slide and the RNA capture slide. Since 
the immobilised DNA IVT templates are in close proximity to the RNA capture surface, during IVT, the nascent RNA 
molecules directly immobilise to the SA-coated surface on the opposite slide, via the 3 SA aptamer, with limited lateral 
diffusion. The slides are then separated and washed in 1 x Phosphate-Buffered Saline supplemented with 0.02% Tween 
20 (PBST). (B) The unlabelled immobilised RNA on the RNA array slide may be probed with a fluorescently labelled 
antisense ssDNA probe complementary to the linker region between the mRNA and the SA aptamer. 
 
4.3.2. IVT and in situ capture of the ilvI mRNA target 
 
100 nM 5-biotinylated and 3-Alexa532 labelled ilvI DNA IVT template was spotted 
onto a SA-coated slide to generate a DNA IVT template array (Figure 4.8, 1). This DNA IVT 
template array was used to generate an ilvI RNA array by IVT and in situ capture. The ilvI 
RNA array was probed with the 5-Alexa647-GTGTGTGTGTGTGTGTGTGT-3 antisense 
ssDNA probe (SA-linker probe), complementary to the linker between the ROI (ilvI) and the 
SA aptamer (Figure 4.8, 2). The SA-linker probe was designed in-house and synthesised by 




Figure 4.8. IVT and in situ capture of the ilvI mRNA target. (1) 100 nM of 5-biotinylated and 3-Alexa532 labelled ilvI DNA 
IVT template visualised using an excitation wavelength of 532 nm and a Standard Green emission filter. The spot boundary 
was defined using a regular circle feature shape (1A) or an irregular feature shape (1B). (2) ilvI RNA generated by IVT and 
in situ capture of the DNA IVT template in (1), probed with 5-Alexa647-GTGTGTGTGTGTGTGTGTGT-3 antisense ssDNA 
(SA-linker probe) and visualised using an excitation wavelength of 635 nm and a Standard Red emission filter. The spot 
boundary was defined using a regular circle feature shape (2A) or an irregular feature shape (2B). 
 
4.3.2.1. Defining the array spot boundaries with regular and irregular spot shapes 
 
The boundaries of the DNA IVT template spots and the SA-linker probe bound to 
the immobilised ilvI mRNA target spots were defined in the integrated scanner software 
using a regular circle feature shape (Figure 4.8, 1A and 2A) and an irregular feature shape 
(Figure 4.8, 2A and 2B). Although the DNA IVT template spots are often consistent in size 
and shape, as discussed above, the size and shape of the RNA spot is less uniform due to 
diffusion during IVT and in situ capture (compare Figure 4.8, 1 and 4.8, 2). Transcribed and 
immobilised RNA has clearly diffused outside the boundaries set by a regular circle feature 
shape based on the corresponding DNA IVT template spot (Figure 4.8, 2A). This would lead 
to the incorrect exclusion of FI when calculating the mean FI of the spot/feature and also 
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the incorrect inclusion of FI when calculating the mean background FI. However, this can 
be avoided by using the irregular feature alignment (Figure 4.8, 2B). 
 
4.3.2.2. Regular vs irregular alignment features of RNA spots 
 
The choice of feature shape for the RNA spots is particularly important when 
comparing two or more RNA spots because the RNA spots may differ in shape and size due 
to different relative transcription efficiencies. For example, a DNA IVT template with a high 
transcription efficiency may produce more RNA, more quickly allowing diffusion over a 
wider area during IVT and in situ capture, than a DNA IVT template with a low transcription 
efficiency. When using a regular circle feature shape to define the boundary of these RNA 
spots, more FI will be excluded for the RNA that is transcribed with high efficiency than for 
the RNA that is transcribed with lower efficiency (Figure 4.9). This will underestimate the 
RNA yield for the RNA transcribed with high efficiency. In contrast, when using the irregular 
feature shape to define the spot boundaries, the total FI, and therefore total RNA yield, is 
calculated for both RNAs. For the analysis presented in this thesis, the irregular feature 
shape was used to define the RNA spot boundaries and the mean FI minus the mean 
background FI was calculated. 
  
Figure 4.9. Defining RNA spot boundaries using regular and irregular feature shape. Two RNA spots probed with SA-
linker probe and visualised using an excitation wavelength of 635 nm and a Standard Red emission filter. (Left) FI statistical 
analysis for the two RNA spots using a regular circle feature shape to define the spot/feature boundaries. (Right) FI 








Having designed the strategy for generating, visualising, and quantifying an RNA 
array of putative mRNA targets of GcvB, the next step was to generate the mRNA target 
array in vitro. In this section, a preliminary experiment is presented in which a low-density 
array of the DNA IVT templates for each of the mRNA targets was prepared by manual 
spotting. This was then used to generate a low-density RNA array of the mRNA targets. The 
aim of this experiment was to provide a yes-no output as to whether the DNA IVT templates 
immobilised to the DNA IVT template array slide were transcribed, and the RNA produce 
captured by the RNA capture slide.  
 
4.4.2. Generating a low-density array of putative mRNA targets of GcvB 
 
A sample (0.2 µl) of 200 nM of each 5-biotinylated and 3-Alexa647 labelled DNA 
IVT template was spotted, in duplicate, onto an SA-coated slide by manual spotting to 
generate the mRNA target DNA IVT template array. This DNA IVT template array was then 
used to generate an unlabelled mRNA target array following the standard RNA array 
protocol (Chapter 2, section 2.2.5). The mRNA target array was then probed with 500 nM 
SA-linker probe. A schematic of the experimental design is shown in Figure 4.10. The aim 
of this experiment was to provide a yes-no output as to whether the DNA IVT templates 
immobilised to the DNA IVT template array slide were transcribed and captured by the RNA 
capture slide. 
In order to facilitate RNA immobilisation on the RNA capture slide, the mRNA target 
RNA, including the SA aptamer, must be fully transcribed and folded correctly. The 
secondary structure(s) of each mRNA target were predicted using RNAFold and suggested 
that the conjugated SA aptamer was likely to fold into the correct structure in each case 
(for each mRNA target) (Appendix 10). Furthermore, the 3 location of the SA aptamer in 
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the RNA construct for each mRNA target ensures that only fully transcribed RNA molecules 
should be immobilised on the RNA capture slide. To confirm these predictions and validate 
the experimental strategy, it is necessary to check that the DNA IVT templates are 
transcribed into full-length RNA products and captured by the SA-coated RNA capture slide.  
 
Figure 4.10. Schematic of the generation of a low-density RNA array of the putative mRNA targets of GcvB. (1) Samples 
(0.2 µl) of 200 nM of the 5-biotinylated and 3-Alexa647 labelled DNA IVT template for each of the predicted mRNA 
targets of GcvB manually spotted, in duplicate, on an SA-coated slide to produce a DNA IVT template array. The DNA IVT 
template array is visualised using an excitation wavelength of 635 nm and a Standard Red emission filter. (2) A 
corresponding unlabelled mRNA target array is generated from the DNA IVT template array in (1) by IVT and in situ 
capture. (2A) The mRNA target array is probed with Alexa647-labelled SA-linker probe and visualised using an excitation 




As shown Figure 4.11, 1, each of the DNA IVT templates were successfully 
immobilised to the SA-coated slide to generate the DNA IVT template array. FI was only 
detected at locations where the DNA IVT template had been manually spotted, there was 
no non-specific binding to other parts of the slide. Similarly, all the mRNA targets were 
successfully transcribed and immobilised on the RNA capture surface as an RNA array 
(Figure 4.11, 2). Following probing of the mRNA target array with the SA-linker probe, FI 
was only detected in discrete spots indicating that the RNA was immobilised in sites 
correspondent to their DNA IVT template spots and that the SA-linker probe bound 
specifically to the immobilised RNA.  
 
Figure 4.11. Generation of a low-density RNA array of putative mRNA targets of GcvB. (1) Samples (0.2 µl) of 200 nM of 
the 5-biotinylated and 3-Alexa647 labelled DNA IVT template for each of the predicted mRNA targets of GcvB was 
manually spotted, in duplicate, on an SA-coated slide to produce a DNA IVT template array. The DNA IVT template array 
was visualised using an excitation wavelength of 635 nm and a Standard Red emission filter. (2) A corresponding 
unlabelled mRNA target array was generated from the DNA IVT template array in (1) by IVT and in situ capture. 
Visualisation using an excitation wavelength of 635 nm and a Standard Red emission filter revealed no FI. (2A) The mRNA 
target array was probed with Alexa647-labelled SA-linker probe and visualised using an excitation wavelength of 635 nm 




4.4.3. Generating high-density arrays of putative mRNA targets of GcvB 
 
Having demonstrated that a low-density array of DNA IVT templates could be 
produced and used to generate a low-density RNA array of the putative mRNA targets of 
GcvB, the aim of the next set of experiments was to produce a high-density DNA IVT 
template array by automated spotting with an arrayer robot and use this to generate a 
high-density RNA array of mRNA targets. Moving to a high-density array format allows for 
rapid, high-throughput optimisation and analysis of the RNA array generation process e.g. 




Figure 4.12. Schematic of the layout of high-density arrays. (1) 5-biotinylated and 3-Alexa532 labelled DNA IVT 
templates are spotted by an automated arrayer robot in three grids (Repeat 1, 2 and 3) of 3 x 3 fields of 3 x 3 spots (243 
spots per array). Each grid typically contains one field for each of the putative mRNA targets of GcvB. The DNA IVT 
template array is visualised using an excitation wavelength of 532 nm and a Standard Green emission filter. (2) A 
corresponding unlabelled mRNA target array is generated from the DNA IVT template array in (1) by IVT and in situ 
capture. (2A) The mRNA target array is probed with Alexa647-labelled SA-linker probe and visualised using an excitation 
wavelength of 635 nm and a Standard Red emission filter. 
 
The general array layout for the high-density array experiments is shown in Figure 
4.12. Two sets of experiments were then planned. The first experiment involved spotting 
concentration gradients for each DNA IVT template to determine the transcription 
efficiency for each DNA IVT template (Figure 4.13, A). The second experiment involved 
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spotting each DNA IVT template multiple times at the fixed concentration of 200 nM to 
compare the relative transcription efficiencies between DNA IVT templates (Figure 4.13, 
B).    
 
 
Figure 4.13. Schematics of the layout of grids and fields on high density DNA IVT template arrays.  Each grid contains 3 
x 3 fields with each field containing 3 x 3 spots of one of the DNA IVT templates. (A) A concentration gradient of DNA IVT 
template is spotted (0 nM, 25 nM, 50 nM, 100 nM, 150 nM, 200 nM, 250 nM, 300 nM and 350 nM). (B) A fixed 
concentration of 200 nM DNA IVT template is spotted multiple times.  
 
4.4.3.1. Transcription efficiencies of individual DNA IVT templates 
 
It is expected that for a given DNA IVT template the amount of RNA that is 
transcribed and captured in situ will be proportional to the amount of DNA IVT template 
immobilised. However, each DNA IVT template may be transcribed and captured with a 
different efficiency. To investigate this, each 5-biotinylated and 3-Alexa532 labelled DNA 
IVT template was spotted at a concentration of 0, 25 nM, 50 nM, 100 nM, 150 nM, 200 nM, 
250 nM, 300 nM and 350 nM by an automated arrayer robot (Figure 4.14). The resulting 
DNA IVT template array was used to generate an unlabelled mRNA target array that was 







Figure 4.14. Spotting a concentration range of DNA IVT templates. (Left-hand side) A grid of 3 x 3 fields with each field 
containing 3 x 3 spots of one of the 5-biotinylated and 3-Alexa532 labelled DNA IVT templates spotted in a concentration 
gradient (0 nM, 25 nM, 50 nM, 100 nM, 150 nM, 200 nM, 250 nM, 300 nM and 350 nM) by an automated arrayer robot. 
The DNA IVT array was visualised using an excitation wavelength of 532 nm and a Standard Green emission filter. (Right-
hand side) An RNA array was generated by IVT and in situ capture, probed with 500 nM Alexa647-labelled SA-linker probe 
and visualised using an excitation wavelength of 635 nm and a Standard Red emission filter. Grids were repeated in 
triplicate on a single slide. 
 
DNA spots were clearly visible for each of the DNA IVT templates spotted at a 
concentration of 50 nM and above. The size and shape of the DNA spots is relatively 
uniform. As expected, the DNA FI signal appears to increase with increasing concentration 
of spotted DNA IVT template for each of the templates. Similarly, RNA spots could be 
detected at locations corresponding to DNA IVT template concentrations of 50 nM and 
above for all each of the DNA IVT templates, confirming that the mRNA targets had been 
transcribed and captured on the RNA capture slide. In the ilvE and ureA fields, a faint RNA 
spot is detected in the location corresponding to 25 nM DNA IVT template spot, implying 
that a low level of DNA IVT template was immobilised when spotted at a concentration 25 
nM. The size and shape of the RNA spots is more variable than for the DNA spots, 
presumably due to variable diffusion of the mRNA target, and may reflect variable 
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transcription efficiencies. For example, spots in the ureA and hisG fields clearly show RNA 
diffusion out of the corresponding DNA IVT template spot boundaries, suggesting that 
these DNA templates may have a higher transcription efficiency than the other mRNA 
targets. For each of the mRNA targets, the levels of RNA appear to increase with increasing 
concentration of spotted DNA IVT template.  
 
 
Figure 4.15. Plot of mean DNA spot FI (a.u.) against concentration of spotted DNA IVT template (nM). Data have been 
normalised to the DNA spot with the highest FI using the min-max normalisation. Data are the mean of three experimental 
repeats and error bars represent the standard error of the mean. Data are fit to a linear equation. Data points within the 





The mean FI was calculated for each of the DNA IVT template spots and plotted 
against the spotted concentration (Figure 4.15). The mean FI for the DNA IVT template 
spots increases linearly with increasing spotted concentration, up to a spotted 
concentration of 200 nM, for all templates. At concentrations of spotted IVT DNA template 
above 200 nM the FI of some is non-linear. This might suggest that the spot location 
becomes saturated with DNA IVT template molecules when spotted at concentrations over 
200 nM and that the capacity of the surface has been reached at this concentration. 
Therefore, DNA IVT template concentrations up to 200 nM may be a more suitable working 
range for subsequent experiments. 
 
Figure 4.16. Plot of RNA spot FI (a.u.) against DNA spot FI (a.u). Data have been normalised to the RNA spot with the 
highest FI using the min-max normalisation. Data are the mean of three experimental repeats and error bars represent 
the standard error of the mean.  Only data points corresponding to the DNA FI linear range are plotted. Data are fit to a 




The mean FI was calculated for SA-linker probe bound to each of the mRNA target 
spots and plotted against the mean FI for the corresponding DNA IVT template spot for 
DNA IVT template spots in the DNA spot FI linear range (Figure 4.16). Similar to the results 
for the DNA IVT template FI, RNA spot fluorescence increases with increasing DNA IVT 
template spot FI. A moderate linear correlation is observed between DNA and RNA spot FI. 
The maximum RNA levels varied from 0.2 a.u. for tehB and ilvI up to 0.6 a.u. for hisG and 1 
a.u. for ureA. This suggests variable transcription efficiencies between the DNA IVT 
templates with low transcription efficiencies for tehB and ilvI and higher transcription 
efficiencies for hisG and ureA.   
 
4.4.3.2. Transcription efficiencies between DNA IVT templates 
 
The data presented in the previous section suggest that there are differences in the 
transcription efficiency for the different DNA IVT templates. To investigate this further it 
was decided to compare the transcription efficiency for each DNA IVT template by spotting 
each 5-biotinylated and 3-Alexa532 labelled DNA IVT template 27 times (three 3 x 3 fields), 
on a single array, at a fixed concentration of 200 nM (Figure 4.17). A concentration of 200 
nM DNA IVT template was chosen because this generated the highest RNA yield within the 
linear range for each of the templates (Figure 4.16). The DNA IVT template array was used 
to generate the corresponding mRNA target array, and this was probed with 500 nM SA-





Figure 4.17. Spotting DNA IVT templates at a fixed concentration of 200 nM. (1) A grid of 3 x 3 fields with each field 
containing 3 x 3 spots of one of the 5-biotinylated and 3-Alexa532 labelled DNA IVT templates spotted at a fixed 
concentration of 200 nM using an automated arrayer robot. The DNA IVT array was visualised using an excitation 
wavelength of 532 nm and a Standard Green emission filter. (2A) An RNA array was generated by IVT and in situ capture, 
probed with 500 nM Alexa647-labelled SA-linker probe and visualised using an excitation wavelength of 635 nm and a 
Standard Red emission filter. Grids were repeated in triplicate on a single slide. (A) A plot of mean FI (in a.u.) for the DNA 
IVT template spots (blue bars) and the SA-linker probe bound to the corresponding mRNA target spots (red bars). Data 
are the mean of 27 spots and error bars represent the standard error of the mean. (B) The transcription efficiencies were 
calculated by normalising the mean FI for the SA-linker bound to the mRNA target spots to the mean FI for the 
corresponding DNA IVT template spots. For example, for ilvE, mRNA Fl of 2.7/1.1 Fl for DNA gives a transcription efficiency 
for ilvE of 2.4. 
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DNA spots were clearly visible for each of the DNA IVT templates spotted and they 
appear relatively uniform. Corresponding RNA spots are also visible for each of the DNA 
spots indicating that each DNA IVT template spot was transcribed, and the RNA captured. 
For a given DNA IVT template, the resultant RNA spots appear relatively uniform. However, 
there are clear differences in the RNA levels between different mRNA targets. For example, 
the ilvE and ilvC mRNA target levels appear to be consistently high and the serC and hisG 
mRNA target levels appear to be consistently low. This confirms the previous data 
suggesting that DNA IVT templates are transcribed with varying efficiencies.  
The mean FI was calculated for each of the DNA IVT template spots and for the SA-
linker bound to each of the mRNA target spots (Figure 4.17, A). As expected, given that 
each of the DNA IVT templates were spotted at the fixed concentration of 200 nM, the FI 
for the DNA spots is similar for each of the DNA IVT templates. In contrast, the FI for the 
SA-linker probe bound to the mRNA target spots is highly dependent on the mRNA target. 
Normalising the mean FI for the SA-linker bound to the mRNA target spots to the mean FI 
for the DNA IVT template (Figure 4.17, B) confirms that the levels of the immobilised mRNA 




4.5. Application of RNA arrays to the validation of putative sRNA-mRNA 
interactions  
 
Once the conditions for generating RNA arrays of putative mRNA targets of GcvB 
had been established, the next step was to investigate whether GcvB could interact with 
the target mRNAs on an RNA array. RNA interaction studies can be carried out post-RNA 
array production, by adding the interacting partner in solution (Phillips et al., 2018, 
Henderson et al., 2019), or in situ, by including a DNA IVT template encoding the interacting 
partner (Norouzi et al., 2019) or by supplementing the IVT mixture with the interacting 
partner (Henderson et al., 2019). Here, two strategies were tested. The first strategy 
involved probing an RNA array of the putative mRNA targets of GcvB post-array production 
with a solution of fluorescently labelled GcvB. The second strategy involved co-spotting the 
DNA IVT template for the putative mRNA target together with the DNA IVT template for 
GcvB, so that transcription of both the mRNA target and the sRNA occurs simultaneously. 
This allows GcvB to bind to the mRNA targets in situ, during the IVT/capture step of the 
RNA array protocol. The bound GcvB is then probed post-array production with a 
fluorescently labelled antisense ssDNA probe. Both strategies are detailed below. 
 
4.5.1. Probing RNA arrays of the putative mRNA targets of GcvB post-array production with 
fluorescently labelled GcvB 
 
The initial strategy to investigate the interaction between GcvB and the putative 
mRNA targets was to probe the mRNA target array post-array production with a 
fluorescently labelled GcvB (GcvB-Cy3) (Figure 4.18). GcvB-Cy3 was GcvB, internally 
labelled with Cy3, and was synthesised by IVT using an IVT mixture supplemented with Cy3-
labelled UTP (Chapter 2, section 2.2.3.5 and 2.2.7.1), with random but proportional 
incorporation. Cy3 fluorescence will only be detected for spots containing an mRNA target 
to which GcvB-Cy3 is bound. The presence of the mRNA targets on the array is confirmed 
for each position by probing with SA-linker probe. GcvB-Cy3 and SA-linker probe (Alexa647 




Figure 4.18. Schematic of an mRNA target array probed with internally labelled GcvB-Cy3. (1) An SA-coated slide is 
spotted with 5-biotinylated, 3-Alexa488/Alexa647 labelled DNA IVT templates encoding the putative mRNA targets of 
GcvB to generate the DNA IVT template array. (2) An mRNA target array is generated from the DNA IVT template array 
by IVT and in situ RNA capture. (2A) The mRNA target array is probed post-array production with GcvB-Cy3 to screen for 
GcvB-mRNA target interactions, (2B) and then with SA-linker probe, to enable visualisation and quantification of the levels 
of mRNA target on the RNA array. The probed array is visualised using an excitation wavelength of 532 nm and a Standard 




4.5.1.1. Probing low-density RNA arrays of putative mRNA targets of GcvB post-
array production with GcvB-Cy3 
 
Samples (0.2 µl) of 200 nM of each 5-biotinylated and 3-Alexa647 labelled DNA IVT 
template were spotted, in duplicate, onto a SA-coated slide by manual spotting to generate 
the mRNA target DNA IVT template array. This DNA IVT template array was then used to 
generate an unlabelled mRNA target array. The mRNA target array was then probed with 
500 nM of GcvB-Cy3, to screen for GcvB-mRNA target interactions. Finally, the mRNA target 
array was probed with 500 nM SA-linker probe, to visualise and quantify the RNA levels. A 





Figure 4.19. Schematic of the generation and probing of a low-density RNA array of putative mRNA targets of GcvB. (1) 
A sample (0.2 µl) of 200 nM of the 5-biotinylated and 3-Alexa647 labelled DNA IVT template for each of the predicted 
mRNA targets of GcvB was manually spotted, in duplicate, on an SA-coated slide to produce a DNA IVT template array. 
The DNA IVT template array is visualised using an excitation wavelength of 635 nm and a Standard Red emission filter. 
(2) A corresponding unlabelled mRNA target array is generated from the DNA IVT template array in (1) by IVT and in situ 
capture. (2A) The mRNA target array is probed with GcvB-Cy3 and visualised using an excitation wavelength of 532 nm 
and a Standard Green emission filter. (2B) The mRNA target array is probed with Alexa647-labelled SA-linker probe and 
visualised using an excitation wavelength of 635 nm and a Standard Red emission filter. 
 
As shown Figure 4.20, 1, each of the DNA IVT templates were successfully 
immobilised to the SA-coated slide to generate the DNA IVT template array. Prior to 
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probing, no FI was detected for the unlabelled RNA slide (Figure 4.20, 2). Following probing 
of the mRNA target array with GcvB-Cy3, significant FI was detected for spots containing 
the ilvI, ilvC and hisG mRNA targets (Figure 4.20, 2A), indicating that GcvB-Cy3 had bound 
to these mRNA targets on the RNA array. Weaker FI was detected for spots containing the 
remaining mRNA targets. To confirm that these mRNA targets were present on the array, 
and that the apparent lack of GcvB-Cy3 binding was not due to low levels of RNA, the mRNA 
target array was probed with SA-linker probe (Figure 4.20, 2B). Following probing of the 
mRNA target array with the SA-linker, FI was detected at each of the positions expected to 
contain immobilised RNA. Therefore, dimmed Cy3 fluorescence suggests that GcvB binds 
significantly less to the remaining mRNAs.  
 
 
Figure 4.20. Generation and probing of a low-density RNA array of putative mRNA targets for GcvB. (1) A sample (0.2 
µl) of 200 nM of the 5-biotinylated and 3-Alexa647 labelled DNA IVT template for each of the predicted mRNA targets 
of GcvB was manually spotted, in duplicate, on an SA-coated slide to produce a DNA IVT template array. The DNA IVT 
template array was visualised using an excitation wavelength of 635 nm and a Standard Red emission filter. (2) A 
corresponding unlabelled mRNA target array was generated from the DNA IVT template array in (1) by IVT and in situ 
capture. Visualisation using an excitation wavelength of 532 nm and a Standard Green emission filter revealed no FI. (2A) 
The mRNA target array was probed with 500 nM GcvB-Cy3 and visualised using an excitation wavelength of 532 nm and 
a Standard Green emission filter. (2B) The mRNA target array was probed with 500 nM Alexa647-labelled SA-linker probe 




4.5.1.2. Probing high-density RNA arrays of putative mRNA targets of GcvB post-
array production with GcvB-Cy3 
 
Having demonstrated that GcvB-Cy3 binds to the potential mRNA targets on a low-
density mRNA target array, the next step was to investigate this further using high-density 
RNA arrays. Moving to a high-density array format allows for rapid, high-throughput 
analysis of the GcvB-mRNA target interactions. For the high-density array experiments, 
each DNA IVT template was spotted multiple times at the fixed concentration of 200 nM in 
the general array layout shown in Figure 4.21.    
 
Figure 4.21. Schematic of the generation and probing of a high-density RNA array of putative mRNA targets of GcvB. 
(1) 5-biotinylated and 3-Alexa532 labelled DNA IVT templates are spotted by an automated arrayer robot in three grids 
(Repeat 1, 2 and 3) of 3 x 3 fields of 3 x 3 spots (243 spots per array). Each grid typically contains one field for each of the 
putative mRNA targets of GcvB. The DNA IVT template array is visualised using an excitation wavelength of 532 nm and 
a Standard Green emission filter. (2) A corresponding unlabelled mRNA target array is generated from the DNA IVT 
template array in (1) by IVT and in situ capture. (2A) The mRNA target array is probed with GcvB-Cy3 and visualised using 
an excitation wavelength of 532 nm and a Standard Green emission filter. (2B) The mRNA target array is probed with 
Alexa647-labelled SA-linker probe and visualised using an excitation wavelength of 635 nm and a Standard Red emission 
filter.  
 
Each 5-biotinylated and 3-Alexa532 labelled DNA IVT template was spotted 27 
times (three 3 x 3 fields), on a single array, at a fixed concentration of 200 nM to generate 
a DNA IVT template array. The DNA IVT template array was used to generate the 
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corresponding mRNA target array, and this was probed with 500 nM GcvB-Cy3 and 500 nM 
SA-linker probe (Figure 4.22).  
 
Figure 4.22. Generation and probing of a high-density RNA array of putative mRNA targets of GcvB. Three grids of 3 x 
3 fields with each field containing 3 x 3 spots of one of the 5-biotinylated and 3-Alexa532 labelled DNA IVT templates 
were spotted at a fixed concentration of 200 nM using an automated arrayer robot. An RNA array was generated by IVT 
and in situ capture. The RNA array was probed with 500 nM GcvB-Cy3 and visualised using an excitation wavelength of 
532 nM and a Standard Green emission filter. A schematic of GcvB-Cy3 bound to an mRNA target on the RNA array is 
shown. The RNA array was subsequently probed with 500 nM Alexa647-labelled SA-linker probe and visualised using an 
excitation wavelength of 635 nm and a Standard Red emission filter. A plot of mean FI (in a.u.) for GcvB-Cy3 bound to the 
RNA spots (green bars) and for SA-linker probe bound to the same spot (red bars).  
 
SA-linker probe FI was detected for each of the mRNA target spots indicating that 
each DNA IVT template spot was transcribed, and the RNA captured in situ. For a given DNA 
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IVT template, the resultant RNA spots appear relatively uniform. However, as observed 
previously, there are differences in the immobilised RNA levels between different mRNA 
targets. GcvB-Cy3 FI was also detected for each of the RNA spots indicating that GcvB-Cy3 
interacts with each of the mRNA targets. This was expected based on the results obtained 
for GcvB probing of the low-density mRNA target array; although the significant binding 
seen for ilvI, ilvC and hisG, and weaker binding for the remining targets was not so 
pronounced in the case for the high-density array results. However, this may simply reflect 
the level of RNA present on the array. This highlights the need for quantification to 
normalise the binding seen to the RNA level immobilised so that interaction efficiencies 
between GcvB and its mRNA targets can be compared.  
Normalising the mean FI for the SA-linker bound to the mRNA target spots to the 
mean FI for the DNA IVT template (Figure 4.23, A) to generate a transcription efficiency 
confirmed differences between the mRNA targets. This trend was similar to that observed 
previously. The mean FI for GcvB-Cy3 bound to the mRNA target spots was normalised to 
the mean FI for the SA-linker bound to the same mRNA target spots to give an interaction 
efficiency (Figure 4.23, B). This analysis confirmed the qualitative observation that the level 
of GcvB-Cy3 binding may be mRNA target specific. The highest interaction efficiency was 
seen for GcvB-Cy3 binding to ilvC mRNA target. This was significantly higher than for the 




Figure 4.23. Quantification of the probing of a high-density RNA array of putative mRNA targets of GcvB. A) The 
transcription efficiencies were calculated by normalising the mean FI for the SA-linker bound to the mRNA target spots 
to the mean FI for the corresponding DNA IVT template spots. B) The GcvB-Cy3-mRNA target interaction efficiencies were 
calculated by normalising the mean FI for the GcvB-Cy3 bound to the mRNA spot to the mean FI for the SA-linker probe 
bound to the same spot. 
 
 
4.5.2. Co-spotting the DNA IVT templates for GcvB and its putative mRNA targets: in situ 
binding of GcvB followed by probing of bound GcvB post-array production with a 
fluorescently labelled antisense ssDNA probe 
 
A second strategy to investigate the interaction between GcvB and the putative 
mRNA targets was developed which involved in situ binding of GcvB followed by probing of 
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the bound GcvB, post-array production, with a fluorescently labelled antisense ssDNA 
probe (GAG-linker probe) (Figure 4.24). The first step of this strategy involved co-spotting 
DNA IVT templates for both the putative mRNA targets and GcvB (Figure 4.24, 1). Then, 
during the RNA array generation step (IVT and in situ capture), both RNAs are transcribed 
simultaneously. This allows GcvB to bind to the mRNA target as the RNA is being 
transcribed, mimicking the in vivo scenario more closely than the probing of the mRNA 
array with GcvB-Cy3 post-array production.  
As previously, the mRNA target RNA is conjugated to an SA-aptamer to facilitate 
capture of the RNA on an SA-coated surface. However, GcvB is not tagged in this manner. 
This means that GcvB is only immobilised on the RNA array if it binds to the mRNA target 
(Figure 4.24, 2A). Bound GcvB is then probed post-array production with Alexa488 labelled 
antisense ssDNA GAG-linker probe and the immobilised mRNA targets are probed post-
array production with Alexa647 SA-linker probe (Figure 4.24, 2B). The use of orthogonal 





Figure 4.24. Schematic of in situ binding of GcvB to mRNA targets followed by probing bound GcvB post-array 
production with GAG probe. (1) An SA-coated slide is co-spotted with 5-biotinylated, 3-Alexa488/Alexa647 labelled DNA 
IVT templates encoding the putative mRNA targets of GcvB and 5-biotinylated DNA IVT template encoding GcvB to 
generate the DNA IVT template array. (2) GcvB and the mRNA targets are transcribed. The mRNA targets are conjugated 
to an SA aptamer which facilitates immobilisation on the capture slide. GcvB is not conjugated to an SA aptamer and is 
only immobilised on the capture slide if it binds to the mRNA target. (2A) Bound GcvB is probed post-array production 
with Alexa488-labelled GAG-linker probe and the mRNA target is probed post-array production with Alexa647/Alexa488-
labelled SA-linker probe. The probed array is visualised using an excitation wavelength of 488 nm and a Standard Blue 
emission filter or using an excitation wavelength of 488 nm and a Standard Blue emission filter and using an excitation 
wavelength of 635 nm and a Standard Red emission filter. 
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4.5.2.1. GcvB DNA IVT template design and synthesis 
 
A DNA IVT template was designed for GcvB. The key features and sequence 
elements of this template are described in Figure 4.25. Similar to the DNA IVT templates 
for the mRNA targets, the GcvB DNA IVT template consists of a series of functional 
sequence features that are required for producing the DNA IVT template array, producing 
the RNA array or visualising the arrays. These include: 1 – A biotinylated linker at the 5 end 
to facilitate DNA IVT template immobilisation onto a SA-coated slide; 2 – A T7 
bacteriophage RNA polymerase (RNAP) promoter for IVT; 3 – Two guanine nucleotides (GG) 
to optimise transcription by the T7 RNAP; 4 – Sequence encoding GcvB; 5 – Sequence 
encoding an unstructured linker to serve as a recognition region for a fluorescently labelled 
antisense ssDNA probe used for visualisation and quantification of the levels of GcvB bound 
to the mRNA targets on the RNA array; 6 – A 3 stem loop to stabilise the transcript. This 
construct of GcvB was referred to as Modified GcvB (GcvB-MG) from this point onwards, 
as it includes a specific linker for probing. Key differences between the GcvB-MG DNA IVT 
template and the DNA IVT templates for the mRNA targets is that there is no SA aptamer 
to facilitate in situ capture of the RNA by an SA-coated capture slide and there is no 3 
fluorophore. This lack of the SA aptamer ensures that GcvB-MG is only immobilised on the 






Figure 4.25. Design of the DNA in vitro transcription template for GcvB-MG. A schematic of the DNA IVT template. The 






In order to interact with the mRNA targets on the RNA array, GcvB must fold 
correctly. Therefore, RNAFold was used to predict the secondary structure of GcvB and 
compare it to the expected RNA product of GcvB-MG. Figure 4.26 shows that the key 
structural elements predicted to be present in GcvB (SL1-5, R1 and R2) are also predicted 
to be present in GcvB-MG. It was possible that the addition of an unstructured linker region 
to GcvB, to create GcvB-MG, could interact with the mRNA targets. Therefore, the IntaRNA 
webtool was used to determine if interactions would be predicted. The results showed that 
the additional unstructured linker is unlikely to interact with any of the putative mRNA 




Figure 4.26. Comparison of the predicted secondary structure of GcvB and GcvB-MG. (Top) The predicted secondary 
structure of GcvB contains 5 stem-loops (grey rectangles labelled SL1-5) and interaction regions in areas with low base-
pairing probability (red lines labelled R1 and R2). (Bottom) The predicted secondary structure of GcvB-MG also contains 
5 stem-loops (grey rectangles labelled SL1-5) and two interaction regions (red lines labelled R1 and R2). In addition, it 
contains a 3 stem-loop (orange rectangle) and an unstructured linker (orange line).  
 
Following DNA IVT template design, gene synthesis primers were designed and 
obtained from Invitrogen (Thermo Fisher Scientific). The IVT DNA template was synthesised 
de novo in-house by TBIO-PCR using a 5-biotinylated primer to incorporate the 5 biotin 
(Chapter 2, section 2.2.3.2). The size of the DNA IVT template was verified by gel 
electrophoresis (Appendix 12) and the DNA template produced an IVT product of the 
expected length in solution (Appendix 13). 
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4.5.2.2. In situ binding of GcvB-MG on low-density arrays followed by probing of 
bound GcvB-MG post-array production with GAG-linker probe  
 
To confirm that GcvB can bind, and remain bound, to the mRNA targets when it is 
co-transcribed with its putative mRNA targets, a preliminary experiment was conducted 
using a low-density RNA array of a subset of the mRNA targets. ilvI and hisG mRNA targets 
were selected for this initial experiment because GcvB has consistently interacted with 
these mRNA targets when added post-array production. A sample (0.2 µl) of 200 nM of the 
5-biotinylated and 3-Alexa647 labelled ilvI, hisG, serC, thrC and ureA mRNA target DNA 
IVT templates and a sample (0.2 µl) of a mixture of 200 nM 5-biotinylated and 3-Alexa647 
labelled ilvI or hisG mRNA target DNA IVT template with 200 nM 5-biotinylated GcvB-MG 
DNA IVT template were spotted, in duplicate, onto a SA-coated slide, by manual spotting, 
to generate a DNA IVT template array.  
Since each of the mRNA target DNA IVT templates were fluorescently labelled, this 
allowed visualisation of the DNA IVT template array. The DNA IVT template array was then 
used to generate an unlabelled mRNA target array. During this step, the co-transcribed 
GcvB-MG binds to the mRNA targets. The RNA array was probed with 500 nM Alexa488-
labelled GAG-linker probe, to detect bound GcvB-MG. Finally, the mRNA target array was 
probed with 500 nM Alexa488-labelled SA-linker probe, to detect the mRNA targets. A 





Figure 4.27. Schematic of in situ binding of GcvB-MG on low-density arrays followed by probing of bound GcvB-MG 
post-array production with GAG-linker probe. (1) Samples (0.2 µl) of 200 nM of the 5-biotinylated and 3-Alexa647 
labelled ilvI, hisG, serC, thrC and ureA mRNA target DNA IVT templates are manually spotted, in duplicate, on an SA-
coated slide, by manual spotting, in the spotting control area. Samples (0.2 µl) of a mixture of 200 nM 5-biotinylated and 
3-Alexa647 labelled ilvI or hisG mRNA target DNA IVT template and 200 nM 5-biotinylated GcvB-MG DNA IVT template 
are co-spotted, in duplicate, onto a SA-coated slide, by manual spotting, in the co-spotting area. This generates a DNA 
IVT template array that can be visualised using an excitation wavelength of 635 nm and a Standard Red emission filter.  
(2) A corresponding unlabelled mRNA target array is generated from the DNA IVT template array in (1) by IVT and in situ 
capture. Co-transcribed unlabelled GcvB-MG binds to the mRNA targets in the co-spotting area. (2A) Bound GcvB-MG is 
probed with 500 nM antisense ssDNA 5-Alexa488-GAGAGAGAGAGAGAGAGAGA-3 (GAG-linker probe) and visualised 
using an excitation wavelength of 488 nm and a Standard Blue emission filter. (2B) The RNA array is probed with 500 nM 
Alexa488-labelled SA-linker probe and visualised using an excitation wavelength of 488 nm and a Standard Blue emission 
filter. 
 
As shown Figure 4.28, 1, each of the DNA IVT templates for the mRNA targets were 
successfully immobilised to the SA-coated slide. The presence of GcvB-MG does not appear 
to have affected the immobilisation of the ilvI or hisG DNA IVT templates. Since the GcvB-
MG DNA IVT template is unlabelled, it is not possible to determine if this template has also 
been immobilised. The GcvB-MG DNA IVT template was not labelled because an orthogonal 
fluorophore was not available. Prior to probing, no FI was detected for the unlabelled RNA 
slide (Figure 4.28, 2). Following probing of bound GcvB-MG with GAG-linker probe, 
significant FI was detected for the ilvI and hisG mRNA targets in the co-spotting area (Figure 
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4.28, 2A), indicating that GcvB-MG had been transcribed and bound to the mRNA targets 
in this area. As expected, no FI was detected for any of the mRNA targets in the control 
spotting area, presumably because no GcvB-MG was transcribed or bound in this area. To 
confirm that these mRNA targets were present on the array, and that the lack of GAG-linker 
probe FI signal in this area is due to a lack of GcvB-MG, the RNA array was probed with 
Alexa488-labelled SA-linker probe (Figure 4.28, 2B).  
Following probing with SA-linker probe, FI signal was present for each of the RNA 
spots indicating that the mRNA targets were transcribed and captured in the control 
spotting area, but GcvB-MG was not present. The FI RNA spots in the co-spotting area also 
appear to increase following probing with the SA-linker probe, presumably due to the SA-
linker probe binding to the mRNA targets in this region as well. Overall, this experiment 
showed that GcvB-MG binds to the ilvI and hisG mRNA targets when they are co-
transcribed.   
 
Figure 4.28. In situ binding of GcvB-MG on low-density arrays followed by probing of bound GcvB-MG post-array 
production with GAG-linker probe. (1) Samples (0.2 µl) of 200 nM of the 5-biotinylated and 3-Alexa647 labelled ilvI, 
hisG, serC, thrC and ureA mRNA target DNA IVT templates were manually spotted, in duplicate, on an SA-coated slide, by 
manual spotting, in the spotting control area. Samples (0.2 µl) of a mixture of 200 nM 5-biotinylated and 3-Alexa647 
labelled ilvI or hisG mRNA target DNA IVT template and 200 nM 5-biotinylated GcvB-MG DNA IVT template were co-
spotted, in duplicate, onto a SA-coated slide, by manual spotting, in the co-spotting area. This generates a DNA IVT 
template array that can be visualised using an excitation wavelength of 635 nm and a Standard Red emission filter. (2) A 
corresponding unlabelled mRNA target array is generated from the DNA IVT template array in (1) by IVT and in situ 
capture. Co-transcribed unlabelled GcvB-MG binds to the mRNA targets in the co-spotting area. (2A) Bound GcvB-MG is 
probed with 500 nM Alexa488-labelled GAG-linker probe and visualised using an excitation wavelength of 488 nm and a 
Standard Blue emission filter. (2B) The RNA array is probed with 500 nM Alexa488-labelled SA-linker probe and visualised 
using an excitation wavelength of 488 nm and a Standard Blue emission filter. 
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4.5.2.3. In situ binding of GcvB-MG on high-density arrays followed by probing of 
bound GcvB-MG post-array production with GAG-linker probe  
 
Having confirmed that GcvB-MG binds to the ilvI and hisG mRNA targets when they 
are co-transcribed, the next step was to screen each of the putative mRNA targets of GcvB 
using this strategy. A high-density array with the layout shown in Figure 4.29 was used for 
this experiment. The 5-biotinylated and 3-Alexa488 labelled DNA IVT template for each of 
the mRNA targets was spotted, in triplicate, on an SA-coated slide, and at a fixed 
concentration of 100 nM using an automated arrayer robot. A mixture of 100 nM 5-
biotinylated and 3-Alexa488 labelled DNA IVT template for each of the mRNA targets 
together with 100 nM 5-biotinylated GcvB-MG DNA IVT template was also spotted, in 
triplicate, for each of the mRNA targets.  
Finally, four negative controls were also spotted: 1 – buffer; 2 – 100 nM 5-
biotinylated GcvB-MG DNA IVT template; 3 – 100 nM 5-biotinylated and 3-Alexa488 
labelled DNA IVT template for a control ilvC mRNA target (ilvC-S) in which the GcvB-
interacting region has been scrambled on the mRNA (Figure 4.30); 4 – a mixture of 100 nM 
5-biotinylated and 3-Alexa488 labelled DNA IVT template for ilvC S together with 100 nM 
5-biotinylated GcvB-MG DNA IVT template.  
Since fluorescently labelled DNA IVT templates for the mRNA targets were used, the 
DNA IVT template array could be visualised. The DNA IVT template array was then used to 
generate an unlabelled mRNA target array. During this step, co-transcribed GcvB-MG binds 
to the mRNA targets. The RNA array was probed with 500 nM Alexa488-labelled GAG-linker 
probe, to detect bound GcvB-MG. Finally, the mRNA target array was probed with 500 nM 
Alexa647-labelled SA-linker probe, to detect the mRNA targets. A schematic of the 





Figure 4.29. Schematic of in situ binding of GcvB on high-density arrays followed by probing of bound GcvB post-array 
production with GAG-linker probe. (1) (Top) Three fields (R1, R2 and R3) of 3 x 4 spots were spotted with 100 nM 5-
biotinylated and 3-Alexa488 labelled mRNA target DNA IVT template with an automated arrayer robot. (Bottom) Three 
fields (R1, R2 and R3) of 3 x 4 spots were spotted with a mixture of 100 nM 5-biotinylated and 3-Alexa488 labelled mRNA 
target DNA IVT template together with 100 nM 5-biotinylated GcvB-MG DNA IVT template with an automated arrayer 
robot. A buffer control and a 100 nM 5-biotinylated GcvB-MG DNA IVT template control were spotted in all six fields. The 
DNA IVT template array was visualised using an excitation wavelength of 488 nm and a Standard Blue emission filter. (2) 
A corresponding unlabelled mRNA target array is generated from the DNA IVT template array in (1) by IVT and in situ 
capture. (2A) GcvB-MG bound to the mRNA target array is probed with 500 nM Alexa488-labelled GAG-linker probe and 
visualised using an excitation wavelength of 488 nm and a Standard Blue emission filter. (2B) The RNA array is probed 
with 500 nM Alexa647-labelled SA-linker probe and visualised using an excitation wavelength of 635 nm and a Standard 
Red emission filter. 
 
 
Figure 4.30. Design of the DNA in vitro transcription template for the ilvC-S mRNA. The DNA IVT template for the ilvC-S 
mRNA has the same general architecture as that presented in Figure 4.2. The RNA of interest (ROI) region for this DNA 
IVT template is shown with the sequence for ilvC (left) and ilvC-S (right). The seed region of ilvC that is predicted to interact 





As shown Figure 4.31, 1, visualisation of the DNA IVT template array reveals FI for 
each of the spots containing immobilised 5-biotinylated and 3-Alexa488 labelled mRNA 
target DNA IVT template, including the ilvC-S mRNA. As expected, no FI was detected for 
the buffer spots or the spots containing immobilised unlabelled 5-biotinylated GcvB-MG 
DNA IVT template. The presence of GcvB-MG does not appear to have adversely affected 
the immobilisation of the mRNA target DNA IVT templates. Since the GcvB-MG DNA IVT 
template is unlabelled, it is not possible to determine if this template has also been 
immobilised. Prior to probing, no FI was detected for the unlabelled RNA slide generated 
from the DNA IVT template array by IVT and RNA capture (Figure 4.31, 2). Following probing 
of bound GcvB-MG with Alexa488-labelled GAG-linker probe, significant FI was detected 
for each of the RNA spots generated by co-transcription of the mRNA target and GcvB-MG, 
except for the RNA spot generated by co-transcription of ilvC-S mRNA and GcvB-MG (Figure 
4.31, 2A). This indicates that GcvB-MG had been transcribed and has bound to each of the 
mRNA targets except for ilvC-S mRNA.  
The level of bound GcvB detected was dependent on the mRNA target. Also, as 
expected, no FI was detected for the buffer spots and the GcvB-MG spots, suggesting that 
the GcvB-MG RNA is not captured directly by the SA-coated slide, or any of the mRNA 
targets transcribed in the absence of GcvB-MG. To confirm that the mRNA targets 
transcribed in the absence of GcvB-MG, and ilvC-S mRNA transcribed in the presence of 
GcvB-MG are immobilised on the RNA array, the array was probed with Alexa647-labelled 
SA-linker probe (Figure 4.31, 2B). The use of orthogonal fluorophores for the GAG-linker 
probe and the SA-linker probe allowed independent detection of the mRNA target co-
transcribed with GcvB-MG.  
Following probing with SA-linker probe, FI signal was present for each of the RNA 
spots, except for the buffer spots and the GcvB-MG spots. This indicates that each of the 
mRNA targets that were expected to be transcribed and captured were transcribed and 
captured. The levels of RNA that were transcribed and captured were dependent on the 
mRNA target, as observed previously. Co-transcription of GcvB-MG does not appear to 
have significantly affected this trend. Overall, this experiment showed that GcvB-MG binds 




Figure 4.31 In situ binding of GcvB on a high-density array followed by probing of bound GcvB post-array production 
with GAG-linker probe. (1) (Top) A representative field of 3 x 4 spots spotted with 100 nM 5-biotinylated and 3-Alexa488 
labelled mRNA target DNA IVT template with an automated arrayer robot. (Bottom) A representative field of 3 x 4 spots 
spotted with a mixture of 100 nM 5-biotinylated and 3-Alexa488 labelled mRNA target DNA IVT template and 100 nM 
5-biotinylated GcvB-MG DNA IVT template with an automated arrayer robot. A buffer control and a 100 nM 5-
biotinylated GcvB-MG DNA IVT template control were spotted in both fields. The DNA IVT template array was visualised 
using an excitation wavelength of 488 nm and a Standard Blue emission filter. (2) The corresponding fields of the 
unlabelled mRNA target array generated from the DNA IVT template array in (1) by IVT and in situ capture. (2A) GcvB-MG 
bound to the mRNA target array probed with 500 nM Alexa488-labelled GAG-linker probe and visualised using an 
excitation wavelength of 488 nm and a Standard Blue emission filter. (2B) The RNA array probed with 500 nM Alexa647-
labelled SA-linker probe and visualised using an excitation wavelength of 635 nm and a Standard Red emission filter. A 
plot of mean FI (in a.u.) for SA-linker probe bound to the mRNA target (red bars) and for GAG-linker probe bound to GcvB-




Normalising the mean FI for the SA-linker bound to the mRNA target spots to the 
mean FI for the DNA IVT template (Figure 4.32, A) confirms that the levels of the 
immobilised mRNA targets differ. The mean FI for GAG-linker probe, bound to GcvB-MG, 
bound to the mRNA target, was normalised to the mean FI for the SA-linker bound to the 
same mRNA target to give an interaction efficiency (Figure 4.32, B). This analysis confirmed 
the observation that the level of GcvB-MG binding may be mRNA target specific. The trend 
in interaction efficiencies for GcvB-MG binding was similar to the trend observed for GcvB-
Cy3 binding. Therefore, similar results were obtained whether GcvB bound to the mRNA 
target post-array production or in situ during co-transcription and mRNA target capture.  
The highest interaction efficiency for GcvB-MG binding was to the mRNA target ilvI, 
closely followed by ilvC. GcvB-MG interaction efficiencies for the other seven mRNA targets 
were seen to be lower. As expected, the interaction efficiency for GcvB-MG binding to the 
control mRNA, ilvC-S was significantly reduced compared to the test mRNAs, but not zero. 
The relative ratio between ilvC and ilvC-S indicated a 9.5-fold decrease. Despite IntaRNA 
not predicting an interaction between GcvB seed region and ilvC-S scrambled interaction 
region, visual inspection of the ilvC-S sequence shows it contains three CACAA 
pentanucleotide repeats which are complementary to part of the GcvB seed region: 
(CATAACAACATAACAATGATGATGGTGATGAGTAGATAACAACACACTCAACATCATACAATAA
ATAAGGAAGCACAAAATGGCTAACTATTTCAACACATTAAACTTACGTCAAAAATTAGAC), which 




Figure 4.32. Quantification of in situ binding of GcvB on a high-density array by probing of bound GcvB post-array 
production with GAG-linker probe. (A) The transcription efficiencies were calculated by normalising the mean FI for the 
SA-linker bound to the mRNA target spots to the mean FI for the corresponding DNA IVT template spots. (B) The GcvB-
MG interaction efficiency was calculated by normalising the mean FI for the GAG-linker probe, bound to GcvB-MG, bound 
to the mRNA target, to the mean FI for the SA-linker probe bound to the same mRNA target. 
 
To further investigate the relative interaction efficiency of GcvB-MG binding to each 
of the predicted mRNA targets preliminary experiments were conducted that involved co-
spotting a fixed concentration of DNA IVT template for the mRNA target and a 
concentration range of GcvB-MG. Four mRNA targets were selected to test this approach, 
ilvI, ilvC, hisG and ilvC-S. ilvI, ilvC and hisG were chosen because GcvB-MG bound to these 
mRNA targets with the highest interaction efficiencies in previous experiments, and ilvC-S 
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provides a control. A mixture of 100 nM 5-biotinylated and 3-Alexa647 labelled DNA IVT 
template for the ilvI, ilvC, hisG and ilvC-S mRNA targets and 0, 5, 10, 25, 50, 100, 125, 150, 
200, 250, 250 or 300 nM 5-biotinylated GcvB-MG DNA IVT template was spotted, in 
triplicate, on an SA-coated slide, using an automated arrayer robot, to generate an DNA 
IVT template array. This was visualised using the Alexa647 fluorophore. The layout of the 
DNA IVT template array is shown in Figure 4.33.  
 
Figure 4.33. Schematic of the layout of the high-density DNA IVT template array for in situ binding of a concentration 
range of GcvB. (1) Three grids of 2 x 2 fields of 4 x 3 spots were spotted with a mixture of 100 nM 5-biotinylated and 3-
Alexa647 labelled ilvI, ilvC, hisG or ilvC-S mRNA DNA IVT template and 0, 5, 10, 25, 50, 100, 125, 150, 200, 250, 250 or 300 
nM 5-biotinylated GcvB-MG DNA IVT template with an automated arrayer robot. The DNA IVT template array is visualised 
using an excitation wavelength of 647 nm and a Standard Red emission filter. 
 
This DNA IVT template array was used to generate an unlabelled RNA array by IVT 
and RNA capture on an SA-coated slide. During this step, co-transcribed GcvB-MG binds to 
the mRNA targets. The RNA array was then probed with 500 nM Alexa488-labelled GAG-
linker probe, to detect bound GcvB-MG and with 500 nM Alexa647-labelled SA-linker 
probe, to detect the mRNA targets. As shown in Figure 4.34, A, visualisation of the DNA IVT 
template array reveals FI for each of the spots containing immobilised 5-biotinylated and 
3-Alexa647 labelled mRNA target DNA IVT template. Following probing of bound GcvB-MG 
  
 172 
with Alexa488-labelled GAG-linker probe, increasing FI was detected for the RNA spots 
generated by co-transcription of the ilvI, ilvC and hisG mRNA targets and GcvB-MG with 
increasing concentration of spotted GcvB-MG DNA IVT template (Figure 4.34, 2A). No FI 
was visible for the RNA spots generated by co-transcription of ilvC-S mRNA and GcvB-MG. 
For the ilvI mRNA target, FI was detected for 5 nM GcvB-MG DNA IVT template (the lowest 
concentration spotted) and above. For the ilvC and hisG mRNA targets, FI was not detected 
until approximately 50 nM GcvB-MG DNA IVT template. This suggests that the efficiency of 
GcvB-MG binding may depend on the mRNA target. To confirm that the differential binding 
was not due to the mRNA target level on the RNA array, the array was probed with 
Alexa647-labelled SA-linker probe (Figure 4.34, 2B). Following probing with SA-linker 
probe, FI signal was present for each of the RNA spots.  
 
 
Figure 4.34. In situ binding of a concentration range of GcvB to mRNA targets. (1) A representative grid of 2 x 2 fields of 
4 x 3 spots spotted with a mixture of 100 nM 5-biotinylated and 3-Alexa647 labelled ilvI, ilvC, hisG or ilvC-S mRNA DNA 
IVT template and 0, 5, 10, 25, 50, 100, 125, 150, 200, 250, 250 or 300 nM 5-biotinylated GcvB-MG DNA IVT template with 
an automated arrayer robot. The DNA IVT template array was visualised using an excitation wavelength of 635 nm and a 
Standard Red emission filter. (2A) GcvB-MG bound to the corresponding mRNA target array probed with 500 nM 
Alexa488-labelled GAG-linker probe and visualised using an excitation wavelength of 488 nm and a Standard Blue 
emission filter. (2B) The RNA array probed with 500 nM Alexa647-labelled SA-linker probe and visualised using an 




 To investigate the relative binding of GcvB-MG to ilvI, ilvC and hisG further, the 
mean Alexa488 GAG-linker probe FI, representing the level of bound GcvB-MG, was 
normalised to the mean Alexa647 SA-linker probe FI, representing the mRNA target level, 
and plotted against the concentration of GcvB-MG DNA IVT template that was spotted 
(Figure 4.35). The level of GcvB-MG bound appears to increase with increasing 
concentration of GcvB-MG DNA IVT template, before reaching a plateau. The level of the 
plateau is highest for ilvI, followed by ilvC and lowest for hisG.  
 
 
Figure 4.35. Analysis of in situ binding of a concentration range of GcvB to mRNA targets. Mean Alexa488 GAG-linker 
probe FI, normalised to the mean Alexa647 SA-linker probe FI, plotted against the concentration of GcvB-MG DNA IVT 





4.6. Summary and conclusions 
 
In this chapter, the novel RNA array platform that has been developed in the 
Callaghan group at the University of Portsmouth, has been applied to the validation of the 
GcvB-mRNA target interactions that were predicted in Chapter 3. Initially, an RNA array of 
the nine putative mRNA targets of GcvB was designed and synthesised. Analysis of the RNA 
levels on this RNA array indicated that each of the RNAs may be transcribed/captured with 
a different transcription efficiency. This suggests that the observed transcription efficiency 
is a property of the DNA IVT template/mRNA, or RNA capture efficiency by the transcribed 
RNA conjugate. This variability in the RNA levels for different RNA species should therefore 
be considered when analysing interaction data.  
Having successfully generated an RNA of putative mRNA targets of GcvB, two 
strategies were devised to screen them for GcvB binding. The first strategy involved 
probing the RNA array post-array production with in vitro transcribed GcvB. This strategy 
has been used successfully for other sRNA-mRNA interactions and RNA-small molecule 
interactions (Phillips et al., 2018; Henderson et al., 2019). Using this strategy, GcvB bound 
to each of the putative mRNA targets identified in Chapter 3. Once the levels of mRNA 
target RNA had been accounted for, differences in interaction efficiencies were clearly 
identified for GcvB binding to each of the mRNA targets.  
 The second strategy to investigate GcvB binding was to co-transcribe the GcvB with 
the mRNA target to allow binding of GcvB to the mRNA target in situ. This strategy may 
more closely mimic the situation in vivo and has also been used successfully to investigate 
regulatory RNA interactions (Norouzi et al., 2019). This strategy also suggested interaction 
between GcvB and each of the predicted mRNA targets. Further, the interactions identified 
appears to be specific as a control mRNA target, in which the GcvB-interacting region had 
been scrambled, bound GcvB with a significant decreased rate.  
Similar to the results obtained when adding GcvB post-array production, the data 
suggested that there are GcvB-interaction preferences between the mRNA targets which 
warrant further study. As discussed in the Introduction Chapter, due to their role in 
bacterial pathogenesis, sRNAs potentially represent a novel therapeutic target. Having 
experimentally validated that GcvB interacts with the predicted mRNA targets, with 
recognised links to bacterial virulence, the following Chapter will explore targeting the 
  
 175 
GcvB with an antisense nucleic acid mimic (NAM) to disrupt these interactions as a 






5. Analysis of the use of a PNA molecule to disrupt sRNA-




Section 1.3.3 in the Introduction Chapter discussed the possibility of therapeutic 
targeting of bacterial small RNAs (sRNAs) due to their role in bacterial virulence. Among 
sRNA types, bacterial trans-acting sRNAs regulate gene expression by targeting a set of 
genes located in distant loci in the genome, which are often involved in similar metabolic 
pathways that may be linked to virulence. This type of post-transcriptional regulation 
occurs when the sRNA binds to specific sequences of their target mRNAs, altering 
translation through post-transcriptional mechanisms. The sRNA-mRNA base-pairing region 
consists of imperfect complementarity of a short stretch of sequence, known as the seed 
region.  
Following in silico analysis in Chapter 3, a seed region has been predicted to be 
present in a single stranded region of GcvB. Consecutive target prediction analysis of GcvB 
confirmed that a set of putative mRNAs linked to pathogenicity in APP may interact with 
GcvB in this predicted seed region. The interaction validation pipeline carried out in 
Chapter 4 revealed that all of the nine selected predicted mRNA targets interact with the 
GcvB with differing interaction efficiencies. These outputs lead to the second part of the in 
vitro experiments regarding exploring GcvB-mRNA target interaction disruption. Therefore, 
the aim of this final chapter was to specifically disrupt GcvB pairing to mRNA targets using 
a nucleic acid mimic (NAM) which binds specifically to the GcvB seed region (Figure 5.1). 
Evidence that a nucleic acid mimic can disrupt GcvB pairing to mRNA targets responsible 





Figure 5.1.  Interaction disruption assays. The predicted GcvB-mRNA interactions were validated by the interaction assays. The final part of this study utilises the RNA Array method to explore 
the disruption of the validated GcvB-mRNA interactions using a final strategy where a specifically designed PNA molecule is added to the established interaction assays. The expected output is 
an effective PNA molecule that disrupts these interactions. 
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5.1.1. Antisense inhibition of sRNAs by PNAs 
 
The concept of antisense inhibition of sRNAs is based on the possibility of 
interfering in the regulation of gene expression in the bacterial cell, by modulating the 
mechanisms of mRNA regulation by sRNAs. As reviewed in Chapter 1 (section 1.3.3), 
antisense inhibition technology by NAMs, such as PNA, has been previously used in 
prokaryote cells to target mRNAs and inhibit their expression. However, the use of 
antisense NAMs for targeting trans-acting sRNAs, instead of mRNAs, is a more versatile 
strategy, as it enables the regulation of an entire metabolic pathway to be controlled 
through the disruption of the functionality of a single sRNA. This is because trans-acting 
sRNAs often interact with a multitude of mRNA targets linked to a bacterial pathway, such 
as those involved in virulence or pathogenicity, thus only one NAM specific to the seed 
region of the targeted sRNA would be necessary to affect a pathway, replacing the 
necessity to introduce a NAM for each targeted mRNA.  
Antisense targeting of sRNAs by NAMs works by blocking the seed region of the 
sRNA, preventing its mechanisms of regulation, as shown in Figure 5.2. Different to the 
imperfect base-pairing of sRNA-mRNA interactions, a NAM may be designed to pair with a 
given sRNA with perfect complementarity to its full or partial seed region sequence, 
offering a high affinity interaction which may favour NAM binding, instead of the mRNA, in 
a competition for the sRNA seed region. Once the NAM specifically binds to the 
complementary region in the sRNA, it disrupts seed region functionality, which may 
eventually lead to sRNA degradation by nucleases. 
A short literature review on antisense therapy in Chapter 1 (section 1.3.3) 
introduced a few types of NAMs currently used in biotechnology. However, more 
commonly used in antibacterial studies are peptide nucleic acids (PNAs), and morpholinos 
(MOs) (Good et al., 2001; Geller et al., 2003; reviewed in Summerton, 2006; Verona et al., 
2017). Like morpholinos, PNAs are uncharged nucleic acid mimics that lack a deoxyribose 
or ribose sugar backbone. The modified backbone of PNAs and MOs increases protection 
against enzymatic degradation, making them an ideal option for in vivo as well as in vitro 
studies. However, a higher affinity for RNA molecules is observed in PNAs in comparison to 
MOs (Summerton, 2006). For this study, PNA was chosen as the most suitable option of 
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antisense molecule due to its chemical simplicity, biological stability, and high affinity 
hybridisation with RNA. 
 
 
Figure 5.2. Controlling bacterial gene expression by targeting sRNAs with antisense NAMs. A) In bacterial cells, post-
transcriptional regulation of mRNAs is often regulated by interaction with the seed region of sRNAs through a variety of 
mechanisms, resulting in the mRNA-sRNA duplex degradation by nucleases (1), concealing of the ribosomal binding site 
(RBS) inhibiting mRNA translation (2), or change of the mRNA structural conformation to expose its RBS and facilitate 
translation (3). These mRNAs may be involved in metabolic pathways linked to virulence, thus the versatile regulation by 
sRNAs may promote the amplification of bacterial pathogenicity. B) Inhibiting the sRNA seed region by antisense NAMs 
may revert mRNA regulation in the opposite direction of its original regulation; discontinue the recruiting of nucleases 
prolonging mRNA availability for translation by ribosomes (1), halt influence on the RBS of the mRNA for up (2) or down 
(3) regulation of a specific protein. 
 
5.2. Method development to test PNA disruption of GcvB-mRNA interactions 
 
In the previous chapter, separate co-spotting of IVT DNA templates of modified 
GcvB (GcvB-MG) with each of the nine predicted target mRNAs has been established as the 
preferred RNA Array method to study RNA-RNA interactions. This is due to the flexibility of 
the approach in testing the interactions of different pairs of molecules in a high throughput 
manner, in choice of different concentration gradients of the GcvB, and with reduced 
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probing and washing steps. Incorporating these positives assay aspects, a modified version 
of the co-spotting strategy described in section 4.5.2 was proposed for the next set of 
experiments to explore disruption of the validated GcvB-mRNA interactions, through 
addition of an antisense PNA molecule designed to bind to the seed region of GcvB. The 
PNA was incorporated in the IVT step of the RNA Array protocol and details of the PNA 
design and disruption assay strategy are detailed below. 
 
 
5.2.1. Designing a PNA molecule to disrupt GcvB pairing to mRNA targets 
 
As previously observed (Chapter 4, section 4.5.2.3), when the predicted binding 
region of the target mRNA ilvC is scrambled (creating ilvC-S), a decrease in the interaction 
efficiency of GcvB-ilvC vs GcvB-ilvC-S of approximately 90% is observed. The 5-nucleotide 
sequence 5’ – CACAA – 3’ is located in the core of the predicted mRNA binding site for GcvB 
and repeated three times along the ilvC mRNA. This was therefore used as the basis for the 
PNA sequence design. This A/C-rich sequence is perfectly complimentary to the core 
portion of the 13-nucleotide sequence of the predicted G/U-rich seed region of GcvB. This 
suggests optimal GcvB-mRNA target sequence complementarity around this area 
supporting interaction pairing, and therefore serves as the candidate region for PNA 
targeting to promote GcvB-mRNA interaction disruption. Based on these observations, and 
the in silico studies from Chapter 3, the inhibitor PNA molecule sequence was designed 
antisense to the putative G/U-rich seed region of GcvB (Figure 5.3), using a PNA design tool 
from PNA Bio (Chapter 2, section 2.3.3). 
The PNA molecule was synthesised by Panagene Inc. The 10-nucleotide construct 
included a cell penetrating peptide (CPP) at the 5’ end of the PNA. CPPs facilitate cellular 
intake of a range of molecules, including DNA and NAMs such as PNA. Inclusion of a CPP-
tag supports potential future in vivo experiments, so will not be considered further as part 





Figure 5.3. PNA sequence design antisense to the G/U-rich seed region of GcvB. A) A schematic of GcvB containing 5 
stem-loops and two single stranded conserved regions (R1 and R2). The putative G/U-rich seed region of GcvB is located 
in R1, and the nine predicted targets mRNAs are anticipated to interact with partial complementarity in this area. The 
PNA molecule was designed to target this region by antisense complementarity. B) The actual seed region (R1) sequence 
perfectly paired against the designed PNA sequence. C) The final PNA design with the addition of a cell penetrating 
peptide. The PNA nucleotide sequence was verified for non-specific binding to mRNA target sequences using the IntaRNA 
webtool and no interaction was predicted in any functional region of the RNA constructs for all targets. 
 
 
5.2.2. An experimental strategy for testing PNA disruption of GcvB-mRNA interactions  
 
The co-spotting strategy to exploit the disruption of GcvB-mRNA interactions 
consisted of mixing the IVT DNA templates of GcvB-MG (often referred to as simply GcvB 
going forwards in this chapter) and target mRNAs prior to the immobilisation step on the 
streptavidin coated (SA-coated) slide, as described in the section 4.5.2 of Chapter 4. The 
standard RNA array protocol was modified to accommodate the addition of the PNA in the 
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IVT mixture prior to the IVT step, in which SA-coated slides are sandwiched and incubated 
for 30 minutes at 37oC. However, the addition of PNA to the IVT mixture was expected to 
disrupt the previously validated GcvB-mRNA interactions, as PNAs present high affinity 
properties for hybridisation in comparison to RNAs and single stranded DNAs (Summerton, 
2006), suggesting the PNA would preferentially bind GcvB instead of an mRNA target. The 
slides were then separated, and any unbound molecules were removed in a modified 
washing step, using hybridisation buffer (Appendix 14) instead of the standard protocol of 
1 x Phosphate-Buffered Saline (PBS) with 0.02% (v/v) Tween 20 (1 x PBST) (Appendix 14). 
The washing steps removed molecules unbound to the immobilised mRNAs, specifically 
GcvB bound to PNA.  
Since the RNA slide contains the immobilised mRNAs and any bound GcvB, both of 
which are unlabelled, probing steps were required to detect both sets of molecules. This 
involved the addition of two fluorescently labelled antisense ssDNA probes: namely the SA-
Linker probe against the SA-Linker of the target mRNA to detect its presence within the 
spot (described in Figure 4.8, section 4.3.2), and the GAG-Linker probe to detect the 
presence of GcvB interacting with the immobilised target mRNA (described in Figure 4.27 
of section 4.5.2.2). Finally, the probed RNA slide containing the immobilised target mRNAs 
and any interacting GcvB was analysed to provide information on whether GcvB-mRNA 
interaction efficiencies had decreased following the addition of PNA. A schematic summary 
of the strategy is shown in Figure 5.4. Assay configuration and results are presented and 






Figure 5.4. Experimental strategy schematic for PNA disruption of a GcvB-mRNA interaction. An SA-coated slide 
containing the fluorescently labelled (Alexa488 or Alexa647) DNA templates of the target mRNAs and unlabelled IVT DNA 
templates of GcvB-MG, was used to produce the corresponding unlabelled RNA slide following IVT. The target mRNAs 
containing the RNA SA Aptamer are captured and immobilised on the SA-coated slide. PNA is free in the IVT mixture and 
may hybridise with GcvB-MG at a given rate. Transcribed GcvB-MG molecules may bind to PNAs, interact with a target 
mRNA or remain unbound in the liquid. Unbound molecules are removed during the washing step. The RNA slide is then 
probed with the GcvB-MG GAG-Linker Alexa488 probe to explore whether any GcvB-mRNA interaction occurred. The 
signal from the GAG-Linker probe is expected to be weaker following with the addition of PNA, which has been designed 
to block GcvB pairing to target mRNAs. The SA-Linker Alexa647 probe is also added to the RNA slide to confirm the 
presence of the mRNA targets in their specific spot, making it possible to quantify interaction efficiencies and to validate 






5.3.  Exploring disruption of validated GcvB-mRNA interactions using PNA 
 
Chapter 4 demonstrated successfully using the RNA array approach to investigate 
GcvB-mRNA interactions. Building on learnings, and as described in 5.2, a PNA has been 
designed to inhibit GcvB-mRNA pairing through binding to the G/C-rich putative GcvB seed 
region, and a strategy developed to test PNA impact on the GcvB-mRNA interactions using 
the RNA array. Details of establishing the PNA-disruption assay on the RNA array, together 
with the findings and analysis of the impact of PNA on the GcvB-mRNA interactions, are 
provided below. 
 
5.3.1. Establishing a PNA-disruption assay on the RNA array 
 
Using the experimental strategy in section 5.2.2, DNA templates of GcvB-MG and 
the mRNAs were synthesised with the 5’ biotinylated immobilisation oligo, but only the 
target mRNA DNA templates were synthesised with 3’ fluorescent Alexa488 label. Because 
template spotting concentrations over 200 nM may saturate the spot for some DNA IVT 
templates, the final concentration of each molecule was set to 100 nM to accommodate 
for co-spotting. Two DNA slides were generated by co-spotting the DNA templates with an 





Figure 5.5. DNA slide spotting schematic for the PNA-disruption assay. The SA-coated DNA slide contained automated 
high throughput spotting of IVT DNA templates: each field accommodated a four-spot repetition of co-spotted IVT DNA 
templates for GcvB-MG and the nine predicted target mRNAs plus ilvC-S, with final constant concentration of 100 nM 
each. The IVT DNA templates for the targets were fluorescently labelled with Alexa488, while GcvB-MG templates were 
unlabelled. Two control fields were added, one with buffer only and the other was reserved for the GcvB-MG DNA 
template on its own. 
 
Once the DNA templates were immobilised, one of the DNA slides was sandwiched 
with its partner RNA slide with a standard IVT mixture recipe, without the PNA molecule. 
The remaining DNA slide was also sandwiched with its partner RNA slide, but the IVT 
mixture was complemented with 500 nM of the previously designed PNA molecule. The 
choice of concentration for the inhibitory molecule was based on the standard 
concentration used for the added detection probes. Both sandwiched slide pairs were 
incubated in a humidified chamber following the standard RNA array protocol, and then 
transferred to room temperature for extra 30 minutes to allow for GcvB interaction with 
its target mRNAs. The slides were then separated and washed with hybridisation buffer. 
The slides with the captured RNA and any interacting GcvB were incubated with 500 nM of 
the GAG-Linker Alexa 488 probe, against the extra linker in GcvB (i.e., GcvB-MG), and with 
the SA-Linker probe Alexa647 antisense to the SA linker in the mRNA constructs (Chapter 
4, section 4.5.2). Both slides were then visualised using excitation wavelengths of 488 nm 






Figure 5.6. Visualisation of the PNA-disruption assay results. Actual visualisation of slides by the GenePix scanner. A) 
Schematic of the DNA IVT template slide layout is shown adjacent to visualisation of the fluorescently labelled templates 
on the slide. The RNA array is generated without the addition of PNA, probed with the GcvB-MG GAG-Linker probe 
Alexa488 visualised at 488 nm (2A) and the SA-Linker Alexa647 probe at 635 nm (2B). B) Schematic of the DNA IVT 
template slide layout and visualised slide is as in (A). The RNA array is produced with the addition of PNA in the IVT 
mixture, and the slide visualised following identical probing steps to those described in A.  
 
Visual analysis of the RNA slide generated without the addition of PNA, scanned at 
635 nm to detect the mRNA-bound SA-Linker probe, exhibited signal for all of the nine 
target mRNAs and ilvC-S. This confirmed successful immobilisation of the mRNAs on the 
RNA slide. The same RNA slide, scanned at 488 nm, confirmed the presence of GcvB, 
through identification of the bound GAG-Linker probe indicating GcvB-mRNA interaction 
for all of the nine target ROIs, excluding the negative control ilvC-S, as expected. These 
results are consistent with the findings in Chapter 4, and for this reason, further detailed 
analysis of interaction studies is not provided in this section. Importantly, the control fields 
spotted with buffer, and the IVT DNA template for GcvB-MG, displayed no notable 
fluorescence signal for both wavelengths, indicating that no non-specific binding of GcvB-
MG or spotting contamination had occurred. By contrast, for the RNA slide generated with 
the addition of PNA in the IVT mixture, scanned at 635 nm to detect the mRNA-bound SA-
Linker probe exhibited signals for all the nine target mRNAs and ilvC-S, whilst scanning at 
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488nm revealed that fluorescent signal for the GcvB-MG-bound GAG-Linker probe was 
substantially reduced. This suggested that the addition of PNA may have reduced the 
interactions between GcvB and its target mRNAs, possibly as a consequence of the PNA 
binding to GcvB and thereby disrupting its ability to pair with its partner mRNA. This 
evidence of PNA-disruption of GcvB-mRNA interactions, generated from a modified RNA 
array assay, will be expanded and explored further below.  
 
5.3.2. Disrupting GcvB-mRNA interactions with PNA  
 
Section 5.3.1 established the PNA-disruption assay on the RNA array and 
demonstrated that the addition of 500 nM PNA to the IVT mixture in the IVT step of the 
RNA Array protocol affects GcvB-mRNA pairing for all the nine mRNA targets. However, 
under the conditions tested, it was seen that concentrations higher than 500nM would be 
required to completely inhibit GcvB-mRNA pairing. To explore this, it was necessary to 
undertake further experiments in which higher PNA concentrations were tested. The DNA 
IVT template slide layout is shown in Figure 5.7 and experiments were carried out as in 
5.3.1, except for that 4 slides were prepared to allow testing of 0 nM, 500 nm, 750 nM and 
1000 nM PNA concentrations. The maximum concentration of 1000 nM PNA was chosen 
as it represents double the final concentration of both probes (GAG-Linker for GcvB-MG 
and SA-Linker for the target mRNAs) and was therefore thought suitable for array studies. 
Additionally, a number of repeated technical controls were removed or reduced, as it has 
been consistently shown that GcvB-MG specifically binds to the immobilised mRNAs, 





Figure 5.7. DNA slide spotting schematic for the PNA-disruption assay and associated RNA array details. The SA-coated 
DNA IVT template slide (1) contains nine fields. Each field accommodates 11 spots in total representing the IVT DNA 
templates for each of the nine target mRNAs and ilvC-S co-spotted with GcvB-MG, plus a spot for the DNA template of 
GcvB-MG spotted on its own as a control monitoring for non-specific binding of GcvB-MG. The templates were spotted 
with a final constant concentration of 100 nM each. The IVT DNA templates for the target mRNAs and ilvC-S were 
fluorescently labelled with Alexa647, while GcvB-MG templates were unlabelled. Following IVT, the unlabelled RNA slide 
(2) is then probed with (2A) GAG-Linker probe labelled with Alexa488 which is visualised at an excitation wavelength of 
488 nm using a standard blue emission filter and indicates GcvB presence on the RNA array, and (2B) the SA-Linker probe 
labelled with Alexa647 which is visualised at an excitation wavelength of 635 nm using a standard red emission filter and 
identifies immobilised mRNAs. 
 
Visual inspection of the data produced (Figure 5.8), indicated a significant reduction 
in fluorescence signal for the GAG-linker probe at 488 nm, which identifies bound GcvB, 
aligned with an increasing concentration of PNA within the IVT step of the RNA array 
protocol. Specifically, in the absence of PNA (Figure 5.8, A), all co-spotted target mRNAs, 
with exception of the negative control ilvC-S, showed signal indicating interaction with 
GcvB to immobilised target mRNAs, identified by the SA-Linker probe when visualised at 
635 nm. For the same experiment in the presence of 500 nM, 750 nM, and 1000 nM PNA, 
immobilised target mRNAs were identified by the SA-Linker probe when visualised at 635 
nm. However, the level of bound GcvB was reduced for the 500 nM (Figure 5.8, B) and 750 
nM (Figure 5.8, C) PNA conditions, identified by the reduced signal following probing with 
the GAG-linker probe and scanning at 488 nm. This suggests the PNA has partially disrupted 
GcvB from pairing to its partner mRNAs. When PNA was present at 1000 nM (Figure 5.8, 
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D), no GcvB signal was identified, suggesting the complete disruption of GcvB pairing to its 
mRNAs. In line with previous results, no significant evidence of GcvB interacting with 
immobilised ilvC-S was obtained for any of the conditions tested.  
 
Figure 5.8. Visualisation of the results from the PNA-disruption assay. Actual visualisation of slides by the GenePix 
scanner: four identically spotted DNA slides (1) were used to generate the corresponding RNA array on the RNA capture 
slides. A) RNA array generated without the addition of PNA in the IVT step of the RNA Array protocol, probed with the 
GcvB-MG GAG-Linker probe Alexa488 visualised at 488 nm (2A) and the SA-Linker Alexa647 probe at 635 nm (2B). This 
strategy was repeated for the other three slides generated with the addition of 500 nM (B), 750 nM PNA (C) and 1000 
nM PNA in the IVT mixture (D).  
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The mean fluorescence for the bound GcvB was normalised for level of immobilised 
mRNA, for each PNA condition tested, and the interaction efficiencies displayed graphically 
in Figure 5.9, A. The data shows that in the absence of PNA, in line with previous findings, 
GcvB specifically interacts with all nine targets with differing levels of efficiency, except for 
the control, ilvC-S, for which no significant binding was seen and so has been omitted from 
the graph. As the level of PNA increases to 500 nM and 750 nM, the interaction efficiency 
is reduced, such that by 1000 nM PNA, there is no notable GcvB-mRNA interaction evident.    
Considering the disruption efficiency of the PNA for each of the GcvB-mRNA 
interactions, which identifies the change in interaction efficiency upon PNA addition, GcvB-
ilvI is most impacted. With the highest interaction efficiency, the presence of 500 nM PNA 
disrupts this by 63%, compared to GcvB-serC which has one of the lowest interaction 
efficiencies and is only disrupted by 30% by the presence of PNA, under the same 
conditions. Disruption efficiencies for 500 nM PNA show the most difference between the 
various GcvB-mRNA interactions (Figure 5.9, B). This can be considered as reflecting 
differences between the interaction efficiencies of the pairings themselves (Chapter 4, 
section 4.4.3.2), the binding preferences of GcvB to the PNA vs the mRNA, the possible 
differences in the region of GcvB that pairs to each mRNA and the associated impact of 
whether or not the PNA binding the GcvB completely or partially blocks the pairing site. 
These differences are not apparent for the 750 nM and 1000 nM PNA concentrations, 
which result in disruption efficiencies around the 80% and 90% levels respectively for all 





Figure 5.9. Analysis of PNA disruption of GcvB-mRNA pairing. The figure contains two graphs; A) the graph shows the 
interaction efficiency of GcvB bound to the immobilised target mRNAs in the presence of PNA concentrations from 0-
1000 nM, represented by dark blue bars (0 nM PNA) and orange bars coloured in three tones, light (500 nM PNA), 
moderate (750 nM PNA) and dark (1000 nM PNA) shades. B) The graph plots the disruption efficiency for GcvB and each 
target mRNA, for each concentration of PNA, and represents the interaction efficiency disrupted as a percentage of the 
total seen for the GcvB-mRNA interaction in the absence of PNA. The colour scheme is the same as that used for the 
upper graph.  
 
5.3.3. Exploring PNA-disruption of specific GcvB-mRNAs interactions in more detail  
 
Section 5.3.2 identified that the PNA designed to bind to the putative G/U-rich seed 
region of GcvB was capable of disrupting all GcvB-mRNA interactions tested. By 
comparison, section 4.5.2.3. allowed a more detailed assessment of GcvB pairing to specific 
mRNAs, namely ilvI, ilvC and hisG. These two approaches were combined to explore, in 
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more detail, disruption of GcvB interactions with ilvI, ilvC and hisG as a consequence of PNA 
presence. The DNA IVT template slide schematic is shown in Figure 5.10 and consisted of a 
concentration gradient of GcvB-MG co-spotted with a constant concentration of either ilvI, 
ilvC, hisG or ilvC-S as a control. The experiment was carried out as in 5.3.1, except that three 
slides were generated to allow testing of 0 nM, 500 nm, and 1000 nM PNA concentrations. 
As previously, the RNA slide was probed with the GcvB GAG-Linker probe to determine the 
presence of GcvB, and with the SA-Linker Alexa647, to quantify the amount of immobilised 
target mRNAs.  
 
 
Figure 5.10. DNA slide spotting schematic for the PNA-disruption assay involving co-spotting different concentrations 
of GcvB-MG with a set concentration of target mRNA. The spotting configuration of the mixed DNA IVT templates was 
set in a 4 x 3 pattern for a selection of three targets (ilvI, ilvC and hisG) and ilvC-S (control) only. The pattern was repeated 
three times in the same slide to generate replicates. The IVT DNA template for GcvB-MG was added to the co-spotting 
sample in a 16-spot gradient concentration ranging from 0 nM to 300 nM, while the concentration for the DNA IVT 




Visual inspection of the resulting data once again indicated that PNA disrupts GcvB 
pairing to mRNA targets ilvI, ilvC and hisG (Figure 5.11), as seen by the loss of probe signal 
indicative of GcvB presence, compared to mRNA probe levels, for experiments with PNA 
present compare to when PNA was absent.  
 
Figure 5.11. Visualisation of the results exploring disruption of specific GcvB-mRNA interactions with PNA in more 
detail. Actual visualisation of slides by the GenePix scanner: three identical DNA IVT template slides co-spotted with IVT 
DNA templates of the target mRNAs labelled with Alexa647 and unlabelled GcvB-MG were used to generate the 
corresponding RNA array on the RNA capture slides. A) RNA array generated without the addition of PNA, probed with 
the GcvB-MG GAG-Linker probe Alexa488 visualised at 488 nm (2A) and the SA-Linker Alexa647 probe at 635 nm (2B). 




The fluorescence of the bound GcvB was normalised for the level of immobilised 
mRNA for each different co-spotted GcvB concentration and PNA condition tested, and the 
interaction efficiencies displayed graphically in Figure 5.12. Logarithmic trendlines have 
been added as a visual aid only. The data shows that in the absence of PNA, for increasing 
concentrations of co-spotted GcvB, the interaction efficiency of GcvB to the immobilised 
mRNA target increased with increasing concentration of GcvB-MG DNA IVT template, 
before reaching a plateau. This trend applied to all three mRNAs tested, with ilvI having 
higher interaction efficiencies for all GcvB concentrations tested, compared to ilvC, and 
hisG having the lowest interaction efficiency for all GcvB concentrations tested. A similar 
profile was observed when 500nM PNA was included in the assay, although for each mRNA, 
the interaction efficiency was lower for all GcvB concentrations tested compared to in the 
absence of PNA. Finally, in the presence of 1000nM PNA, only minimal interaction 
efficiencies were seen for all GcvB concentrations tested.  
Considering each mRNA target, addition of 500nM PNA affects the interaction 
efficiencies differently. For example, 500 nM of PNA approximately halves the interaction 
efficiency of GcvB-ilvI and GcvB-hisG whereas it only reduces it by a third for GcvB-ilvC. In 
comparison addition of 1000nM PNA similarly affects the interaction efficiencies for all 
GcvB-mRNAs, reducing them by approximately 90% or more. This starts to give insights into 
the comparative affinities of the interactions, indicating differences in the competition of 
GcvB for PNA vs ilvI, hisG or ilvC. Whilst PNA similarly affects the GcvB-ilvI and GcvB-hisG 
interactions, GcvB seems to have more preference for ilvC binding compared to PNA, as 
the PNA does not reduce GcvB-ilvC interaction efficiency by as much. This provides a basis 
for informing future experiments to explore PNA-disruption of GcvB-mRNA interactions in 






Figure 5.12. Analysis of the results exploring disruption of specific GcvB-mRNA interactions with PNA in more detail. 
The graphs show the analysis of the interaction efficiency of GcvB-MG bound to the immobilised target mRNAs when 
PNA is added at different concentrations, represented by orange bars coloured in two tones, light (500 nM) and dark 
(1000 nM) shades. The blue bars represent the 0 nM PNA control. The interaction efficiencies are plotted for the 





5.4. Summary  
 
Building on the work in Chapter 3, coupled with insights on the GcvB-mRNA 
interactions from the studies in Chapter 4, this chapter has focused on the design and 
testing of a PNA to specifically disrupt GcvB-mRNA interactions. The PNA was designed 
antisense to the putative G/U-rich seed region of GcvB. A PNA-disruption assay was 
established on the RNA array. This built on the GcvB/mRNA co-spotting approach 
developed in Chapter 4 but incorporated the PNA within the IVT step of the RNA array 
protocol. Data indicated that the PNA successfully disrupted GcvB-mRNA interactions 
efficiencies to varying levels at the lower concentration tested, and almost completely 
disrupted the interactions at the higher concentrations tested.  
Work in Chapter 3 had noted that the predicted hybridisation energies for the 
pairing of GcvB to its mRNA targets vary, recognising that GcvB-ilvC and GcvB-ilvI have 
lower hybridisation energies than GcvB-hisG, for example (Table 3.3; Appendix 7). Such 
differences can partially be explained by the degree of pairing between GcvB and its mRNA 
targets (Figure 3.12). These predictive results aligned with the experimental findings in 
Chapter 4 where different interaction efficiencies were seen for the GcvB-mRNA target 
pairs, and with ilvI and ilvC repeatedly being identified as having the highest interaction 
efficiencies compared to GcvB-hisG as well as the other mRNA targets (Figure 4.32 and 
Figure 4.35).  
Given these differences, it is unsurprising that the addition of PNA results in 
different disruption efficiencies for the various GcvB-mRNA pairs. For example, GcvB-ilvC 
hybridisation involves a region of 18 consecutive nucleotides, whereas for ilvI it involves 10 
nucleotides. With a PNA of 10 nucleotides binding to a region that only partially disrupts 
these pairing sites, it is therefore not unexpected that the PNA has less disruptive effect on 
GcvB-ilvC (it reduces it by ~30% when added at 500nM), which has a larger region involved 
in hybridisation pairing, when compared to GcvB-ilvI which is more significantly disrupted 







Figure 5.13. Schematic illustration of the PNA aligned with the predicted pairing site for GcvB hybridised with ilvC and 
ilvI. The illustration shows the GcvB sequence within the R1 region seed region hybridised to either ilvC (upper) or ilvI 
(lower). The percentage identity for the mRNAs was coloured in purple gradient. The PNA sequence (red) is aligned to 
where it is expected to pair with GcvB, in place of the partner mRNA. 
 
Whilst focusing on pairing sites and hybridisation energies can be informative, other 
aspects, such as RNA structure, can also come in to play in terms of determining the 
strength of an interaction between GcvB and its mRNA target. However, considering the 
hybridisation energies and size of the GcvB-mRNA pairing sites, together with details of the 
PNA sequence and it’s predicted binding site on GcvB, can help towards understanding 
trends observed. This is important for informing improvement strategies for PNA design 
with the aim of enhancing PNA disruption for reduced PNA concentrations. With the PNA-
disruption assay established for the RNA array, testing the GcvB-mRNA pairs with 











Although transcriptional gene regulation controls RNA transcript production, the 
ability of tightly regulate existing transcripts is highly important for unicellular organisms, 
such as bacteria, in order to conserve energy to survive and thrive in rapidly changing 
environments. Post-transcriptional gene regulation (PTGR) supports energy trade-off 
throughout all protein synthesis processes (transcription, translation and decay of mRNAs 
and proteins) by promoting a prompt shift of energy expenditure and nutrients to more 
urgent or essential processes in the cell in response to environmental changes (Hausser et 
al., 2019). However, protein translation is the most expensive anabolic process for a 
growing unicellular organism, as it is estimated to use up to 70% of the ATP budget 
(Stouthamer, 1973; Pontes et al., 2015). For example, to produce an average single protein 
containing 300 amino-acids, translational machinery may use approximately 1350 ATP and 
GTP molecules (for amino-acid incorporation and enzymatic activity), 1650 carbon and 540 
nitrogen atoms (Stouthamer, 1973; Kafri et al., 2016; Hu et al., 2020). Thus, halting 
translation of mRNA transcripts into protein seems an advantageous strategy to conserve 
energy as quickly as possible when the protein is no longer required. 
There is growing evidence that bacterial non-coding small RNAs (sRNAs) play a 
major role in PTGR, controlling key metabolic pathways which, in many cases, are directly 
linked to bacterial virulence (Waters & Storz, 2009; Vogel & Luisi, 2011; Holmqvist et al., 
2012). Thus, the goal of this research was to investigate novel trans-acting sRNAs linked to 
pathogenicity in the Gram-negative bacterium Actinobacillus pleuropneumoniae (APP), the 
causative agent of porcine pleuropneumoniae, for therapeutic targeting purposes. The 
research findings and outputs achieved as part of this study, and the steps that future work 
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could take, will be summarised below, before considering the work within the broader 
context of the field.  
 
6.2. A bioinformatic pipeline identifies novel trans-acting sRNAs in APP 
relevant to virulence 
 
In Chapter 3, a selection of trans-acting sRNA candidates in APP serovar 8 
MIDG2331 and their putative mRNA targets were produced. This was accomplished by the 
creation of a bioinformatics pipeline based on a combination of existing computational 
approaches utilising genomic and RNA-seq data from MIDG2331 provided by collaborators 
from Imperial College London. The collaborators had previously developed an initial 
computational strategy to predict sRNAs in bacteria (Rossi et al., 2016). However, as the 
current tools predict cis and trans-acting sRNAs alike, the pipeline was organised to 
chronologically mine and scrutinise prediction data by using conditional parameters to 
select for trans-acting sRNAs only.  
The result was a selection of nine novel sRNA candidates in APP MIDG2331 curated 
from RNA-seq data. From this, homology studies identified the predicted sRNA ARRC01 as 
the putative sRNA GcvB in APP serovar 8 MIDG2331 (GcvB), a previously predicted novel 
sRNA in APP by collaborators (Rossi et al., 2016) and widely studied in E. coli and 
Salmonella. Surprisingly, none of the other predicted novel sRNAs in the list were identified 
in Pasteurellaceae.  
The prediction of mRNA targets of GcvB in APP was also generated from the RNA-
seq data, resulting in a selection of nine putative mRNA partners, of which seven are 
involved in amino-acid biosynthesis (ilvE, ilvI, ilvC, thrC, serB, serC, and hisG), one is 
associated with urea degradation (ureA), and the final one is associated with oxidative 
stress resistance (tehB). The final output generated was therefore a list of potential mRNA 
partners to the sRNA putatively identified as GcvB. Given the established structural profile 
of GcvB and its predicted mRNA targets being linked to metabolic pathways associated with 
bacterial pathogenicity, the GcvB-mRNA target pairs were viewed as ideal candidates for 
taking forward for further study.  
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Using the RNA array technology, these interactions were therefore experimentally 
tested (Chapter 4; and considered below in 6.3), following appropriate establishment of a 
suitable RNA array methodology. Further, with links to pathways involved in bacterial 
virulence, a PNA specific to the GcvB seed region was designed and its ability to disrupt 
GcvB-mRNA interactions was tested using an RNA array PNA-disruption assay (Chapter 5; 
and considered below in 6.4).  
Finally, the remaining list of novel sRNA candidates identified from the APP RNA-
seq data form the basis for future in silico studies using the bioinformatics pipeline 
developed here to identify mRNA partners. These can then be taken forward for 
experimental sRNA-mRNA interaction and associated PNA-disruption studies. Importantly, 
the bioinformatics pipeline itself also provides a valuable tool for identification of trans-
acting sRNAs, and predicting their mRNA partners, using RNA-seq data for other bacteria 
of interest, including “ESKAPE” bacteria, which comprise Enterococcus faecium, S. aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, P. aeruginosa, and Enterobacter spp 
(Rice, 2008). These are antibiotic resistant and major worldwide life-threatening 
pathogens, requiring therefore, development of novel antibacterial solutions (reviewed in 
Felden & Cattoir, 2008). 
 
6.3. The RNA Array technology verifies predicted GcvB-mRNA interactions 
 
The RNA array technology is a novel approach developed by the Callaghan group at 
the University of Portsmouth. It can be widely applied to biophysically characterise RNA 
interactions in a high throughput (HTP) manner. It is particularly relevant to investigating 
post-transcriptional gene regulation by sRNAs in bacteria due to them having a wide and 
varied number of mRNA targets (Chapter 1, section 1.5 and Chapter 2, section 2.2.1). 
Specifically, the numerous mRNA targets can be simply generated on an RNA array in one 
step, and then probed all at once with the sRNA target, thus experimentally identifying 
many mRNAs interacting with a single sRNA in one experiment.  
The RNA array standard protocol was adapted to accommodate the specific 
requirements of this research. In this study, the technique was used to repeatedly 
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immobilise numerous distinct mRNAs on the same slide, for probing with a single 
interaction partner molecule (sRNA) with associated detection probing steps to confirm 
surface-bound and interacting molecules (Chapter 4, section 4.5.1 and 4.5.2).  
Although the RNA array standard protocol is robust and has been previously 
modified by colleagues (Phillips et al., 2018; Norouzi et al., 2019; Henderson et al., 2019) 
strategies were further adapted in this work. For example, the number of different mRNAs 
tested made it possible to analyse transcription efficiencies among a wider range of IVT 
DNA templates than has been possible previously. Although all IVT DNA templates of the 
target mRNAs contained a G(GG) sequence to ensure that there is a G in positions +1, +2 
and +3, as required for optimal transcription efficiency using T7 (Imburgio et al., 2000), the 
results showed that there was a difference in relative transcription efficiency across the 
templates. Whilst the total amounts of transcribed RNA may differ among experiments and 
technical repeats for the same template, there is a constant relative pattern of 
transcription efficiency by template.  
For instance, the IVT DNA template for the target mRNA serC has consistently 
displayed the lowest transcription efficiency in comparison to the other templates in all 
performed assays, while RNA yield produced by the DNA template of the target mRNAs ilvE 
and ilvI has been consistently high in comparison (Chapter 4, section 4.4.3.1). With 
increased data for a range of additional targets, and computational analysis to mine 
transcription efficiencies relative to nucleotide sequence, future work could allow it to be 
possible to explore further if there is a link between T7 transcription efficiency and 
sequence requirements in addition of what is already known about the preference for G in 
positions +1, +2 and +3. The RNA array is ideally suited to generating this data, as the 
transcription efficiencies of many transcripts can be output in one experiment for 
subsequent assessment.  
Regarding the interaction studies, GcvB molecules were synthetically altered to 
accommodate a strategy for detection of binding. This included either internally Cy-
labelling GcvB for direct probing studies (Chapter 4, section 4.5.1), or modifying GcvB (i.e., 
GcvB-MG) such that it contained a specific linker sequence for subsequent probing 
(Chapter 4, section 4.5.2), as used in the co-spotting studies. Both strategies were shown 
to demonstrate GcvB-mRNA interactions for the nine mRNA targets. However, whilst 
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interaction efficiencies varied between GcvB and the mRNA targets, consistent patterns 
emerged suggestive, and in line with, the hybridisation energy trends noted for pairing 
predicted as part of the in silico studies in Chapter 1. For example, interaction between 
GcvB-tehB has regularly produced lower binding efficiencies, whilst GcvB-ilvI and GcvB-ilvC 
has consistently produced higher binding efficiencies.  
Further, to show whether these interactions were specific, negative controls were 
added to the RNA array. These including spotting of the IVT DNA template for GcvB-MG on 
its own and inclusion of scrambled version of the target ilvC (ilvC-S), where the mRNA 
binding region was scrambled to disrupt GcvB interaction. The results of the control tests 
showed that GcvB-MG was only present where target mRNAs were immobilised, so no non-
specific binding was evident, and by altering the GcvB-binding region of ilvC, to create ilvC-
S, there was a drop in the fluorescence intensity of bound GcvB-MG of 90%, indicating 
binding of GcvB to ilvC to be specific.  
With proof of concept demonstrated for using the RNA array technology to verify 
in silico predicted GcvB-mRNA target interactions, the next step for this work would be to 
use the approach to test the interactions of the other novel APP sRNAs identified in Chapter 
1 with their potential mRNA partners, once predicted. Further, it’s clear that coupling the 
bioinformatics steps with the RNA array technology generates a unique pipeline capable of 
both predicting and experimentally verifying sRNA-mRNA interactions. This has broad 
applications within the bacterial sRNA field, as well as the wider non-coding RNA research 
domain, where predicting and testing RNA-RNA interactions is crucial for unravelling 
molecular mechanism details. 
 
6.4. Disruption of GcvB-mRNA interactions using a PNA  
 
GcvB is recognised as an sRNA important in controlling metabolic pathways linked 
to virulence and pathogenesis. Consequently, anti-virulence/antibacterial strategies for 
treating bacterial infections, such as APP, could involve targeting GcvB to disrupt its 
interactions with mRNA targets to mediate a therapeutic effect. Therefore, having 
demonstrated the capability of the RNA array technology in validating the predicted GcvB-
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mRNA target interactions, this work sought to design and test a PNA capable of specifically 
disrupting these interactions, monitoring for any PNA-disruption effects using the RNA 
array. The output of this work was both a PNA, designed to specifically target the G/U-rich 
seed region of GcvB, which specifically disrupted GcvB-mRNA interactions, as well as a 
proof-of-concept demonstration of using the RNA array for a sRNA-mRNA disruption assay.  
The next steps for this work would be to test the GcvB-binding PNA in vivo in APP 
and explore whether it mediates an anti-virulence/antibacterial effect. However, given the 
concentrations required on the array, which may not translate to suitable levels for in vivo 
testing, it may be required to further improve the PNA. This could involve an iterative 
design process to support optimisation of the PNA binding to GcvB and disrupting its 
interactions with mRNAs, for example through altering nucleotide sequence composition 
and molecule length. Given the capability of the RNA array for testing interaction 
disruption, this approach could be used to rapidly test different PNA designs for impact on 
a range of GcvB-mRNA pairs.  
Furthermore, applications testing off-target impact of PNA designs on broader RNA-
RNA interactions, that may wish to be avoided, could also be undertaken. This could help 
determine the specificity of the PNA’s effect on RNA-interactions and inform further re-
design steps to improve the PNA’s utility as a potential therapeutic. Finally, considering 
PNA uptake into cells, a range of peptide tags may need to be explored to support this, and 
inclusion of a fluorescent tag on the PNA can facilitate monitoring this using microscopy as 
one of the first steps. 
 
 
6.5.  Broader context: An emerging therapeutic discovery pipeline targeting 
bacterial sRNAs  
 
Bacterial pathogenesis is often regulated by sRNA-controlled pathways (Svensson 
& Sharma, 2016). GcvB is recognised as one of these sRNAs, and therefore represents a 
suitable therapeutic target. Other well characterised sRNAs identified as antibacterial 
targets include the Quorum Regulatory RNAs (Qrr sRNAs), as these link quorum sensing 
systems and pathogenesis (Rutherford & Bassler, 2012; Defoirdt, 2018). Indeed, with new 
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antibacterial targets desperately needed, as antibiotic resistance to current drugs 
continues to rise (World Health Organisation, 2015), coupled with pace gaining in the RNA 
therapeutics area, bacterial RNAs, such as sRNAs involved in controlling critical pathways 
or virulence mechanisms, represent an untapped pool of potential targets for exploitation.  
Excitingly, the approach of using antisense nucleic acid mimics (NAMs) to inhibit 
RNA targets has expanded in recent years. Whilst early attempts to use this approach 
suffered from issues with cellular uptake and NAM stability, advances have seen 
improvements in nuclease resistance, enhanced interaction capabilities, and improved 
delivery approaches using peptide tags to support uptake (Khvorova & Watts, 2017; 
Hegarty & Stewart, 2018).  
Nevertheless, with the expansion of drug discovery moving into the RNA space, new 
approaches are required to discover sRNA antibacterial targets, as well as new methods to 
support high-throughput screening and testing work as part of understanding drug 
interactions with their target sRNAs, and impact on the sRNAs mechanism of action, such 
as impact on binding to mRNA partners. The bioinformatics pipeline developed in this 
thesis, coupled with the validation and PNA testing studies undertaken using the RNA array 
technology, represent suitable tools to fill the gap. Collectively, this work can be recognised 
as taking the first steps towards developing a therapeutic discovery pipeline targeting 







Figure 6.1. Schematic illustration of a therapeutic discovery pipeline targeting bacterial sRNAs. The input for the 
pipeline is RNA-seq data relevant to infectious/non-infectious samples. This is mined and assessed using various 
bioinformatic tools to predict a target sRNA, and associated mRNA partners. An understanding of the mRNA partners, 
coupled with RNA-seq conditions, can infer the relevance of the sRNA as an antibacterial target. Using the RNA array 
technology, an interaction assay is established to monitor the predicted sRNA-mRNA interactions. In silico approaches, 
coupled with bioinformatic hybridisation data and array interaction efficiency data for the sRNA-mRNA pairs, can help 
inform NAM design. The RNA array can be used to monitor sRNA-mRNA disruption following PNA addition. These steps 
were all completed as part of this study based on GcvB and its mRNA targets. The pipeline is completed by undertaking 
in vivo testing which results in a lead NAM being identified as an sRNA inhibitor. The pipeline may involve iterative repeats 
of the NAM design and testing steps in order to improve NAM design. Ultimately, the pipeline outputs can be taken 
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Appendix 1 – List of predicted sRNAs provided by Imperial College London 
(ICL_UoV_2016). 
ID Gene Location Size Strand 
ARRC01/RNA05  GcvB 149359..149554 202 complement  
ARRC02 
 
418351..418426 75 forward 
ARRC03 Lys Riboswitch 522806..522977 171 forward 
ARRC05 MOCO_RNA 760650..760819 169 complement 
ARRC06 SRP small 896728..896872 144 forward 
ARRC07 Gly Riboswitch 1279189..1279418 229 complement 
ARRC08 
 
1997375..1997567 192 forward 
ARRC10 6S 131769..131951 182 complement 
ARRC11 
 
1997375..1997567 237 forward 
ARRC12 
 
249050..249119 69 forward 
ARRC13/RNA11 FMN riboswitch 440504..440700 196 forward 
ARRC14/RNA08 
 
451950..452112 162 forward 
ARRC15 RNaseP 563243..563676 433 forward 
ARRC16 
 
1710971..1711121 150 forward 
ARRC16b 
 
1711050..1711121 72 forward 
ARRC17 Alpha_RBS 2064968..2065114 146 forward 
ARRC19 His leader 2308407..2308602 195 forward 
ARRC22 MOCO_RNA 762120..762308 188 forward 
cspA cspA 137954..138368 414 complement  
Lys riboswitch Lys riboswitch 791357..791578 221 forward 
RNA01 
 
738604..738689 85 complement 
RNA02 
 
662472..662552 80 forward 
RNA03 
 
2035731..2035807 76 forward 
RNA04 
 
358279..358387 108 forward 
RNA07 S15 1144541..1144667 126 forward 
RNA10 
 
1996019..1996142 123 forward 
RNA12 
 
2292548..2292720 172 forward 
RNA12a 
 
2292439..2292513 74 forward 
RNA13 RNA_out 1546752..1546840 88 complement 
RNA14 RNA_out 1555757..1555844 87 forward 
RNA15 
 
123028..123186 158 forward 
RNA16 
 
195041..195194 153 complement 
RNA17 
 
516723..516916 193 forward 
RNA18 
 
562723..562809 86 forward 
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ID Gene Location Size Strand 
RNA19 
 
808647..808776 129 complement 
RNA20 
 
896366..896461 95 complement 
RNA21 
 
1011268..1011367 99 forward 
RNA22 
 
1231995..1232196 201 complement 
RNA23 
 
1345522..1345653 131 forward 
RNA24 
 
1482564..1482686 122 forward 
RNA25 
 
1558420..1558683 263 complement 
RNA26 
 
1558660..1558900 240 complement 
RNA27 
 
1565840..1565919 79 forward 
RNA28 
 
1847012..1847242 230 complement 
RNA29 
 
1980934..1981119 185 forward 
RNA30 
 
2021324..2021575 251 complement 
RNA31 
 
2129217..2129562 345 complement 
SECIS_3 SECIS_3 1003073..1003138 65 forward 
t44 t44 602581..602722 141 forward 
TPP TPP 195281..195375 94 forward 
TPP TPP 567060..567171 111 forward 
JB_01 
 
674005..674232 227 forward 
JB_02 
 
883531..883613 82 forward 
JB_03 
 
911548..911651 103 complement 
JB_04 
 
968916..969087 171 complement 
JB_05 
 
1432323..1432455 132 complement 
JB_06 
 
60804..60906 102 forward 
JB_07 
 
205917..206272 355 forward 
JB_08 
 
217434..217566 132 complement 
JB_09 
 
223800..223873 73 complement 
JB_10 
 
249020..249119 99 forward 
JB_11 
 
262647..262775 128 complement 
JB_12 
 
269386..269460 74 complement 
JB_13 
 
351320..351534 214 forward 
JB_14 
 
453832..453909 77 forward 
JB_15 
 
521540..521801 261 forward 
JB_16 
 
521839..522126 287 forward 
JB_17 
 
613410..613706 296 complement 
JB_18 
 
804971..805056 85 forward 
JB_19 
 
896438..896872 434 forward 
JB_20 
 
1002322..1002396 74 forward 
JB_21 
 
1130623..1130880 257 complement 
JB_22 
 
1130864..1131096 232 forward 
JB_23 
 
1225977..1226060 83 complement 
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JB_24 
 
1245037..1245264 227 forward 
JB_25 C4 1435557..1435797 240 forward 
JB_26 
 
1514415..1514489 74 complement 
JB_27 
 
1654302..1654387 85 complement 
JB_28 
 
1821900..1822016 116 forward 
JB_29 
 
1826334..1826438 104 forward 
JB_30 
 
1836223..1836481 258 forward 
JB_31 
 
1843180..1843494 314 Forward 
JB_32 
 
1847162..1847293 131 Forward 
JB_33 
 
1947542..1947634 92 complement 
JB_34 
 
2003547..2003623 76 forward 
JB_35 
 
2026728..2026907 179 complement 
JB_36 
 
2035311..2035394 83 forward 
JB_37 
 
2053974..2054153 179 forward 
tmRNA tmRNA 2118112..2118483 371 Forward 
JB_38 
 
2129671..2129760 89 complement 
JB_39 
 
2218790..2219245 455 complement 
JB_40 
 
2263805..2263903 98 forward 
JB_41 
 






Appendix 2 – Complete list of novel sRNAs generated in this thesis 
(UoP_ICL_UoV_2020). 
 
1 - Due to their size and content, the data frame for ICL_UoP_2020 with full details and re-




2 - Link for RNA-seq data from APP serovar 8 MIDG2331 mapped to the LN908249.1 
reference sequence genome in JBrowse: 
http://hinton-jbrowse.s3-website-eu-west-
1.amazonaws.com/JBrowse/index.html?data=00_SAMPLES/app-2017/app/data 





Appendix 3 – NCBI accession numbers of Proteobacteria. 
 
Serovar Family Ref. Seq. 
Haemophilus parainfluenzae T3T1 Pasteurellaceae NC_015964 
Haemophilus parasuis SH0165 Pasteurellaceae NC_011852 
Haemophilus influenzae R2846 Pasteurellaceae CP002276 
Actinobacillus pleuropneumoniae 8 MIDG2331 Pasteurellaceae NZ_LN908249.1 
Pasteurella multocida Pm70 Pasteurellaceae NC_002663 
Mannheimia haemolytica M42548  Pasteurellaceae NC_021082 
Actinobacillus suis H91-0380 Pasteurellaceae NC_018690 
Salmonella enterica serovar Typhimurium SL1344 Enterobacteriaceae NC_016810.1 
Escherichia coli str. K-12 MG1655 Enterobacteriaceae MF521836.1 
Proteus mirabilis HI4320 Morganellaceae NR_075212.1 
Yersinia pestis D182038 Yersiniaceae NC_017160.1 
Vibrio cholerae 12129 Vibrionaceae NZ_ACFQ00000000.1 
 
 
Appendix 4 – NCBI accession numbers of APP serovars. 
 
Serovar Ref. Seq. Size (Mb) GC% Protein Gene 
APP serovar 1 str. 4074 NZ_AACK00000000.1 2.29 41.4 1987 2273 
APP serovar 2 str. 4226  NZ_ADXN00000000.1 2.31 41.2 2100 2182 
APP serovar 3 str. JL03 NC_010278.1 2.24 41.2 1972 2126 
APP serovar 4 str. M62 NZ_ADOF00000000.1 2.27 41.2 2203 2253 
APP serovar 5b str. L20 NC_009053.1 2.27 41.3 2030 2171 
APP serovar 6 str. Femo NZ_ADXO00000000.1 2.38 41 2168 2241 
APP serovar 7 str. AP76 NC_010939.1 2.33 41.2 2079 2232 
APP serovar 8 MIDG2331 NZ_LN908249.1 2.34 41.1 2106 2247 
APP serovar 9 str. CVJ13261 NZ_ADOI00000000.1 2.26 41.2 2188 2244 
APP serovar 10 str. D13039 NZ_ADOJ00000000.1 2.27 41.2 2158 2210 
APP serovar 11 str. 56153 NZ_ADOK00000000.1 2.27 41.2 2179 2232 
APP serovar 12 str. 1096 NZ_ADOL00000000.1 2.19 41.2 2082 2134 





Appendix 5 – MultiQC statistical report from RNA-seq data. 
 







Total_WT BHI Plate Aerobic 
Total Wild Type Vertis 1 99.90% 51% 104 1.1 
Total_WT_anaerobic BHI Plate Anaerobic 
Total Wild Type Vertis 1 100.00% 51% 95 1.3 
2331WT_S1_R1_001 BHI Plate Wild Type 
Aerobic Vertis 2 89.70% 42% 75 22.6 
2331WT_S1_R1_001-
CTGAAGCT 
BHI Plate Wild Type 
Aerobic Vertis 2 99.70% 38% 55 3.7 
2331WT_S1_R1_001-
TAATGCGC 
BHI Plate Wild Type 
Aerobic Vertis 2 95.30% 37% 54 1.6 
2331hfq_S2_R1_001 BHI Plate Aerobic 
Delta-Hfq Vertis 2 94.10% 38% 75 19.7 
2331hfq_S2_R1_001-
CTGAAGCT 
BHI Plate Aerobic 
Delta-Hfq Vertis 2 99.10% 36% 54 3.9 
2331hfq_S2_R1_001-
TAATGCGC 
BHI Plate Aerobic 
Delta-Hfq Vertis 2 97.10% 36% 54 1.6 
2331BR_S5_R1_001 BHI Broth Aerobic 
Wild Type  Vertis 2 95.00% 39% 75 24.3 
2331BR_S5_R1_001-
CTGAAGCT 
BHI Broth Aerobic 
Wild Type  Vertis 2 99.70% 34% 55 2.5 
2331BR_S5_R1_001-
TAATGCGC 
BHI Broth Aerobic 
Wild Type  Vertis 2 98.40% 34% 54 1.8 
2331AMP_S6_R1_001 BHI Broth Aerobic 
Ampicillin Vertis 2 94.60% 40% 75 24.3 
2331AMP_S6_R1_001
-CTGAAGCT 
BHI Broth Aerobic 
Ampicillin Vertis 2 99.70% 34% 55 2.2 
2331AMP_S6_R1_001
-TAATGCGC 
BHI Broth Aerobic 
Ampicillin Vertis 2 98.00% 34% 54 1.5 
2331TY_S7_R1_001 BHI Broth Aerobic 
Tylosin Vertis 2 95.50% 40% 75 19.4 
2331TY_S7_R1_001-
CTGAAGCT 
BHI Broth Aerobic 
Tylosin Vertis 2 99.70% 35% 55 1.7 
2331TY_S7_R1_001-
TAATGCGC 
BHI Broth Aerobic 
Tylosin Vertis 2 98.60% 34% 54 1.6 
RNA-BHI_S7_R1_001 BHI Broth Aerobic 
Wild Type  Vertis 3 98.60% 39% 150 14.6 
RNA-BHI_S7_R3_001 BHI Broth Aerobic 
Wild Type  Vertis 3 98.00% 39% 150 14.6 
RNA-PS_S8_R1_001 Porcine Serum 
Aerobic Wild Type Vertis 3 99.50% 41% 150 13.5 
RNA-PS_S8_R3_001 Porcine Serum 
Aerobic Wild Type Vertis 3 99.00% 41% 150 13.5 
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Appendix 6 – STRING enrichment for potential mRNA targets of the putative trans-acting sRNA GcvB MIDG2331. 
Biological Processes 





GO:1901607 alpha-amino acid biosynthetic process ilvD, leuC, dapA, trpD, ilvC, dapE, hisG 7 30 1.19 
GO:0044283 small molecule biosynthetic process ilvD, leuC, dxs, dapA, trpD, ilvC, dapE, hisG 8 82 0.82 
GO:0009082 branched-chain amino acid biosynthetic process ilvD, leuC, ilvC 3 4 1.7 
GO:0044281 small molecule metabolic process ilvD, leuC, dxs, dapA, trpD, ureA, ilvC, dapE, hisG 9 160 0.58 
GO:1901564 organonitrogen compound metabolic process ilvD, leuC, dxs, dapA, gcp, trpD, ureA, ilvC, dapE, hisG 10 213 0.5 
GO:0006549 isoleucine metabolic process ilvD, ilvC 2 2 1.83 
GO:0009097 isoleucine biosynthetic process ilvD, ilvC 2 2 1.83 
GO:0009099 valine biosynthetic process ilvD, ilvC 2 2 1.83 
GO:0019877 diaminopimelate biosynthetic process dapA, dapE 2 4 1.53 
GO:0009089 lysine biosynthetic process via diaminopimelate dapA, dapE 2 5 1.43 
GO:1901566 organonitrogen compound biosynthetic process ilvD, leuC, dxs, dapA, trpD, ilvC, dapE, hisG 8 181 0.47 
Molecular Processes 






GO:0046872 metal ion binding ilvD, leuC, dxs, gcp, trpD, ureA, ilvC, dapE, hisG 9 106 0.76 
GO:0016836 hydro-lyase activity ilvD, leuC, dapA 3 11 1.26 
GO:0003824 catalytic activity ilvD, leuC, dxs, dapA, gcp, trpD, ureA, ilvC, dapE, hisG 10 280 0.38 
GO:0016811 
hydrolase activity, acting on carbon-nitrogen 
bonds 
ureA, dapE 2 6 1.35 
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1 arcD arginine/ornithine antiporter -18.62 0 -29 to -14 100% 
2 ilvC ketol-acid reductoisomerase -18.15 0 -62 to -44 100% 
3 ilvI acetolactate synthase 3 catalytic subunits -15.74 0 -41 to -26 100% 
4 dapE succinyl-diaminopimelate desuccinylase -14.6 0.001 +3 to 19 100% 
5 thrC threonine synthase -13.03 0.004 +5 to 20 100% 
6 fabG 3-ketoacyl-ACP reductase -12.73 0.005 -67 to -53 100% 
7 ilvD dihydroxy-acid dehydratase -12.55 0.005 -32 to -20 100% 
8 menA 1,4-dihydroxy-2-naphthoate octaprenyltransferase -12.1 0.007 -19 to -5 92% 
9 hisD histidinol dehydrogenase -11.53 0.01 -9 to 9 100% 
10 serC phosphoserine aminotransferase -11.42 0.011 -10 to +6 100% 
11 ftsK DNA translocase FtsK -11.34 0.011 -48 to -37 100% 
12 dxs 1-deoxy-D-xylulose-5-phosphate synthase -11.04 0.013 -5 to +12 100% 
13 plpA outer membrane lipoprotein 1 -10.77 0.016 -32 to -15 100% 
14 ureA urease subunit gamma -10.64 0.017 -28 to -15 100% 
15 sfsA sugar fermentation stimulation protein A -10.55 0.018 -8 to +7 100% 
16 hisC histidinol-phosphate aminotransferase -10.32 0.02 2 to 20 100% 















18 dapA dihydrodipicolinate synthase -9.72 0.027 -21 to -2 100% 
19 hisI phosphoribosyl-ATP pyrophosphatase -9.65 0.028 -9 to 12 100% 
20 gcp DNA-binding/iron metalloprotein/AP endonuclease -9.49 0.03 -10 to +9 100% 
21 hisG ATP phosphoribosyltransferase -9.21 0.034 -25 to -10 100% 
22 leuC isopropylmalate isomerase large subunit -9.14 0.035 -46 to -26 100% 
23 gntR HTH-type transcriptional regulator -9.02 0.037 -3 to +15 100% 
24 secE preprotein translocase subunit SecE -8.87 0.039 -79 to -64 100% 
25 lrp leucine-responsive transcriptional regulator -8.66 0.043 -76 to -63 100% 
26 ilvE branched-chain amino acid aminotransferase -8.5 0.046 -12 to +8 100% 
27 uxaC uronate isomerase -8.49 0.046 -43 to -30 100% 
28 serA D-3-phosphoglycerate dehydrogenase -8.4 0.048 -24 to -10 100% 
29 tehB tellurite resistance protein TehB -8.35 0.049 -8 to +10 100% 
30 trpD anthranilate phosphoribosyltransferase -8.35 0.049 -69 to -54 100% 
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Appendix 8 – IntaRNA interaction location results for Modified GcvB (GcvB-
MG) against mRNA targets. 
 
Target Start(T) End(T)  Query Start(Q) End(Q) Energy 
ilvI 11 37  GcvB-MG 63 89 -23.60 
ilvC 14 36  GcvB-MG 73 95 -22.88 
thrC 41 62  GcvB-MG 72 91 -11.09 
serC 31 40  GcvB-MG 80 89 -10.46 
hisG 58 68  GcvB-MG 77 87 -9.23 
serB 52 88  GcvB-MG 61 92 -8.46 
ilvE 33 59  GcvB-MG 62 85 -8.29 
ureA 10 21  GcvB-MG 78 88 -8.29 










Blue T7 promoter 
Grey Three Gs between promoter and sequence recommended for IVT 
Orange GcvB putative seed region (RNATarget 2) 
Red Predicted translation start site, normally ATG 
Black Actual sequence e.g. mRNA target sequence including 5’ UTR 
Green Streptavidin aptamer (SA) 
Purple SA Middle Linker containing GT repetition 
Yellow SA End Linker 
Underline Oligonucleotides overlapping region 
Underline Overlapping region for 3’ Alexa Fluorophore oligonucleotide 
FW Forward oligonucleotides 
RV Reverse oligonucleotides 
MW Molecular weight of the DNA IVT template 
MW (B) MW of the DNA IVT template with biotin 
MW (F) MW of the DNA IVT template with fluorophore and biotin  
RNA MW Molecular weight of the RNA product  
 







3’ end standard oligonucleotides 
Used in all constructs for slide immobilisation on DNA slide 
 
Biotin T7 Promoter Biotin  
FW Oligo 
5’ – Biotin -
cgaggcagatctTAATACGACTCACTATAG – 3’  
 
5’ end standard oligonucleotides 
Used in all constructs for slide immobilisation on RNA slide and detection 
 











SA Aptamer  













5’ – Alexa(488, 532 or 647) –
GCATGCATCCCGGCCCGCGACTATCTTAC 







DNA IVT templates of mRNA targets 
 














ilvE construct length = 199  
MW(B): 123634   MW(F): 124830   GC = 43% 
 
Primers: ilvE FW1 

























ilvI construct length = 207  
MW(B): 128577   MW(F): 129773   GC = 43% 
 
Primers: ilvI FW1 




























thrC construct length = 197  
MW(B): 122397   MW(F): 123593   GC = 42% 
Primers: thrC FW1 

























serB construct length = 209  
MW(B): 129812   MW(F): 131008   GC = 43% 
Primers: serB FW1 




























serC construct length = 196  
MW(B): 121788   MW(F): 122985   GC = 47% 
Primers: serC FW1 


























tehB construct length = 194  
MW(B): 120544   MW(F): 121740   GC = 42% 
Primers: tehB FW1 





























ureA construct length = 193  
MW(B): 119924   MW(F): 121121   GC = 41% 
Primers: ureA FW1 




























ilvC construct length = 236  
MW(B): 146487   MW(F): 147684   GC = 40% 
Primers: ilvC FW1 




































hisG construct length = 232  
MW(B): 147118   MW(F): 148314   GC = 46% 
































ilvC-S construct length = 236 (scrambled areas in bold) 
MW(B): 147107   MW(F): 148303   GC = 41% 
Primers: ilvC FW1 
























Designed DNA templates and associated primer sequences for preparing RNAs 












DNA MW: 132689 Length = 215  
RNA MW: 63427  Length = 198 
Primers: GcvB Fw1  






GcvB FW2  





GcvB Rv1  















Designed DNA templates and associated primer sequences for preparing RNAs 















DNA MW(B): 176757 Length = 285  
RNA MW: 81903 Length = 256 
Primers: GcvB-MG 
Fw1 










































Appendix 11 – PCR-TBIO and IVT of GcvB, fluorescently labelled by IVT with 
Cyanine 3 (Cy3) UTP. 
 
 
A) A 1.8% (w/v) agarose gel run in 1 x TBE containing lane (1): Low Molecular 
Weight DNA Ladder, lane (2) DNA IVT template for GcvB, visualised under a 
Syngene UV transilluminator 
B) A pre-staining 8% (w/v) denaturing urea-PAGE gel run in 1 x TBE containing 
product of the IVT of the GcvB DNA IVT template from A, fluorescently 
labelled with Cy3 UTP, visualised by a Fuji FLA5000 phosphorimager using the 
Cy3 channel. 
C) An 8% (w/v) denaturing Urea-PAGE gel stained with SYBR GoldTM containing 
lane (1): Low Range RNA Ladder, lane (2): product of the IVT of the GcvB DNA 
IVT template from A, fluorescently labelled with Cy3 UTP, visualised by a Fuji 





Appendix 12 – PCR-TBIO of the DNA IVT templates for the predicted mRNA 
targets and the sRNA Modified GcvB (GcvB-MG). 
 
A 1.8% (w/v) agarose gel run in 1 x TBE, visualised under a Syngene UV 
transilluminator, containing lane (M) Low Molecular Weight DNA Ladder, and: 
A) Construct A DNA IVT templates with 5 overlapping oligonucleotides:  
ilvE (1), ilvI (2), thrC (3), serB (4), serC (5), tehB (6), ureA (7). 
B) Construct B DNA IVT templates with 6 overlapping oligonucleotides: 
ilvC (8), ilvC-S (9) and hisG (10). 







Appendix 13 – IVT product of DNA templates for the predicted mRNA targets 
and the sRNA Modified GcvB (GcvB-MG). 
 
 
An 8% (w/v) denaturing Urea-PAGE gel run in 1 x TBE, gel stained with SYBR 
GoldTM, and visualised under a Syngene UV transilluminator, containing lane 
(M): Low Range RNA Ladder, and: 
A) IVT products of the respective DNA IVT templates in Appendix 9 (A):  
ilvE (1), ilvI (2), thrC (3), serB (4), serC (5), tehB (6), ureA (7). 
B) IVT products of the respective DNA IVT templates in Appendix 9 (B):  
ilvC (8), ilvC-S (9) and hisG (10). 
C) IVT product of the respective DNA IVT template for GcvB-MG (11). Note that 
this template two bands, one just under the 200 nucleotide (nt) mark, 
possibily related to the non-modified GcvB size (196 nt), and the other just 
under the 300 nt with the correct size for Gcvb-MG (288 nt). This may occur 
due to the RNA Polymerase detaching when reaching the termination signal 




Appendix 14 – Buffer recipes. 
 
10 x TBE (pH 8.4) 
Component Concentration 
Tris 0.89 M 
Borate 0.89 M 
EDTA 0.02 M 
 
10 x PBS (pH 7.4) 
Component Concentration 
NaCl 1.37 M 
KCl 0.027 M 
Phosphate buffer 0.119 M 
 
1 x PBST 
Component Concentration 
PBS 1 x 
Tween-20 (pH 7.4) 0.02% (v/v) 
 
Amine blocking buffer 
Component Concentration 
Ethanolamine (Fisher M251-1) 50 mM 
PBST (pH 8.5 with HCl) 1 x 
 
20 x SSC (pH 7.0) 
Component Concentration 
NaCl 3 M 




Tris (pH 7.8) 40 mM 
MgCl2 6 mM 
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Generation of functional-RNA arrays by in vitro transcription and in situ 
RNA capture for the detection of RNA-RNA interactions 
(Running head: Generation of functional-RNA arrays) 
Helen A. Vincent, Charlotte A. Henderson, Daniela Lopes Cardoso and Anastasia J. Callaghan* 
 
School of Biological Sciences and Institute of Biological and Biomedical Sciences, University of 
Portsmouth, Portsmouth, PO1 2DY, United Kingdom 
 





RNA performs a wide variety of vital cellular functions. These functions typically require interactions 
with other biological macromolecules, often as part of an intricate communication network. High-
throughput techniques capable of analysing RNA-based interactions are therefore essential. 
Functional-RNA arrays address this need, providing the capability of performing hundreds of 
miniature assays in parallel. Here we describe a method to generate functional-RNA arrays using in 
vitro transcription of a DNA template array and in situ RNA capture. We also suggest how functional-
RNA arrays could be applied to investigating RNA-RNA interactions. 
 
Key words:  
Binding partner; Functional-RNA; In situ capture; In vitro transcription; Microarray; RNA array; 





RNA is a structurally and functionally diverse molecule. Our understanding of its function(s) has 
transitioned from it playing relatively passive roles in translation (mRNA, rRNA and tRNA) to it 
performing a myriad of catalytic and/or regulatory activities (e.g. ribozymes, snRNAs, snoRNAs, 
miRNAs, riboswitches, sRNAs, lncRNAs, CRISPR) (Cech & Steitz, 2014). In many cases, it is 
known that regulatory activity of an RNA depends on interactions between the RNA and other 
molecules, for example complementary base-pairing with nucleic acids (RNA and DNA), formation 
of ribonucleoprotein complexes, or binding of small molecules (Marz & Stadler, 2011). These 
interactions, either in isolation or as part of a wider network, typically affect transcription, translation 
and/or RNA processing. Understanding the mechanistic details of the regulatory activities of RNA is 
critical for understanding both normal cellular function and disease, and has implications for 
therapeutic and synthetic biology applications. This in turn requires high-throughput techniques that 
are capable of detecting RNA-based interactions and analysing their functional outputs at the 
molecular level.  
 
Microarray technology (Li et al., 2016), which can allow thousands of miniature assays to be 
performed in parallel on a single surface, has immense potential in this regard. RNA microarrays are 
in their infancy compared to DNA microarrays but, recently, a number of methods have been 
developed for generating RNA microarrays (Lietard and Somoza, 2019). These can be broadly 
classified into spotting, “on-array” transcription and in situ chemical synthesis (Lietard and Somoza, 
2019).  Applications such as detecting RNA-RNA (Phillips et al., 2018), small molecule-RNA 
(Phillips et al., 2018; Henderson et al., 2019) and protein-RNA (Beunrostro et al., 2014; She et al., 
2017; Tome et al., 2014) interactions; monitoring regulatory outputs e.g. protein expression (Norouzi 
et al., 2019); and assaying RNA cleavage (Wu et al., 2014) are beginning to be explored.  
 
“On-array” transcription methods for producing RNA arrays (Lietard and Somoza, 2019) are 
especially useful when arrays of longer, structured, functional RNAs are required rather than arrays of 
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shorter oligonucleotides. In this chapter, we provide the detailed protocols that are necessary for 
generating functional-RNA microarrays through an “on-array” method that involves in vitro 
transcription of a DNA in vitro transcription template array and in situ surface capture of the RNA on 
a facing surface (Phillips et al., 2018) (Fig. 1). As shown schematically in Fig. 1, this method first 
involves producing a DNA in vitro transcription template array by spotting custom-designed DNA in 
vitro transcription templates onto a microarray slide. A DNA in vitro transcription template array – in 
vitro transcription reagent mix – RNA capture surface “sandwich” is then assembled. As in vitro 
transcription proceeds, RNA synthesised from each DNA in vitro transcription template is captured in 
situ on an RNA capture surface to generate a corresponding functional-RNA array. The specific 
protocols that we include here are: in vitro transcription template design, generation of the DNA in 
vitro transcription template array by spotting, and generation of the functional-RNA array by in vitro 
transcription and in situ capture of the RNA.   
 
[Fig. 1 near here] 
 
We have utilised functional-RNA arrays that were generated following these protocols to detect 
regulatory RNA-RNA interactions (Phillips et al., 2018; Norouzi et al., 2019) and have investigated 
both RNA-RNA binding (Phillips et al., 2018) and the functional consequence of RNA-RNA 
interactions on protein expression (Norouzi et al., 2019). Since these applications have been reported 
elsewhere, and because the application of a functional-RNA array will be highly user-specific, we will 
not discuss the applications of RNA arrays in detail here. However, as an example, we will include a 
basic protocol for probing a functional-RNA array with a single binding partner in order to evaluate 
the specificity of an RNA-RNA binding interaction. This could be useful if a particular RNA has 
many RNA binding targets. For example, the regulatory RNA-RNA binding interactions between 
mRNAs and sRNAs, where a functional-RNA array of mRNA binding targets could be probed with 
an sRNA. Alternatively, it could be useful to investigate the importance of key nucleotides within a 
binding site, where a functional-RNA array of RNA binding target mutants could be probed with the 




To minimise the risk of RNA degradation, gloves should be worn when handling reagents, materials 
and equipment, and all solutions should be prepared using nuclease-free water (ultrapure water (18.2 
M/cm) filtered through a 0.22 m filter).  
 
2.1. In vitro transcription template design and synthesis 
1. RNA secondary structure prediction software (see Note 1).  
 
2.2 Generation of the DNA in vitro transcription template array 
1. Streptavidin-coated glass microarray slide (see Notes 2-4). 
2. 5-biotinylated DNA in vitro transcription templates in phosphate-buffered saline (PBS), pH 7.4 
(see Notes 5-7). 
3. Automated arrayer (see Note 8) or a micropipette. 
4. PBST: PBS, pH 7.4 supplemented with 0.05% (v/v) Tween 20. 
5. PBS.  
6. H2O. 
7. Microarray slide scanner (see Notes 9 and 10).  
 
2.3 Generation of the functional-RNA array 
1. DNA in vitro transcription template array (see Methods 3.2). 
2. Streptavidin-coated glass microarray slide (see Notes 2-4). 
3. Parafilm. 
4. T7 in vitro transcription reagent mix (see Note 11): 1X MEGAscript T7 Transcription Reaction 
Buffer, 1X MEGAscript T7 Transcription Enzyme Mix, 0.4 mM ATP, 0.4 mM CTP, 0.4 mM GTP, 






8. Linker probe in 2X saline-sodium citrate (SSC) supplemented with 0.1% w/v sodium dodecyl 
sulphate (SDS) (see Notes 12-14). 
9. LifterSlips (Thermo Fisher Scientific) (see Note 15).  
10. Microarray slide scanner (see Notes 9 and 10).  
 
2.4 Application of functional-RNA arrays to the evaluation of RNA-RNA binding specificity 
1. Functional-RNA array (see Methods 3.3). 
2. Fluorescently labelled binding partner probe in hybridisation buffer (see Notes 16-18).  
3. LifterSlips (Thermo Fisher Scientific) (see Note 15).  




The protocols provided below assume that the user has experience working in a molecular biology 
laboratory and is familiar with standard molecular biology techniques. The protocols are intended to 
provide a starting point when generating functional-RNA arrays for the first time. It is anticipated that 
the user will bring their system-specific knowledge to these protocols and will adapt them where 
appropriate.  
 
Methods 3.1 involves the custom design and synthesis of in vitro transcription templates. This will 
require forward planning. Once complete, Methods 3.2-3.4 can be completed in one day or they can 
be split over two days with Methods 3.2 completed on the first day and Methods 3.3 and 3.4 
completed on the second day.  
 
3.1 In vitro transcription template design and synthesis (see Note 19) 
Each custom DNA in vitro transcription template should be designed to have the general architecture 
depicted in Fig. 2. 
 
[Fig. 2 near here] 
 
1. Generate the DNA in vitro transcription template sequence by linking the DNA sequence for each 
of the following components in order from 5 to 3: immobilisation linker (see Note 20) – promoter 
(see Note 21) – transcription system-specific sequence (see Note 22) – RNA of interest (user-defined) 
– unstructured linker (see Note 23) – immobilisation aptamer (see Notes 24 and 25) – fluorophore 
(see Note 26). A suggested starting DNA sequence for each component, except for the user-defined 
RNA of interest, is given in Fig. 2.  
2. Generate RNA sequences for (i) the full-length transcribed RNA (transcription system-specific 
sequence – RNA of interest – unstructured linker – immobilisation aptamer) (see Note 27), (ii) the 
RNA of interest and (ii) the immobilisation aptamer. 
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[Fig. 3 near here] 
 
3. Use RNA secondary structure prediction software (see Note 1) to predict the secondary structure 
for each of the RNA sequences generated in Step 2 (see Fig. 3 for an example).  
4. Compare the predicted secondary structures for the RNA of interest and the immobilisation 
aptamer within the full-length transcript to their predicted secondary structures when they are in 
isolation to ensure that they are equivalent (see Fig. 3) (see Note 28).  
5. Synthesise/source the DNA in vitro transcription templates (see Note 29).  
 
3.2 Generation of the DNA in vitro transcription template array 
1. Thaw a streptavidin-coated glass microarray slide at room temperature for 30 minutes (see Notes 4 
and 30).   
2. Spot the DNA in vitro transcription templates onto a streptavidin-coated microarray slide in the 
desired array layout (see Notes 31 and 32) (see Fig. 4).  
 
[Fig. 4 near here] 
 
2. Incubate in a humidified environment for 30 minutes at room temperature (see Notes 33 and 34). 
3. Dip the DNA in vitro transcription template array into a 50 ml Falcon tube containing PBST (see 
Note 35). 
4. Transfer the DNA in vitro transcription template array to a 50 ml Falcon tube containing 45 ml 
PBST (see Note 35) and rotate the tube on a rolling platform for 5 minutes at room temperature. 
5. Transfer the DNA in vitro transcription template array to a 50 ml Falcon tube containing 45 ml 
PBS (see Note 35) and rotate the tube on a rolling platform for 5 minutes at room temperature. 
6. Transfer the DNA in vitro transcription template array to a 50 ml Falcon tube containing 45 ml H2O 
(see Note 35) and rotate the tube on a rolling platform for 5 minutes at room temperature. 
7. Dry the microarray slide by centrifugation at 500 x g for 5 min at room temperature (see Note 36). 
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8. If the DNA in vitro transcription templates are fluorescently labelled, visualise the array using a 
microarray slide scanner (see Notes 26 and 37). 
9. Use the DNA in vitro transcription template array immediately for Methods 3.3 or store at -20C 
(see Note 38). 
 
3.3 Generation of the functional-RNA array 
1. Thaw a streptavidin-coated glass microarray slide (see Notes 4 and 30) and the DNA in vitro 
transcription template array generated in Methods 3.2 (see Notes 35 and 38) at room temperature for 
30 minutes.   
2. Assemble a DNA in vitro transcription template array – in vitro transcription reagent mix – RNA 
capture surface “sandwich” as shown in Fig. 5. First place a streptavidin-coated RNA capture 
microarray slide surface-side up (see Notes 30 and 39).  Place small pieces of parafilm on the short 
edges of the streptavidin-coated RNA capture microarray slide (see Note 40) (see Fig. 5). and pipette 
90 l in vitro transcription reagent mix on the RNA capture surface (see Note 41). Carefully place the 
DNA in vitro transcription template array (see Note 35) on top of the RNA capture slide array 
surface-side down. 
 
[Fig. 5 near here] 
 
3. Incubate at 37C for 1 hr in a humidified environment (see Note 42). 
4. Separate the DNA in vitro transcription template array slide and the functional-RNA array slide  
(see Notes 43 and 44). 
5. Discard the DNA in vitro transcription template array (see Note 45).  
6. Transfer the functional-RNA array slide to a 50 ml Falcon tube containing 45 ml PBST (see Note 
44) and rotate the tube on a rolling platform for 5 minutes at room temperature. 
7. Transfer the functional-RNA array slide to a 50 ml Falcon tube containing 45 ml PBS (see Note 
44) and rotate the tube on a rolling platform for 5 minutes at room temperature. 
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8. Transfer the functional-RNA array slide to a 50 ml Falcon tube containing 45 ml H2O (see Note 44) 
and rotate the tube on a rolling platform for 5 minutes at room temperature. 
9. Dry the functional-RNA array slide by centrifugation at 500 x g for 5 min at room temperature (see 
Note 36). 
10. Probe the functional-RNA array immediately (see below). 
 
[Fig. 6 near here] 
 
11. Place the functional-RNA array with the array surface-side up (see Note 44) and pipette 90 l 
linker probe (see Notes 12-14 and 46) onto the functional-RNA array and cover with a 24 x 60 mm 
LifterSlip (see Fig. 6).  
12. Incubate at room temperature for 30 minutes in the dark (see Note 47).  
13. Remove the LifterSlip, transfer the functional-RNA array slide to a 50 ml Falcon tube containing 
45 ml PBST (see Note 44) and rotate the tube on a rolling platform for 5 minutes at room 
temperature. 
14. Transfer the functional-RNA array slide to a 50 ml Falcon tube containing 45 ml PBS (see Note 
44) and rotate the tube on a rolling platform for 5 minutes at room temperature. 
15. Transfer the functional-RNA array slide to a 50 ml Falcon tube containing 45 ml H2O (see Note 
44) and rotate the tube on a rolling platform for 5 minutes at room temperature. 
16. Dry the functional-RNA array slide by centrifugation at 500 x g for 5 min at room temperature 
(see Note 36). 
17. Visualise the functional-RNA array using a microarray slide scanner (see Note 48). 
 
3.4 Application of functional-RNA arrays to the evaluation of RNA-RNA binding specificity 
 




1. Design the functional-RNA array layout (see Notes 32 and 49) (see Fig. 7).  
2. Design each in vitro transcription template that will be needed to generate the functional-RNA 
array (see Methods 3.1).  
3. Generate the DNA in vitro transcription template array (see Methods 3.2). 
4. Generate the functional-RNA array (see Methods 3.3). Use immediately. 
5. Probe the functional-RNA array with the RNA binding partner probe (see Notes 16-18 and 51). (i) 
Place the functional-RNA array with the array surface-side up (see Note 44) and pipette 90 l RNA 
binding partner probe (see Notes 16-18 and 52) onto the functional-RNA array and cover with a 24 x 
60 mm LifterSlip (see Note 53). (ii) Incubate for 30 minutes at room temperature in the dark (see 
Note 54). (iii) Remove the LifterSlip, transfer the functional-RNA array slide to a 50 ml Falcon tube 
containing 45 ml hybridisation buffer (see Note 44) and rotate on a rolling platform for 5 minutes at 
room temperature. (iv) Repeat step (iii) two more times (see Note 55). (v) Dry the functional-RNA 
array slide by centrifugation at 500 x g for 5 min at room temperature (see Note 36).   
6. Visualise the functional-RNA array using a microarray slide scanner (see Note 56). 





1. We use RNAfold from the ViennaRNA Package 2.0 (rna.tbi.univie.ac.at) (Lorenz et al., 2011) 
which is freely available online as a web interface. 
2. Streptavidin-coated glass microarray slides are commercially available e.g. Nexterion HS slides 
(Schott). However, we covalently immobilise streptavidin to a Nexterion H slide (Schott) using amine 
coupling to generate our streptavidin-coated surface. This allows us to control the density of 
streptavidin on the surface and we achieve better results when we have a lower density of streptavidin 
on the DNA capture surface than on the RNA capture surface. A protocol for generating streptavidin-
coated surfaces in this manner is provided in Note 3.   
3. (i) Pipette 90 l of 1 M streptavidin (Sigma) in PBS, pH 7.4 (DNA capture surface) or 16.7 M 
streptavidin in PBS, pH 7.4 (RNA capture surface) onto a Nexterion H slide (Schott). Cover with a 24 
x 60 mm LifterSlip (Thermo Fisher Scientific) and incubate at 37C for 1 hour in a humidified 
environment (we use a mini incubator (9.2 L) and a Petri dish containing 25 ml H2O). (ii) Remove the 
LifterSlip, place the microarray slide in a 50 ml Falcon tube containing 45 ml PBST and rotate the 
tube on a rolling platform for 5 minutes at room temperature. (iii) Transfer the microarray slide to a 
50 ml Falcon tube containing 45 ml PBS and rotate the tube on a rolling platform for 5 minutes at 
room temperature. (iv) Transfer the microarray slide to a 50 ml Falcon tube containing 45 ml H2O and 
rotate the tube on a rolling platform for 5 minutes at room temperature. (v) Transfer the microarray 
slide to a 50 ml Falcon tube containing 45 ml 50 mM ethanolamine-HCl, pH 8.5 (to block any 
unreacted NHS functional groups) and rotate the tube on a rolling platform for 30 minutes at room 
temperature. (vi) Repeat the washes in steps (ii)-(iv). (vii) Dry the microarray slide by centrifugation 
at 500 x g for 5 min at room temperature (we place the slide in a 50 ml Falcon tube and use a swing 
bucket centrifuge). (viii) Use the prepared capture surface immediately (see Methods 3.2-3.3) or store 
at -20C for up to 12 months. 
4. Streptavidin-coated glass microarray slides are typically stored at -20C and should be thawed at 
room temperature for 30 minutes prior to use. 
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5. The DNA in vitro transcription templates must be custom designed and synthesised (see Methods 
3.1 and Fig. 2). 
6. When working with a DNA in vitro transcription template for the first time, we typically prepare it, 
and test it, at a range of concentrations between 20 nM and 500 nM to determine the optimal 
concentration. If it is only possible to test a single concentration, 200 nM is a good starting point.  
7. If the DNA in vitro transcription templates are labelled at the 3 end with a fluorophore (see 
Methods 3.1 and Fig. 2) they should be kept in the dark, either by using opaque tubes or wrapping the 
tubes in foil.  
8. We use a Qarray2 (Genetix).  
9. We use a GenePix 4300A microarray scanner with integrated GenePix Pro 7 image analysis 
software (Molecular Devices). The scanner has three lasers that allow excitation at 488 nm, 532 nm or 
635 nm and three emission filters: Standard Blue (534/42 nm), Standard Green (579/34 nm) and 
Standard Red (676/29 nm).  
10. Ensure that the fluorescence properties (excitation and emission wavelengths) of the chosen 
fluorophore(s) are compatible with the excitation and emission capabilities of the available microarray 
slide scanner.  
11. We use the MEGAscript T7 Transcription Kit (Invitrogen) to assemble the T7 in vitro 
transcription reagent mix. However, alternative kits could be substituted or the reagent mix could be 
assembled from individually sourced components. 
12. The linker probe is a fluorescently labelled DNA oligonucleotide with a sequence complementary 
to the unstructured linker between the RNA of interest and the immobilisation aptamer (see Methods 
3.1 and Fig. 2). For the 5-ACA CAC ACA CAC ACA CAC AC-3 linker we use a 5-Dy649-GTG 
TGT GTG TGT GTG TGT GT-3 DNA oligonucleotide linker probe. When designing the linker 
probe and selecting the fluorophore, care should be taken to ensure that its fluorescence properties are 
compatible with the excitation and emission capabilities of the available microarray slide scanner.  
13. We typically prepare and use the linker probe at a concentration between 50 nM and 100 nM.  
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14. The fluorescently labelled linker probe should be kept in the dark, either in opaque tubes or in 
tubes wrapped in foil. 
15. We routinely use 24 x 60 mm LifterSlips to cover the full microarray slide or 22 x22 mm 
LifterSlips to cover approximately 1/3 of the microarray slide.  
16. The functional binding interaction to be detected will be highly user-specific. For RNA-RNA 
interactions the RNA binding partner probe should be a fluorescently labelled RNA containing the 
required elements for binding (e.g. a specific nucleotide sequence and/or a specific RNA structural 
element). The RNA binding probe should be labelled with a fluorophore with orthogonal fluorescence 
properties to that used for the linker probe. This will allow simultaneous/serial binding and detection 
of both the linker probe and the RNA binding partner. We use a standard method to produce internally 
fluorescently labelled RNA binding partner probes by in vitro transcription, supplementing the in 
vitro transcription mix with Cy3/5-UTP (GE Healthcare Life Sciences). When using the Dy649 linker 
probe (see Note 12) we would label our RNA binding partner probe with Cy3. 
17. For the RNA-RNA interactions that we have experience with, we have found that 40 mM Tris, pH 
7.8, 6 mM MgCl2, 20 mM NaCl is a good hybridisation buffer. However, the hybridisation buffer 
composition should be adjusted to accommodate any system-specific requirements. 
18. The required RNA binding partner probe concentration is likely to be system- and/or experiment-
specific. For a yes/no output, we usually select an RNA binding partner probe concentration well 
above the expected Kd for the interaction in the first instance. If the Kd is unknown, a range of RNA 
binding partner probe concentrations spanning several orders of magnitude (e.g. 1 nM, 10 nM, 100 
nM, 1 M) should be tested.  
19. This protocol should be followed for each custom DNA in vitro transcription template that is 
required.  
20. We typically use a 5-biotinylated linker to facilitate surface immobilisation of the in vitro 
transcription template when it is spotted onto a streptavidin-coated glass microarray slide. Alternative 
immobilisation chemistries, e.g. amine coupling, and/or surfaces could be employed with the 
appropriate modification(s) to these protocols (Li et al., 2016). 
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21. We typically use the T7 promoter, which facilitates transcription by T7 RNA polymerase. The T7 
in vitro transcription system is routinely used by molecular biologists and T7 in vitro transcription kits 
are commercially available at a reasonable cost. Alternative promoters and transcription systems 
could be employed with the appropriate modifications(s) to these protocols.   
22. T7 RNA polymerase requires a G to be in the +1 position and a G in the +2 and +3 positions are 
required for optimal transcription efficiency (Imburgio et al., 2000). Depending on the sequence of 
the RNA of interest, we insert between 0 and 3 Gs between the T7 promoter and the RNA of interest 
to ensure that there is a G in positions +1, +2 and +3. On rare occasions, the addition of these 
nucleotides can adversely affect the structure of the RNA of interest (see Note 28). In this case, it is 
possible to omit the G from positions +2 and +3.  
23. This is used to physically separate the RNA of interest and the immobilisation aptamer in order to 
promote the independent folding of each of these RNA modules. The linker can also be utilised as a 
binding site for a fluorescently labelled complementary DNA oligonucleotide linker probe. This 
enables visualisation of the RNA array and quantification of the relative RNA level at each position of 
the array (Norouzi et al., 2019; Henderson et al., 2019).  
24. We typically use the streptavidin-binding RNA aptamer (SAapt) to facilitate in situ capture of the 
in vitro transcribed RNA on a streptavidin-coated glass microarray slide. Alternative immobilisation 
systems may be employed with the appropriate modification(s) to these protocols e.g. the tobramycin-
binding RNA aptamer and a tobramycin-coated surface (Phillips et al., 2018).   
25. The immobilisation aptamer should always be incorporated 3 to the RNA of interest to ensure 
that only fully-transcribed, full-length RNAs are captured. 
26. Inclusion of a 3 fluorophore is optional. However, we typically include a Dy549 fluorophore at 
the 3 end of our DNA in vitro transcription templates to allow visualisation and quantification of the 
relative levels of DNA at each position on the in vitro transcription template array. This can be a 
useful quality control checkpoint when generating the DNA in vitro transcription template array and it 
can be used subsequently to calculate RNA transcription/capture efficiencies (Norouzi et al., 2019; 
Henderson et al., 2019). Alternative fluorophores to Dy549 may be employed (see Note 10).  
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27. RNA polymerase will begin transcribing from the system-specific sequence (GGG for T7 RNA 
polymerase) and continue to transcribe the RNA of interest, the unstructured linker and the 
immobilisation aptamer. The immobilisation linker and the promoter will not be transcribed. 
28. Both the RNA of interest and the immobilisation aptamer must fold correctly to generate a 
functional-RNA array. Misfolding of the RNA of interest can result in a non-functional RNA that may 
be unsuitable for downstream applications and misfolding of the immobilisation aptamer can result in 
the failure of in situ RNA capture by the surface even if the RNA of interest is folded correctly. 
Therefore, it is critical to check that linking the RNA of interest to an immobilisation aptamer does 
not affect the folding of either RNA. Where secondary structure predictions indicate that correct 
folding of both RNAs within the context of the full-length transcript is likely, we accept the DNA in 
vitro transcription template design. However, where RNA secondary structure predictions indicate 
that misfolding of the immobilisation aptamer and/or the RNA of interest is likely, we typically repeat 
the design process with alternative linker and/or modified immobilisation aptamer sequences until 
RNA secondary structure predictions suggest that both are likely to fold correctly. The linker 
sequences and modified streptavidin aptamer sequences that we have successfully utilised are listed in 
Table 1. 
 
[Table 1 near here] 
  
29. DNA in vitro transcription templates can be synthesised using a variety of standard molecular 
biology methods e.g. gene synthesis, primer extension or annealing of complementary 
oligonucleotides and the choice of method will depend primarily on the length of the RNA of interest. 
We typically perform gene synthesis in-house. We use DNAWorks v3.2.4 
(https://hpcwebapps.cit.nih.gov/dnaworks; Hoover and Lubkowski, 2002) to design gene synthesis 
primers and follow standard gene synthesis protocols (Gao et al., 2003) to first produce a double-
stranded non-biotinylated and non-fluorescently labelled template. We then amplify this template in a 
standard PCR reaction with a 5-biotinylated forward primer and a 5-Dy549 fluorescently labelled 
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reverse primer to produce the final 5-biotinylated, 3-fluorescently labelled DNA in vitro 
transcription template (Henderson et al., 2019). DNA in vitro transcription template preparation could 
also be outsourced to commercial gene synthesis services e.g. GeneArt (Thermo Fisher Scientific) or 
custom oligonucleotide manufacturers e.g. Integrated DNA Technologies. 
30. Take care not to touch the streptavidin-coated surface when handling the microarray slides. 
31. As in vitro transcription and in situ capture proceeds, there will be some level of diffusion prior to 
RNA capture which results in larger spots on the functional-RNA array compared to the DNA 
template array (Phillips et al., 2018). This is impacted by factors including in vitro transcription 
efficiency and incubation time, and spacing/volume between the slides. Spacing of the DNA spots on 
the DNA template array may need to be adjusted to account for this. We typically use an automated 
Qarray2 arrayer (Genetix) fitted with a 200 m pinhead to spot the DNA in vitro transcription 
template onto a streptavidin-coated glass microarray slide at a spot separation of 1250 m. This 
allows us to achieve a spot density of ~400 spots per slide. It is also possible to spot the DNA in vitro 
transcription template manually using a micropipette. If we manually pipette 0.2 l per spot we can 
achieve a spot density of 24 spots per slide.  
32. Note that the array layout of the functional-RNA array will be the mirror-image of the DNA in 
vitro template array layout. 
33. If spotting is performed using an automated arrayer, the arrayer can provide the humidified 
environment. If spotting is performed manually with a micropipette, a humidified environment can be 
created using a mini incubator (9.2 L) and a Petri dish containing 25 ml H2O. 
34. If the DNA in vitro transcription templates are fluorescently labelled, they should be kept in the 
dark as much as possible during spotting. The Qarray2 automated arrayer has a tinted cover or, when 
manually spotting, we cover the window panel in the mini incubator with foil during the incubation 
step. 
35. Take care not to touch the DNA in vitro transcription template array surface when handling the 
microarray slides. 
36. We place the slide in a 50 ml Falcon tube and use a swing bucket centrifuge. 
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37. We visualise our array of 3-Dy549 labelled DNA in vitro transcription templates using an 
excitation wavelength of 532 nm and a Standard Green (579/34 nm) emission filter with a GenePix 
4300A microarray scanner (Molecular Devices) (see Note 9). 
38. We typically store the DNA in vitro transcription template array at -20C overnight although it 
can be stored at -20C for at least seven days. The DNA in vitro transcription template array should 
be thawed at room temperature for 30 minutes prior to use.  
39. It is important to assemble the DNA in vitro transcription template array – in vitro transcription 
reagent mix – RNA capture surface “sandwich” with the RNA capture surface as the lower layer so 
that the in vitro transcription reagent mix is pipetted onto this surface. This ensures that transcription 
is not initiated until the DNA in vitro transcription template array is added to complete the “sandwich 
assembly. This in turn helps to confine the in vitro transcription and in situ RNA capture to a discrete 
volume (see Note 31).  
40. The use of parafilm as spacers helps with the separation of the DNA in vitro transcription template 
array and the functional-RNA array following in vitro transcription and in situ RNA capture. 
However, using spacers also increases the distance that the RNA must diffuse between synthesis and 
capture and can result in larger RNA spots (see Note 31). If a high spot density is required, it may be 
beneficial to omit the spacers and reduce the volume of in vitro transcription mix that is used.  
41. We have used in vitro transcription mix volumes between 12 and 150 l. 90 l allows for good 
coverage of the array and for the use of spacers (see Note 40) to assist slide separation following in 
vitro transcription and in situ RNA capture.  
42. We typically incubate at 37C for between 30 and 90 minutes in a mini incubator (9.2 L) that has 
been humidified using a Petri dish containing 25 ml H2O. For most applications, this is sufficient for 
in vitro transcription and in situ RNA capture. Longer incubation times may result in larger spots (see 
Note 31). 
43. The increased surface tension of the in vitro transcription mix as the DNA in vitro transcription 
template array and the functional-RNA array are pulled apart can make it difficult to separate the 
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arrays, especially if parafilm spacers have not been used. It can be helpful to submerge the sandwich 
assembly in PBS when separating the arrays.  
44. Take care not to touch the functional-RNA array surface when handling the microarray slides. 
45. In theory, the DNA in vitro transcription template array slide could be washed and reused. We do 
not currently reuse the DNA in vitro transcription template array.  
46. Probing the functional-RNA array with linker probe provides a quality control checkpoint when 
generating the functional-RNA array and it can be used to calculate RNA transcription/capture 
efficiencies (Norouzi et al., 2019; Henderson et al., 2019).  
47. Since the linker probe is fluorescently labelled, the incubation should be performed in the dark. 
We cover the assembly with foil. 
48. We visualise Dy649 labelled linker probe bound to our functional-RNA array  using an excitation 
wavelength of 635 nm and a Standard Red (676/29 nm) emission filter with a GenePix 4300A 
microarray scanner (Molecular Devices) (see Note 9). 
49. The functional-RNA array will be an array of functional-RNAs that will be probed with a single 
RNA binding partner probe (see Notes 16 and 50). The functional-RNA array should include a 
positive control RNA that the RNA binding partner probe is known to bind, a negative control RNA 
that the RNA binding partner probe is known not to bind, and test RNAs (see Note 51) that may or 
may not be bound by the RNA binding partner probe (see Fig. 7). We typically design a single field 
of between 9 and 16 spots. This field may contain a single RNA at different concentrations, with each 
field containing a different RNA, or multiple RNAs at the same concentration. It is good practice to 
include replicate spots of each RNA, and/or replicate fields.  
50. It is possible to simultaneously probe with more than one RNA binding partner probe provided 
that each RNA binding partner probe can be labelled with an orthogonal fluorophore (Phillips et al., 
2018).  
51. The test RNAs may be potential binding targets of the RNA binding partner probe (e.g. in the case 
of an sRNA that has multiple mRNA targets) or they may be a series of binding-site mutants designed 
to evaluate the key residues required for a specific RNA-RNA interaction.  
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52. The probing conditions needed for the RNA binding partner probe may be highly system-specific. 
For example, it may be necessary to test different hybridisation buffers (see Note 17), different RNA 
binding partner probe concentrations (see Note 18), different incubation temperatures and/or times.    
53. Different conditions and/or different RNA binding partner probes can be tested on the same array 
by using 20 l RNA binding partner probe (see Notes 16-18 and 51) and 22 x 22 mm LifterSlips to 
cover a smaller area of the array. Up to three conditions can be tested per array in this manner. 
54. Since the RNA binding parnter probe is fluorescently labelled, the incubation should be performed 
in the dark. We cover the assembly with foil. 
55. Depending on the affinity of the RNA-RNA interaction and the non-specific binding observed, 
fewer or more wash steps may be desirable. 
56. We visualise Cy3 labelled RNA binding partner probe bound to our functional-RNA array using 
an excitation wavelength of 532 nm and a Standard Green (578/34 nm) emission filter with a GenePix 
4300A microarray scanner (Molecular Devices) (see Note 9).
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Fig. 1.  Generation of functional-RNA arrays by in vitro transcription and in situ RNA 
capture. Custom DNA in vitro transcription templates are designed and synthesised. These are 
spotted onto a microarray slide to produce a DNA in vitro transcription template array. A DNA in 
vitro transcription template array – in vitro transcription reagent mix (IVT) – RNA capture surface 
“sandwich” is assembled. As in vitro transcription proceeds, RNA is captured in situ to produce a 
corresponding functional-RNA array. 
 
Fig. 2. Design of the in vitro transcription template. A schematic of the in vitro transcription 
template which consists of a short immobilisation linker (see Note 20), a promoter (see Note 21), 
transcription system-specific sequence (see Note 22), sequence encoding the RNA of interest, an 
unstructured linker (see Note 23), sequence encoding an immobilisation aptamer (see Notes 24 and 
25) and an optional fluorophore (see Note 26). A suggested starting DNA sequence for each 
component of the in vitro transcription template is indicated, except for the user-specified RNA of 
interest sequence which is represented by …(N)n….  
 
Fig. 3. Predicted secondary structures for an RNA of interest (MicA) transcript. (A) The 
sequence of the full-length RNA transcript which consists of GGG (T7 transcription system-
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specific sequence; grey), MicA (a small regulatory RNA of interest; blue), an unstructured linker 
(magenta) and the streptavidin-binding RNA aptamer (SAapt; immobilisation aptamer; gold). The 
RNA secondary structures, predicted by RNAfold (rna.tbi.univie.ac.at; Lorenz et al., 2011), for the 
full-length RNA transcript, MicA and the streptavidin-binding aptamer are shown below the RNA 
sequence in dot-bracket notation. (B)-(D) The RNA secondary structures, predicted by RNAfold, 
visualised in forna (Kerpedjiev et al., 2015). The predicted secondary structures for MicA and the 
streptavidin-binding aptamer are the same in the context of the full-length transcript and in 
isolation.   
 
Fig. 4. Spotting and visualisation of the DNA in vitro transcription template array. The DNA 
in vitro transcription template array is prepared by spotting 5-biotinylated DNA in vitro 
transcription templates onto a streptavidin-coated microarray slide. Spotting can be performed 
manually using a micropipette, or it can be automated using an arrayer (see Note 30). Both 
methods result in discrete spots containing multiple immobilised DNA in vitro transcription 
template molecules. Following spotting, the DNA in vitro transcription template array is washed. If 
the DNA in vitro transcription templates are also fluorescently labelled, the DNA in vitro 
transcription template array can be visualised using a microarray scanner and quantified (see Note 
37).    
 
Fig. 5. In vitro transcription and in situ RNA capture. (A) Assembly of the DNA in vitro 
transcription template array – in vitro transcription reagent mix (IVT) – RNA capture surface 
“sandwich”. The RNA capture surface (a streptavidin-coated microarray slide) is position surface-
side up. A small piece of parafilm is positioned at each of the short edges of the RNA capture 
surface to act as spacers. In vitro transcription reagent mix is pipetted onto the RNA capture 
surface and the DNA in vitro transcription template array, array-side down, is carefully lowered 
onto the RNA capture surface to complete the “sandwich” assembly. (B) The “sandwich” assembly 
is incubated at 37C for 30-90 minutes during which time RNA is synthesised by in vitro 
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transcription and captured in situ by the RNA capture surface. (C) The DNA in vitro transcription 
template array and the newly generated corresponding functional-RNA array are carefully 
separated.     
 
Fig. 6. Probing the functional-RNA array with linker probe. The functional-RNA array can be 
probed with a fluorescently labelled DNA oligonucleotide with a sequence complementary to the 
unstructured linker region between the RNA of interest and the streptavidin-binding RNA aptamer 
(see Note 12). This allows visualisation and quantification of the RNA levels on the functional-
RNA array (see Note 46). A solution of fluorescently labelled linker probe is pipetted over the 
functional-RNA array (see Note 13). This is covered with a LifterSlip and incubated at room 
temperature for 30 minutes in the dark (see Note 47). During incubation, the linker probe binds to 
the unstructured linker on the immobilised functional-RNAs. Following incubation, the LifterSlip 
is removed, the functional-RNA array is washed and linker probe fluorescence is detected using a 
microarray scanner and quantified (see Note 48).  
 
Fig. 7. Application of functional-RNA arrays to the evaluation of RNA-RNA binding 
specificity. Functional-RNA arrays can be used to detect RNA-RNA interactions (Phillips et al., 
2018). (A) A functional-RNA array is designed with appropriate positive (+) and negative (-) 
control RNAs and a variety of test RNAs (T1-T7) (see Note 49). (B) A DNA in vitro transcription 
template array is generated (see Note 16). (C) A functional-RNA array is generated by in vitro 
transcription and in situ RNA capture and probed with linker probe (see Notes 12-14, 32 and 46). 
(D) The functional-RNA array is probed with RNA binding partner probe (see Notes 16-18, 32 and 
51). Fluorescence should be clearly detected for the positive control and not for the negative 
control. The presence or absence of fluorescence for the test RNAs can give a yes-no output for 
binding or the relative intensity of the RNA detected may be able to give an indication of the 





Table 1. Validated alternative unstructured linker RNA-streptavidin-binding RNA aptamer 
(SAapt) conjugate sequences. The SAapt RNA sequences consist of a core sequence (gold) 
(Leppek, 2014) and a variable sequence at the 5 and 3 ends (gold, bold and underlined) that 
extends a duplex that stabilises the aptamer (Leppek, 2014). 
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